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As more individuals survive into 
advanced age, prevention of cognitive 
impairment and dementia is of 
increasing public health importance. 
Identifying modifiable risk and 
protective factors for dementia/
Alzheimer’s Disease (AD) is 
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investigated the role of midlife 
diet - dietary fat intake, coffee/tea 
consumption and healthy diet - in 
the development of dementia/AD and 
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ABSTRACT 
 
As more individuals survive into advanced age, prevention of dementia and cognitive 
impairments is of increasing public health importance. The aetiology of dementia and 
Alzheimer’s disease (AD) – a major cause of dementia – is considered to be multifactorial, 
resulting from both genetic and environmental factors. The present thesis aimed at 
obtaining a comprehensive understanding of the role of diet in the development of 
dementia/AD and cognitive impairment. The working hypothesis was that a healthy diet at 
midlife would reduce the risk of dementia/AD and cognitive impairment later in life. 
The present thesis was based on the Finnish Cardiovascular Risk Factors, Aging and 
Incidence of Dementia (CAIDE) project. CAIDE is a population-based study investigating 
cardiovascular and lifestyle-related risk factors for dementia. The participants (n=2000) 
were derived from independent population-based random samples (North Karelia Project, 
FINMONICA study) studied in 1972, 1977, 1982 or 1987 (midlife/baseline examination), 
when they were on average 50 years old (range 39-64 years). During the midlife 
examination, dietary information was collected. Re-examination of the cohort was carried 
out in 1998 in two geographically defined areas in Eastern Finland (in Kuopio and 
Joensuu), and altogether 1449 people (73%) aged 65-79 years participated. 
This series of studies showed that an abundant saturated fat (SFA) intake from milk 
products and spreads at midlife was associated with poorer global cognitive functioning 
and prospective memory and with an increased risk of mild cognitive impairment (MCI). A 
high intake of polyunsaturated fatty acids (PUFAs) was associated with better semantic 
memory. Fish consumption tended to be related to better global cognitive functioning and 
semantic memory, and higher PUFA-SFA ratio to better performance in psychomotor speed 
and executive functioning. In addition, a moderate intake of unsaturated fats from spreads 
at midlife was protective, whereas a moderate intake of SFAs increased the risk of dementia 
and AD, especially among individuals carrying the apolipoprotein E (ApoE) ε4 allele. The 
participants who drank moderate amounts of coffee (3-5 cups/day) at midlife had the 
lowest risk of dementia/AD later in life compared to individuals drinking less/not at all. For 
tea drinking, no association was found. Furthermore, the effect of healthy diet on dementia 
risk was examined with a healthy-diet index; this was constructed including both healthy 
and unhealthy dietary components. Adherence to a healthy diet at midlife was associated 
with a decreased risk of dementia/AD in late-life. 
In summary, these results emphasize that unhealthy dietary factors at midlife may 
increase the risk of developing dementia/AD later in life and have a negative effect on 
several cognitive domains, whereas healthier dietary choices may act in the reverse 
manner. The current data suggests that healthy dietary choices at midlife may increase the 
possibility for brain health later in life. 
 
National Library of Medical Classification: QT 235, WT 155, WT 150, WM 220, WL 358.5, WA 105 
Medical Subject Headings: Dementia; Alzheimer Disease; Mild Cognitive Impairment; Epidemiology; Risk 
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TIIVISTELMÄ 
 
Yhä useammat henkilöt elävät vanhuusikään saakka, ja tämän vuoksi dementian ja 
lievemmän kognitiivisen heikentymisen merkitys kansanterveydelle kasvaa. Dementian ja 
erityisesti Alzheimerin taudin (AT), joka on tavallisin dementoiva sairaus, etiologiaa 
pidetään monitekijäisenä, ja siihen vaikuttavat sekä geneettiset että ympäristötekijät. 
Tämän väitöskirjatyön tavoitteena oli selvittää ruokavalion vaikutusta kognitiivisen 
heikentymisen ja dementian kehittymisessä. Yleisenä lähtöoletuksena oli, että terveellinen 
ruokavalio keski-iässä voisi vähentää myöhäisiän dementian ja kognitiivisen 
heikentymisen riskiä. 
Väitöskirjatyö pohjautui suomalaiseen Kardiovaskulaariset Riskitekijät, Ikääntyminen ja 
Dementian Ilmaantuvuus (CAIDE) tutkimukseen. CAIDE-tutkimukseen osallistujat olivat 
peräisin neljästä itsenäisestä väestöpohjaisesta satunnaisotoksesta; henkilöt oli tutkittu 
osana Pohjois-Karjala projektia ja FINMONICA-tutkimusta vuosina 1972, 1977, 1982 tai 
1987, kun he olivat keskimäärin 50-vuotiaita (ikäjakauma 39-64 vuotta). Ruoankäyttötiedot 
kerättiin keski-iän käynnillä. CAIDE-tutkimuksen seurantakäynnille vuonna 1998 
kutsuttiin 2000 henkilön satunnaisotos 65-79-vuotiaita Kuopion ja Joensuun alueella asuvia 
henkilöitä, ja yhteensä 1449 (73 %) heistä osallistui. 
Tutkimukset osoittivat, että runsas tyydyttyneiden rasvahappojen (SFA) saanti 
maitotuotteista ja leipärasvoista keski-iässä oli yhteydessä heikentyneeseen suoriutumiseen 
prospektiivista muistia mittaavassa testissä, MMSE-testissä sekä lisääntyneeseen lievän 
muistihäiriön riskiin myöhemmällä iällä. Runsaalla monityydyttymättömien 
rasvahappojen (PUFA) saannilla ja kalan käytöllä vaikutti puolestaan olevan yhteys mm. 
parempaan semanttiseen muistiin, ja korkeammalla PUFA-SFA-suhteella parempaan 
suoriutumiseen psykomotorista nopeutta ja eksekutiivisia toimintoja mittaavissa testeissä. 
Lisäksi havaitsimme, että kohtalainen kertatyydyttymättömien rasvahappojen (MUFA) ja 
PUFA:n saanti leipärasvoista keski-iässä vähentää riskiä sairastua dementiaan/AT:iin 
myöhemmällä iällä, ja kohtalainen SFA:n saanti lisää riskiä - erityisesti Apolipoproteiini E 
(ApoE) ε4 -alleelin kantajilla. Keski-iässä kahvia 3-5 kuppia/vrk nauttivilla henkilöillä oli 
pienin riski sairastua dementiaan/AT:iin myöhemmällä iällä verrattuna alle 3 kupillista 
kahvia/vrk nauttiviin. Teen juonnin ja dementiariskin välillä ei löydetty yhteyttä. Lisäksi 
selvitimme terveellisen ruokavalion yhteyttä dementiariskiin sekä terveellisiä että 
epäterveellisiä komponentteja sisältävän indeksin avulla. Terveellinen ruokavalio keski-
iässä oli yhteydessä pienentyneeseen myöhäisiän dementia/AT -riskiin. 
Tiivistetysti, väitöskirjatyö osoitti, että keski-iän epäterveelliset ravitsemustekijät voivat 
lisätä myöhäisiän dementian/AT:n riskiä ja vaikuttaa negatiivisesti moniin kognitiivisiin 
toimintoihin, kun taas terveellisillä ravitsemustekijöillä voidaan saada aikaan 
päinvastainen vaikutus. Saatujen tulosten pohjalta voidaankin esittää, että terveellisillä 
keski-iän ravitsemustekijöillä voitaisiin parantaa myöhäisiän aivojen terveyttä. 
 
Luokitus: QT 235, WT 155, WT 150, WM 220, WL 358.5, WA 105 
Yleinen Suomalainen asiasanasto: dementia, Alzheimerin tauti, muistisairaudet, epidemiologia, riskitekijät, 
ruokavaliot, ravintorasvat, kahvi, tee, keski-ikä, seurantatutkimus 
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 1 Introduction 
The proportion of elderly people is increasing all over the world, since human beings live 
longer than ever before. Globally, the current number of persons aged 65 or more is about 
7%, and it is estimated that the size of this sector will increase to 16% by the year 2050 
(Cohen, 2003). As a consequence of the general lengthening of lifespan, a greater number of 
persons will be suffering from age-associated neurodegenerative diseases like dementia 
including Alzheimer's disease (AD) - the most common cause of dementia.  
After age 65, the risk of dementia/AD increases exponentially, with an even sharper up-
sloping curve after 80 years of age (Hofman et al., 1991; Kukull et al., 2002). However, even 
among the oldest age groups (85+), dementia is not inevitable (den Dunnen et al., 2008; 
Savva et al., 2009). In Finland, the annual incidence of dementia is approximately 13 000 
cases/year, of which about 70% are estimated to be due to AD (Suhonen et al., 2010). 
Dementia causes devastating effects on both patients and their families and can excert a 
major impact on the health economics of a society. Based on estimations of 29.3 million 
demented persons in 2005, the total worldwide societal costs were US$315 billion 
(including US$105 billion for informal care) (Wimo et al., 2007). From year 2005 to 2009, the 
costs of dementia have increased by 34%, so that in 2009 the costs were estimated to have 
risen to US$422 billion (of which informal care costs US$142 billion) for a dementia 
population of 34.4 million demented persons (Wimo et al., 2010). The total estimated costs 
of dementia have been constantly increasing, and in 2010 for the 35.6 million people living 
with dementia the costs have been estimated to be as high as US$604 billion (with informal 
care costing US$252 billion) (Wimo et al., 2013). In Finland, dementia is the most expensive 
brain disorder (Sillanpää et al., 2008), and the total societal annual costs of dementia were 
estimated to be US$1335 million for about 72 000 dementia cases in 2009 (Wimo et al., 2010). 
So far, there are no therapies available to cure dementia (Massoud and Léger, 2011), and 
pharmacological and non-pharmacological interventions can at best relieve symptoms and 
perhaps delay the progression of the disease. Thus, the successful development of cost-
effective preventive strategies is extremely important since, if available, it could prevent or 
delay the onset of dementia/AD and affect the lives of millions of people. Identifying 
modifiable risk factors for dementia/AD is important and may help at least in part to 
confront this major public health challenge of the aging population. 
The present set of studies has investigated risk factors for dementia in the general 
Finnish population with a special focus on modifiable dietary factors. A combination of a 
longitudinal, population-based study cohort with a mean follow-up time of 21 years, and 
modern techniques and methods for analyses provided an excellent and unique 
opportunity to conduct the present studies. The impact of midlife dietary fat consumption 
on the development of mild cognitive impairment (MCI) and on the performance on 
various neuropsychological tests was investigated in a Finnish non-demented sample. 
Similarly, the relationship between midlife dietary fat consumption on the subsequent 
development of late-life dementia/AD was examined. Furthermore, the relationships 
between midlife coffee and tea drinking as well as midlife “healthy diet” with late-life 
dementia/AD were examined in the Cardiovascular Risk Factors, Aging and Incidence of 
Dementia (CAIDE) study. Additionally, the relative importance and the putative 
interactions between the above dietary factors and the Apolipoprotein E (ApoE) ε4 allele 
and/or gender differences were analyzed within the limits of the available data. 
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2 Review of the literature 
2.1 COGNITION 
2.1.1 Normal aging and cognitive domains 
Several domains of cognitive functioning have been defined, and it is important to keep in 
mind that they are theoretical constructs rather than directly measurable physical entities. 
One of the most widely studied cognitive domains is memory, which is particularly 
relevant for AD. Memory can be divided into several components as shown in Figure 1 
(Spaan et al., 2003). Short-term memory has two subclasses: auditory/verbal and 
visuospatial span. In addition, long-term memory is often divided into two categories: 
explicit (declarative, conscious) and implicit (non-declarative, unconscious influence of past 
experience on subsequent performance) memory. Explicit memory can be further divided 
into episodic (ability to remember specific personal events situated in time and place) and 
semantic (vast store of general knowledge and skills) memory. Implicit memory includes 
several learning processes, such as priming, procedural memory, and more primitive 
learning processes (e.g. classical conditioning). 
 
 
Figure 1. Components of memory. Modified from Spaan et al., 2003. 
 
There are other cognitive domains for example executive functioning (including abstract 
thinking, judgment, problem solving), psychomotor speed, or language-related domains 
(i.e. verbal fluency). Cognitive domains and their components can be affected by normal 
aging in different ways. Psychomotor speed, word retrieval (ability to retrieve the sound or 
phonology of words), executive functions, and episodic memory decline with normal aging 
(Horn and Cattell, 1967; Burke and Mackay, 1997; Christensen, 2001). However, other facets 
such as semantic memory remain fairly intact. Differences in the cognitive functions 
between individuals become greater with aging. 
Cognitive functioning involves most often several domains working together, but many 
tests are available for evaluating cognition by focusing on one specific cognitive function. A 
person’s score on a test is usually compared to a general population normative sample, 
although age or level of education can be taken into account. A broad range of cognitive 
tests are available for the assessment of elderly or patients with dementia (Burns et al., 
1999); one of the most extensively used tests is the Mini-Mental State Examination (MMSE) 
(Folstein et al., 1975), with a range from 0 to 30 points. 
2.1.2 Cognition between normal aging and dementia 
Several concepts have been formulated to deal with the grey zone between normal 
cognitive aging and dementia (Ritchie and Touchon, 2000). Mild cognitive impairment 
Explicit Visuospatial 
span 
Auditory/ 
verbal 
Implicit 
Long-term Short-term (working) 
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(MCI) is the most widely used concept at the moment, and it refers to those individuals 
with subjective memory or cognitive symptoms, objective memory or cognitive 
impairment, and whose Activities of Daily Living (ADL) are generally normal (Werner and 
Korczyn, 2008; Burns and Iliffe, 2009). 
The definition of MCI has been modified over time, from focusing exclusively on 
memory (Petersen et al., 1999) to including impairments in other cognitive domains as well. 
Patients with MCI are neither normal nor demented (do not meet DSM-IV or ICD-10 
criteria for dementia), but they have cognitive decline, indicated by self and/or informant 
report and impairment on objective cognitive tasks and/or evidence of decline over time on 
objective cognitive tasks. Furthermore, they should have preserved basic activities of daily 
living/minimal impairment in complex instrumental functions (Winblad et al., 2004). 
Several types of MCI have been described in the literature: amnestic (memory deficit only), 
multidomain amnestic (deficit in memory plus other domains), multidomain non-amnestic 
(deficits in several domains but not memory), and single nonmemory (deficit in one non-
memory cognitive domain) (Winblad et al., 2004). 
The prevalence and incidence of MCI tend to vary between studies, depending on the 
type of population being examined (i.e. higher in clinic-based populations compared to the 
general population). The prevalence of MCI ranges between 1.0 and 11.1%, and the 
incidence between 8.5 and 25.9 per 1000 person-years when considering population-based 
studies assessed by the original or revised Mayo Clinic criteria for amnestic MCI 
(Caracciolo, 2011). 
Patients with MCI progress more often to AD or to other dementias than older adults 
without objective evidence of cognitive impairment. However, a substantial variation in the 
annual conversion rates (ACRs) from MCI to AD has been observed across studies ranging 
from 3.0% to over 50.0% in samples defined according to the Mayo Clinic diagnostic criteria 
for MCI; the average ACR has been estimated to be 8.1% in clinical settings and 6.8% in 
population-based studies (Mitchell and Shiri-Feshki, 2009). Patients with amnestic MCI 
tend to progress more to AD, while those with other MCI types may progress to other 
dementias, remain stable or sometimes even improve (Winblad et al., 2004; Maioli et al., 
2007). Recently, it has been postulated that the whole brain atrophy rate can predict clinical 
progression from MCI to AD (Spulber et al., 2010). 
The concept of Vascular Cognitive Impairment (VCI) was formulated to reflect the 
effects of cerebrovascular disease (CBVD) on cognition (Erkinjuntti and Gauthier, 2009). 
VCI includes all levels of cognitive decline from mild deficits in one or more cognitive 
domains to a broad dementia-like syndrome. Deciding whether a patient has MCI or VCI is 
not straightforward, considering that Alzheimer and vascular pathology often co-exist and 
interact with one another (Snowdon et al., 1997). 
2.1.3 Definition and occurrence of dementia 
Dementia is a syndrome that is characterized by deficits in memory and other cognitive 
functions (aphasia, apraxia, agnosia, or executive dysfunction) that are severe enough to 
cause significant impairment in social or occupational functioning and represent a 
significant decline from a previous level of functioning (American Psychiatric Association, 
1994). 
There are several classifications for the diagnosis of dementia, with the currently used 
Diagnostic and Statistical Manual of Mental Disorders, IV edition (DSM-IV) (American 
Psychiatric Association, 1994), as well as International Classification of Diseases, 10th 
revision (ICD-10) (World Health Organization, 1993). In different classification systems the 
core factors are similar, but they differ from each other in some details and this can lead to 
different estimates in the numbers of the demented persons (Erkinjuntti et al., 1997; 
Wancata et al., 2007). Different types of dementia have been associated with distinct 
symptom patterns and distinguishing microscopic brain abnormalities (Alzheimer’s 
Association, 2012). However, there is increasing evidence emerging from long-term 
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epidemiological observation and autopsy studies that many people have brain 
abnormalities associated with more than one type of dementia. The symptoms of different 
types of dementia also overlap and these can be further complicated by co-existing medical 
conditions. 
Dementia has become a focus of great public health interest during the past decades, as 
the world population is aging. In the 2010 World Alzheimer Report, Alzheimer’s Disease 
International estimated that there are 35.6 million people living with dementia worldwide 
in 2010, this will increase to 65.7 million by 2030 and to 115.4 million by 2050 
(http://www.alz.co.uk/research/files/WorldAlzheimerReport2010.pdf). Nearly two-thirds 
live in low and middle income countries, where the sharpest increases in numbers are set to 
occur. 
2.1.4 Alzheimer’s disease 
In 1906, Dr. Alois Alzheimer described a 51-year old female patient called Auguste D(eter) 
with a 5-year history of progressive cognitive impairment, focal symptoms, hallucinations, 
delusions, and social incapability (Maurer et al., 1997; Maurer, 2006). At autopsy, he 
observed (extracellular) amyloid plaques, (intracellular) neurofibrillary tangles (NFT), and 
arteriosclerotic changes in her brain. Later on, the disease became known as Alzheimer's 
disease (AD). 
Nowadays, AD is considered to be the most common form of dementia, accounting for 
about two-thirds of all cases (Nussbaum and Ellis, 2003; Fratiglioni et al., 2007). In 2006, 
hundred years from the description of the first AD patient, approximately 26.6 million 
people worldwide suffered from AD (Brookmeyer et al., 2007). At present in 2009, the 
estimated worldwide prevalence of AD is 29.2 million cases (Brookmeyer et al., 
http://www.biostat.jhsph.edu/project/globalAD/ourfindings.htm). Due to the expanding 
life expectancy, the global prevalence of AD is expected to quadruple by 2050 to more than 
100 million, meaning that 1 in every 85 human beings will be affected by this disease 
(Brookmeyer et al., 2007). It is also estimated that about 40 % of those AD patients will need 
a high level of care in the later stage of the disease, which will place an enormous burden 
on healthcare resources. 
Despite the still ongoing debate concerning the exact cause(s) of AD, the amyloid 
hypothesis has been the most well-defined and best studied conceptual framework for the 
disease since the early 1990s. According to the amyloid hypothesis, AD is the final result of 
increased production or impaired clearance of Aβ peptides generated by the processing of 
amyloid precursor protein (APP), a membrane protein abundantly expressed in the brain 
(Pimplikar, 2009). Aβ1–40 is the most frequent form of Aβ, but the Aβ1–42 and Aβ1–43 forms 
have a higher propensity to aggregate and these forms are greatly enriched in amyloid 
deposits (Cappai and Barnham, 2008; Welander et al., 2009). The amyloid hypothesis has 
undergone several modifications over time, mainly concerning the type of Aβ causing AD: 
amyloid plaques were the initial focus of interest, but later protofibrils, followed by 
increased concentrations of Aβ1–42, then increased Aβ1-42:Aβ1–40 ratio, and currently 
oligomeric Aβ have attracted attention (Pimplikar, 2009). However, there is more to AD 
than simply amyloid and more to amyloid than disease (Holmes et al, 2008; Pimplikar, 
2009). 
The diagnosis of AD is based on a typical clinical picture and specific findings. In AD 
research, the most often used classification criteria are those established by the National 
Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s 
Disease and Related Disorders Association (NINCDS-ADRDA) (McKhann et al., 1984). 
These criteria serve as a guide for the clinical diagnosis of possible, probable, and definite 
AD. The NINCDS-ADRDA criteria for probable AD diagnosis include 1) dementia 
established by clinical examination, and documented by a standard test of cognitive 
function, and confirmed by neuropsychological tests, 2) significant deficiencies in two or 
more areas of cognition, 3) progressive deterioration of memory and other cognitive 
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functions, 4) no loss of consciousness, 5) onset between ages 40 and 90, typically after age 
65, and 6) no other diseases or disorders that could account for the loss of memory or 
cognition. 
However, the NINCDS-ADRDA criteria are now nearly 30 years old, and work is 
currently ongoing to update them. In the recently published DSM-5 (American Psychiatric 
Association, 2013), dementia has been replaced by the term Major Neurocognitive Disorder, 
and a diagnosis of Mild Neurocognitive Disorder has also been added. Mild and Major 
Neurocognitive Disorder no longer certify that memory has to be the compulsory central 
domain of cognitive impairment, as do the criteria for dementia in ICD-10 and DSM-IV. 
There is additionally a diagnosis of Major or Mild Neurocognitive Disorder due to multiple 
etiologies, acknowledging the role of mixed brain pathologies in cognitive impairment at 
older ages. AD diagnosis is focused on memory impairment, but the non-memory features 
are also mentioned. Epidemiological studies will be needed to establish what types of 
pathologies are actually diagnosed as Minor or Major Neurocognitive Disorder, their risk 
factors and prognosis. The updated 11th edition of ICD is expected to be published during 
2015. 
In addition to the DSM-5 criteria, there are two other sets of proposed criteria for use in 
research (Dubois et al., 2007; Jack et al., 2011). In these criteria, the focus has shifted from 
dementia to pre-dementia stages, and from clinically oriented to more biologically-focused 
criteria proposals (i.e. cerebrospinal fluid (CSF), neuroimaging, and genetic markers). It is 
also acknowledged that the correspondence between clinical symptoms and 
neuropathological processes is not as close as previously believed (Jack et al., 2011). While 
previous diagnostic criteria use a two-step approach (first dementia is diagnosed, then the 
type of dementia is identified), the aim of newer criteria proposals is to directly identify the 
disease causing cognitive impairment. The possibility of asymptomatic AD (or preclinical 
AD) has been discussed (Table 1). 
 
Table 1. The 3 stages of AD identified by new proposed diagnostic criteria. 
Disease stage Symptoms Practical significance 
Pre-clinical AD Asymptomatic stage. Changes in biomarkers 
representing the earliest signs of disease 
before the onset of clinical symptoms. 
Currently no diagnostic criteria 
available for this stage. Recent 
recommendations indicate research 
directions enabling the identification 
of pre-clinical AD in the future. 
MCI due to AD Mild impairment in memory and/or other 
cognitive functions. The impairment can be 
objectively measured by cognitive testing, but 
is not severe enough to have a major impact 
on daily life activities. More complex 
instrumental activities may be slightly affected.  
Biomarkers as additional indicators of disease. 
In the future, biomarkers may be 
helpful for identifying patients with 
AD pathology who need to be 
followed-up and treated. 
Dementia due 
to AD 
Memory problems and other cognitive and 
behavioural symptoms affecting daily activities. 
The memory impairment may or may not be 
the central symptom. 
Biomarkers as possible addition. 
Probable AD diagnosis can be made 
based on clinical symptoms, and 
biomarkers can contribute to 
increasing the diagnostic certainty. 
 
Abbreviations: AD = Alzheimer’s disease; MCI = mild cognitive impairment. 
Adapted from Kivipelto et al., 2011. 
 
Another important trend in clinical practice and also in research has been the increased 
recognition of non-cognitive - behavioural and psychological - symptoms in dementia 
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(BPSD) (Burns et al., 2002; Burns, 2003; Robert et al., 2005; Burns and Iliffe, 2009). BPSD can 
include mood changes (i.e. depression), personality changes, delusions, hallucinations, 
misidentifications, and behaviours such as aimless and restless activities, and wandering. 
2.1.5 Other dementias 
2.1.5.1 Vascular dementia and concept of “mixed dementia” 
Vascular dementia (VaD) is a heterogeneous clinical entity (Nagata et al., 2007) including 
loss of cognitive function caused by ischemic, hypoperfusive, or hemorrhagic brain lesions 
due to CBVD or cardiovascular pathology (Román, 2003). Early and severe deficits in 
executive function are commonly seen, but memory may be only mildly affected or remain 
intact. In VaD, gait is also typically disturbed; it turns into a shuffling gait with short steps. 
VaD is recognized as the second most prevalent type of dementia (Lobo et al., 2000; 
Román, 2003) accounting for 15-25% of all dementia cases worldwide (Qiu et al., 2007). The 
prevalence rates vary highly; this variability may be partly explained by the differences in 
the research cohorts and the diagnostic criteria being applied (Grinberg and Heinsen, 2010). 
Currently, the prevalence of VaD is stated to range from 4.5 to 39.0% in clinical studies and 
from 0.03 to 85.2% in neuropathological studies with real means of 8-15% in Western series; 
in Japanese geriatric hospitals the prevalence of VaD has been reported to be between 23.6 
and 35.0% (Jellinger, 2008). 
To date, postmortem examination is required for the diagnosis of “definite” VaD, but in 
order to establish the prevalence of cognitive decline caused by vascular changes and their 
consequences, it is crucial to have a sensitive and specific diagnostic tool that can be 
applied during life (Grinberg and Heinsen, 2010). At present, there are no widely accepted 
neuropathological criteria for VaD (Jellinger, 2008). The criteria by the National Institute of 
Neurological Disorders and Stroke – the Association Internationale pour la Recherché et 
l'Enseignement en Neurosciences (NINDS-AIREN) (Román et al., 1993) were proposed for 
clinical research purposes; these are currently the most widely employed in the clinical 
settings as well as in research fields (Nagata et al., 2007). However, the clinical diagnosis of 
VaD is also complicated by the current conceptual dichotomy between AD and VaD, and 
the lack of clarification of the concepts of “AD with CBVD” or “mixed dementia” (Jellinger 
and Attems, 2007). 
Especially among the subjects older than 65 years, some degree of neurodegenerative 
and vascular changes may coexist (Agüero-Torres and Winblad, 2000; Grinberg and 
Heinsen, 2010), and a 3.4 to 73.0% overlap between AD and VaD has been reported 
(Jellinger, 2009). The strict dichotomy between VaD and AD is often difficult to discern, and 
in fact, “mixed” dementia (AD with vascular encephalopathy) may be more common than 
pure AD and pure VaD (Neuropathology Group, 2001; Kalaria 2002). 
2.1.5.2 Other dementia subtypes 
After AD and VaD, the other most common types of dementia include dementia with Lewy 
bodies (DLB) (McKeith et al., 2005; Dodel et al., 2008), frontotemporal dementia (FTD) 
(Neary et al., 2005) and Parkinson’s disease with dementia (PDD) (Emre et al., 2007; Dodel 
et al., 2008). Additionally, there are a number of other disorders that may lead to dementia. 
These include dementias secondary to disease, such as HIV-associated dementia (Kaul et 
al., 2005), alcohol-related dementia (ARD) (Oslin et al., 1998), or dementia due to normal 
pressure hydrocephalus (Relkin et al., 2005), hyperhomocysteinemia (high plasma total 
homocysteine concentration, a surrogate marker for folate, vitamin B12 or vitamin B6 
deficiency) (Werder, 2010), depression (Caraci et al., 2010), thyroid dysfunction (either 
hypo- or hyperthyroidism) (Tan and Vasan, 2009) or prion diseases, including sporadic, 
inherited (familial), or acquired (iatrogenic or variant) forms of Creutzfeldt-Jakob disease 
(CJD) (Glatzel et al., 2005). All these dementia disorders have their own special features, but 
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as the focus of this thesis will be on dementia as a whole and specifically AD therefore 
other forms of dementias will not be discussed further. 
2.2 COGNITIVE IMPAIRMENT: NON-DIETARY RISK AND PROTECTIVE 
FACTORS 
Several studies have postulated that there are lifestyle-related measures which may prevent 
the development of cognitive impairment and dementia/AD (Flicker, 2010; Fratiglioni et al., 
2010; Williams et al., 2010; Aznar and Knudsen, 2011; Barnes and Yaffe, 2011; Ballard et al., 
2011; Solfrizzi et al., 2011a; Polidori and Pientka, 2012; Dye et al., 2012; Meraz-Ríos et al., 
2013; Gao et al., 2013). Table 2 summarizes some of the proposed risk and protective factors 
that will be addressed in chapters 2.2 and 2.4. Many of  these factors are non-modifiable, such as 
genes and age, whereas modifiable risk or protective factors are related to lifestyle habits 
and vascular factors. However, the exact mechanisms by which these factors contribute to 
the development of cognitive impairment and/or dementia/AD remain unclear partly due 
to the fact that one cannot perform a randomized controlled trial (RCT) and also to the lack 
of homogeneous exposure and outcome measures (Williams et al., 2010; Polidori and 
Pientka, 2012). Rigorous research methods to identify early risk or protective factors with 
confidence are needed for drafting effective guidelines in this field. Additionally, 
improvement is needed in the control strategies e.g. against unhealthy lifestyle habits. 
 
Table 2. Suggested risk and protective factors for cognitive impairment and dementia. 
Non-modifiable 
risk factors 
Modifiable factors 
Risk factors Protective factors 
Advanced age Vascular and metabolic Psychosocial 
  Cerebrovascular disease (CBVD)/   High education 
Genetic Stroke Social network 
 Family history  Cardiovascular disease (CVD)  Cognitive stimulation 
 ApoE ε4  Diabetes Mellitus (DM)   
 Other novel genes:  Hypertension Nutrition and lifestyle 
 (listed at  Hypercholesterolemia  Mediterranean diet 
 www.alzgene.org)  Obesity  PUFAs (e.g. in vegetable and fish oils) 
    MUFAs (e.g. in olive oil) 
 Psychosocial  Antioxidants (e.g. vitamins C and E) 
  Low education  Vitamins B12, folate, B6 
  Loneliness  Coffee 
   Moderate alcohol/wine consumption 
 Nutrition and lifestyle  Physical activity 
  Saturated fatty acids (SFAs)   
  Homocysteine Other 
  High alcohol consumption  Anti-hypertensive drugs 
  Smoking  Statins 
   Hormone replacement therapy (HRT) 
 Other  Non-steroidal anti-inflammatory drugs  
  Psychological stress/ depression  (NSAIDs) 
  Traumatic brain injury (TBI)   
  Respiratory diseases   
  Inflammation   
Abbreviations: ApoE = Apolipoprotein E; MUFA = monounsaturated fatty acid; PUFA = 
polyunsaturated fatty acid. 
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In addition to research on individual risk/protective factors, integrated risk assessment 
tools have also started to be formulated for dementia/AD. Based on the results from the 
CAIDE study in Finland, a midlife risk score for predicting dementia risk 20 years later was 
proposed (Kivipelto et al., 2006). The CAIDE Dementia Risk Score includes several factors 
such as age, sex, education, systolic blood pressure (SBP), body mass index (BMI), 
cholesterol and level of leisure-time physical activity (PA). The risk of dementia increases as 
the score increases in a dose-response trend, making it possible to identify individuals who 
may benefit from preventive interventions. The CAIDE Dementia Risk Score has been used 
to select participants for the ongoing Finnish Geriatric Intervention Study to Prevent 
Cognitive Impairment and Disability (FINGER) trial (Kivipelto et al., 2013). 
2.2.1 Age 
Advanced age is the most obvious risk factor for dementia and AD; with ageing the risk of 
AD doubles approximately every 5 to 6 years (Ziegler-Graham et al., 2008). Among 60-64 
years old individuals, the prevalence of dementia is around 1%, but beyond the age of 65 
the prevalence of dementia/AD increases exponentially such that up to half of 95 year olds 
are affected (Fratiglioni et al., 1999; Lobo et al., 2000; World Alzheimer Report 2009, 
http://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf). The base case age-specific 
dementia percentages are 1.5% for individuals aged 65-69 years, 3% for 70-74, 6% for 75-79, 
13% for 80-84, 24% for 85-89, and 34% for 90-94 years (Fratiglioni and Rocca, 2001). 
2.2.2 Family history and genetic factors 
Another non-modifiable risk factor for AD is family history (Tanzi and Bertram, 2001; 
Bertram and Tanzi, 2005). A positive family history seems to be a consistent risk factor for 
AD, although the role of genetic risk factors seems to decrease with increasing onset age 
(Silverman et al., 2005; McMurtray et al., 2006), as opposed to the role of environmental risk 
factors. From a genetic standpoint, AD is a complex and heterogeneous disease, and 
appears to follow an age-related pattern (Bertram and Tanzi, 2005). 
2.2.2.1 Early-onset familial AD (EOFAD) 
Hereditary/familial AD is an early onset autosomal dominant disease with a very rare - 
below 0.1% - prevalence (Harvey et al., 2003), and it typically presents with onset ages 
younger than 65 years (Bertram and Tanzi, 2005). It is caused by mutations in the β-amyloid 
precursor protein (APP) gene on chromosome 21, presenilin-1 (PSEN1) gene on 
chromosome 14 and presenilin-2 (PSEN2) gene on chromosome 1 (Hardy, 1997; Bird, 2005; 
Goate, 2006). While these AD-causing mutations occur in 3 different genes located on 3 
different chromosomes, they all share a common biochemical pathway, i.e., the disturbed 
production of Aβ, which leads to a proportional overabundance of the Aβ42 species; this 
results eventually in neuronal cell death and dementia (Bertram and Tanzi, 2005). All 
individuals with Down syndrome carry an extra copy of chromosome 21 (codes APP) and 
usually develop AD by middle age (Mann and Esiri, 1989). 
2.2.2.2 Late-onset AD (LOAD) – the role of the Apolipoprotein E ε4 allele 
In contrast, the sporadic AD – predominant form of AD – is classically defined as AD with 
onset at age 65 years or older (Bertram and Tanzi, 2005). While this form of the disease has 
been shown to have a significant genetic background (Gatz et al., 2006), to date, only 1 
genetic susceptibility factor in sporadic and late-onset AD has been established, the ε4 allele 
of the apolipoprotein E (ApoE) gene on chromosome 19q13 (Bertram and Tanzi, 2005). The 
percentage of ApoE ε4 carriers is about 65-75% in sporadic AD cases, and may be up to 20% 
in all dementia cases (Crean et al., 2011), making it one of the most important risk factors 
for dementia and AD. 
ApoE is a glycoprotein of 299 amino acids with a molecular mass of ~34 kDa (Mahley 
and Rall, 2000). It is a major carrier of extracellular lipids and cholesterol in the central 
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nervous system (CNS) and an important component of plasma lipoproteins (de Chaves and 
Narayanaswami, 2008). The human ApoE gene, located on chromosome 19, has three 
different alleles (ε2, ε3, ε4), which are represented in the general population with 
frequencies of about 8%, 77% and 15%, respectively (Mahley and Rall, 2000; de Chaves and 
Narayanaswami, 2008). The frequencies may vary in different geographical areas and 
ethnic populations (Mahley and Rall, 2000; Schiele et al., 2000; Cedazo-Mínguez and 
Cowburn, 2001; Singh et al., 2006; Crean et al., 2011); e.g. the ε4 allele is more frequent in 
the Northern European countries (like Finland) than in Southern countries (Ehnholm et al., 
1986; Lehtimäki et al., 1990; Gerdes et al., 1992; Schiele et al., 2000; Crean et al., 2011). The 
possession of one ε4 allele increases the risk of AD from 2 to 3-fold, and having two ε4 
alleles has been associated with an up to 15-fold increase in the risk (Farrer et al., 1997). The 
ApoE ε4 allele represents a major susceptibility factor for AD across all ages between 40 
and 90 years, and in both men and women. However, carrying one or two copies of ε4 is 
neither necessary nor sufficient to actually cause AD (Tanzi and Bertram, 2005), but rather 
it has a major effect on lowering the age of onset of the disease (Meyer et al., 1998). ApoE’s 
influence, notably homozygosity for ε4, on the risk of AD is most evident primarily prior to 
age 70 years (Corder et al., 1993; Blacker et al., 1997; Silverman et al., 2005), whereas among 
the non-carriers of the ApoE ε4 allele the median age of AD onset is 84 years (Cedazo-
Mínguez, 2007). For the minor ApoE ε2 allele, a weak protective effect has been described 
in several studies (Bertram and Tanzi, 2005). 
2.2.2.3 Novel AD genes 
The four established AD genes (early-onset familial AD genes: APP, PSEN1, PSEN2, and 
late-onset AD risk factor: ApoE ε4) has been suggested to account for less than 30% of the 
genetic variance in age of onset for AD (Tanzi and Bertram, 2001). However, further studies 
with well-characterized families as well as unrelated patients and controls will be needed to 
identify the remaining approximate 70-80% of the unexplained genetic variants. Since the 
majority of AD occurs over the age of 70 years, it is important to search for additional genes 
involved in the development of AD beyond the age 70 (Blacker et al., 1997). 
There is currently a long list of genes that have been related to AD in many studies 
(http://www.alzgene.org). Remarkable progress has happened over the last four years (after 
2009), as large-scale genome-wide association studies (GWAS)  have replicated associations 
between LOAD and genes other than ApoE, including nine new genes ABCA7, BIN1, CD33, 
CD2AP, CLU, CR1, EPHA1, MS4A4A/MS4A4E/MS4A6E, and PICALM (Schellenberg and 
Montine, 2012; Barber, 2012). However, their role as risk factors for dementia/AD has not 
been clearly established due to the extensive variations in results between studies, and 
additional approaches will need to be applied to completely resolve AD genetics. 
Interestingly, some of the putative candidate genes are related to vascular factors, e.g. CYP46 
(cholesterol 24-hydroxylase), IDE (insulin-degrading enzyme) and ACE (angiotensin-
converting enzyme). 
2.2.3 Sex and ethnicity 
The role of sex is not entirely clear, but current studies suggest that women may be more 
susceptible than men to AD (Launer et al., 1999; Andersen et al., 1999; Fratiglioni et al., 
2000; Lobo et al., 2000; Di Carlo et al., 2002). 
Additionally, there might be ethnicity-related differences in suffering AD such that the 
prevalence of AD may be higher within African American and Hispanic populations as 
compared with Caucasians (Demirovic et al., 2003). It has been estimated that the 
prevalence of AD and other dementias among the > 65 years old African Americans is 
about twice and in Hispanics about 1.5 times greater than the rate among elderly whites 
(Alzheimer’s Association, 2012). 
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2.2.4 Vascular factors and conditions 
Findings from several prospective cohort studies have indicated that hypertension (Launer 
et al., 2000; Kivipelto et al., 2001b; Kivipelto et al., 2002; Whitmer et al., 2005), 
hypercholesterolaemia/dyslipidaemia (Notkola et al., 1998; Kivipelto et al., 2001a; Kivipelto 
et al., 2002; Whitmer et al., 2005; Solomon et al., 2009), and type 2 diabetes mellitus (DM) 
(Whitmer et al., 2005) at midlife are highly and independently associated with an increased 
risk of late-life dementia and AD. Furthermore, an association has been detected between 
midlife overweight (BMI 25-30kg/m2) (Whitmer et al., 2007; Hassing et al., 2009; Xu et al., 
2011), obesity (BMI >30kg/m2) (Kivipelto et al., 2005; Whitmer et al., 2007; Beydoun et al., 
2008a; Xu et al., 2011), central obesity (Whitmer et al., 2008; Beydoun et al., 2008a; Gustafson 
et al., 2009) or weight changes (Beydoun et al., 2008a) and the increased risk for dementia 
and AD. 
Recently, it has been also claimed that the presence of multiple cardiovascular risk 
factors at midlife substantially increases the risk of late-life dementia in a dose dependent 
manner (Whitmer et al., 2005; Kivipelto et al., 2005; Kivipelto et al., 2006). Furthermore, an 
aetiological cluster of several cardiovascular disorders, the metabolic syndrome (MetS), 
which contains the components of obesity in general and central obesity, hypertension, 
dyslipidaemia, and type 2 DM, has been linked with an increased risk of dementia (Kalmijn 
et al., 2000) or AD (Vanhanen et al., 2006) or in the progression from MCI to dementia 
(Solfrizzi et al., 2011b). 
In contrast to midlife, the role of vascular factors at older ages in relation to the risk of 
cognitive impairment and dementia is less clear. Epidemiological studies with shorter 
follow-up times and with older populations have produced conflicting results, finding 
either no associations or even showing factors such as elevated blood pressure (Ruitenberg 
et al., 2001), high total cholesterol levels (Mielke et al., 2005; Reitz et al., 2010) or high BMI 
(Dahl et al., 2008) as “protective”. Risk profiles predicting the subsequent development of 
dementia also seem to be different between midlife (Kivipelto et al., 2006) and late-life 
(Barnes et al., 2009). Diseases leading to dementia usually have a long preclinical phase, 
and the current diagnostic criteria identify the symptoms only at a late stage. Thus it is 
difficult to distinguish between true risk relations and reverse causality at older ages. 
Several longitudinal population-based studies have reported a pattern of decline over time 
in blood pressure (BP), BMI and total plasma cholesterol in those individuals who 
subsequently develop cognitive impairment or dementia (Qiu et al., 2010). Another 
contributor to the conflicting findings is survival bias, e.g. people who are at the highest 
risk, may die at younger ages. 
Several cerebrovascular and cardiovascular conditions have also been related to 
dementia/AD, such as clinical stroke and asymptomatic CBVD (Qiu et al., 2010), atrial 
fibrillation (Ott et al., 1997; Bunch et al., 2010), heart failure, intracranial atherosclerosis 
(Dolan et al., 2010; Roher et al., 2011), and extensive peripheral atherosclerosis (Qiu et al., 
2010). 
2.3 NUTRITION: DIETARY ASSESSMENT AND RECOMMENDATIONS 
2.3.1 Dietary assessment 
Dietary assessment has become increasingly important in clinical trials and epidemiological 
studies. At the individual level, several methods can be used; the most common are 
presented in Table 3. When selecting a method, at least the target group, purpose of the 
study and available resources (e.g. skilled personnel, computer facilities, and finances) have 
to be taken into consideration (van Staveren et al., 1994). Briefly, the methods can be 
divided into two categories: record (prospective) and recall (retrospective) methods (Shils 
et al., 1998; Kroes et al., 2002). 
Record methods, such as food record or food diary, collect information on current intake 
over one or more days (usually 1-7 days) (Kroes et al., 2002). In a precise weighed food 
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record, the weights of all ingredients used in the preparation of the meals, uneaten waste, 
the total cooked weight of meal items, the cooked weight of the individual portion and 
plate waste are noted down. Other recording methods include telephone interviews, 
duplicate portion collection and analysis, and direct observation by either video recording 
or trained observers (Shils et al., 1998). As for recall methods, they reflect immediate past 
consumption, varying from intake over the previous day (24-hour recall) to usual food 
intake (dietary history or food frequency questionnaire, FFQ); the food quantities are 
usually assessed with household measures, food models, or photographs, and either in 
person or a telephone interview can be used (Kroes et al., 2002). A FFQ - qualitative, semi-
quantitative or completely quantitative - is a retrospective review of habitual (i.e. daily, 
weekly, monthly or yearly) intake frequency of food groups. All the methods require to be 
accompanied by specific data processing software to calculate the food and nutrient 
intakes, as well as by up-to-date food composition databases. 
 
 
Table 3. Some advantages and disadvantages of the main dietary assessment methods. 
Method Advantages  Disadvantages 
Record methods – current intake 
Food record 
or diary 
- Daily recording at the time of food 
consumption 
- Can provide recorded information on 
quantity of food, how food is 
prepared, and timing of meals/ snacks 
- Requires literacy skills of participants 
- Requires ability to measure/judge portion size; 
underreporting is common 
- Food intake may be altered 
- Sex differences exist (women more competent) 
- High costs of coding and analysis 
Recall methods – past consumption 
24-hour 
recall 
- Quick 
- Easy 
- Inexpensive 
- Useful in clinical settings 
- Good reliability between interviewers 
- Relies on the short-term memory; in the elderly 
often unreliable. 
- May not represent usual intake nor reflect 
nutrient intakes for populations 
- A tendency to over- and underreport 
- Selective forgetting (e.g. fat and alcohol)  
- Requires interviewing skills and comprehensive 
training of the interviewers 
Food 
frequency 
questionnaire 
- Easily standardized 
- Good overall picture of food intake; 
consists usually of 50-150 food items 
- Suitable for large populations 
- Inexpensive 
- Useful in studying the association of 
a specific food/foods and disease 
- Requires literacy skills 
- Requires knowledge of portion sizes 
- No meal pattern data, day-to-day variation, 
longer-term periods of intake, nor quantity-
estimation of specific nutrients 
- Researcher has to know well the current diet 
before being able to develop an appropriate 
questionnaire 
Dietary 
history 
- Good description of usual intake 
- Good for longitudinal studies 
- Observes seasonal variations 
- Difficult to standardize 
- Time-consuming (1-2 h) 
- High costs of analysis 
 
According to: van Staveren et al., 1994; Shils et al., 1998; Kroes et al., 2002; Mahan et al., 
2008. 
 
Even though there are many methods with which to assess dietary intake, none of them 
is perfect, e.g. underreporting of amount and frequency of food intake is considerable in 24-
h recalls (Shils et al., 1998). Sometimes a combination of two or more methods can provide 
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greater accuracy by counterbalancing the shortcomings of one method with the strengths of 
another (Kroes et al., 2002), and with several 24-h recalls the information about usual 
dietary intake can be improved to the level of semi-quantitative FFQs (Shils et al., 1998). 
Lately, promising advances in technology have made possible more sophicated techniques 
for recording dietary intake. Technology-based methods such as computers, web-based 
applications, modified palm and phone devices, may have exciting new possibilities for 
dietary assessment (Long et al., 2010). These techniques may reduce problems with literacy 
and with the burden of recording what has been consumed, but are more expensive than 
pen and paper methods and require knowledge and competence with the method used. 
In addition to dietary data collection with record or recall methods, one can use 
biochemical assessments based on blood or tissue concentrations of various compounds in 
foods e.g. these can be used for estimating alcohol consumption (due to tendency to 
underreport), intake of folic acid (due to instability), and the intake of nutrients the long-
term intakes of which are of particular interest, such as fatty acids (FAs), vitamin E and β-
carotene (Buzzard and Sievert, 1994). For example, n-3 polyunsaturated fatty acids (PUFAs) 
can be measured in adipose tissue, erythrocytes, plasma or serum, of which adipose tissue 
measurement is generally considered as the best way of assessing long-term FA intake, 
erythrocytes can provide an indication of the previous 120-d intake, and plasma FA assess 
consumption over the past few days or more (Øverby et al., 2009). Alternative biochemical - 
not necessarily specific to total fat intake - intake-sensitive indicators are fasting plasma 
triglyceride (TG) and plasma high-density lipoprotein (HDL) cholesterol levels, especially 
when overweight persons are included in the study (Willett et al., 2001). TG levels appear 
to be more sensitive than HDL-cholesterol; TG levels can be reduced by higher dietary fat 
(except trans-FAs [TFAs]) intake, whereas HDL-cholesterol levels will be elevated. 
However on the whole, a combination of dietary, biochemical, clinical, and anthropometric 
methods can be regarded as the “gold standard” in estimating individual nutritional status 
and for developing international dietary approaches (Shils et al., 1998). 
2.3.2 Nutrition recommendations in the Nordic Countries 
The Nordic countries have collaborated for several decades in setting guidelines for dietary 
composition and recommended intakes of nutrients for the general population. The Nordic 
Nutrition Recommendations are the main reference point for the various national nutrition 
recommendations in the Nordic countries; the current 5th edition of the NNRs (Nordic 
Council of Ministers, 2013) emphasizes the role of DPs and food groups that could 
contribute to the prevention of the major diet-related chronic diseases. The national Finnish 
Nutrion Recommendations (National Nutrition Council, 2014) mainly comply with the 
NNRs, while still taking into account Finns’ health and national culinary preferences; the 
goal is to improve the diet of the Finnish people and to benefit public health. 
Accorging to the current NNRs 2012 (Nordic Council of Ministers, 2013), the total fat 
intake should be 25-40 energy % (E%). It is also recommended that at a minimum 2/3 of the 
total FAs (expressed as triglycerides) should come from Cis-monounsaturated fatty acids 
(MUFAs) and cis-PUFAs: Cis-MUFAs should contribute 10-20E% and cis-PUFAs (sum of n-
6 and n-3) 5-10E%, including at least 1E% from n-3 FAs. The intake of saturated fatty acids 
(SFAs) plus TFAs should be reduced to a maximum of 1/3 of the total fat intake: the intake 
of SFAs should be <10E% and the intake of TFAs as low as possible. The recommended 
intake (RI) for total carbohydrate is 45-60E% (<10 E% added sugars) and for proteins 10-
20E% (≥65 years 15-20E%). RI for dietary fibre is at least 25-35g/day (>3g/MJ) from foods 
naturally rich in dietary fibre foods such as wholegrain, fruit and berries, vegetables and 
pulses. The consumption of alcohol should not exceed 5E% (~10g alcohol/day in women, 
~20g alcohol/day in men). The salt intake should be limited; the population target is 6g/day 
for adults. The RIs for the most essential micronutrients (i.e. vitamins and minerals) - 
expressed as average daily intakes over time - can be seen at the NNRs 2012 (Nordic 
Council of Ministers, 2013). The RI of vitamin D for children >2 years and adults is 
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10μg/day, for the elderly (≥75 years) it is more, 20μg/day. In general, the nutrient 
requirements can be met with a varied and balanced diet and using dietary supplements 
cannot be justified as a tool for adjusting an unbalanced diet, even though this might be 
needed by certain population groups or during certain life-stages. 
2.3.3 Finnish nutrition recommendations 
The new Finnish Nutrition Recommendations resemble closely the NNRs; an update-
process has recently being finalized (National Nutrition Council, 2014). The new 
recommendations emphasize that the share of fat in the daily energy intake should be 
raised (in the form of unsaturated fats), while the intake of carbohydrates should be slightly 
lowered, with a recommendation to obtain most carbohydrates from fiber rich foods. The 
recommended salt intake is a little lower, at no more than 5g/day, compared to 6g/day in 
the Nordic recommendations. The reduced consumption of red meats (beef, pork and 
lamb), processed meats and food containing a lot of SFAs is highly recommended. For the 
adults, the recommended daily intake for different vitamins is as follows: vitamin C 75mg, 
vitamin E 8/10mg in women[w]/in men[m], folate 300μg (400μg for women between 18 and 
30 years), vitamin B12 2μg, vitamin D 10μg (20μg after age 60 years), and vitamin A 
700/900μg (w/m). For essential minerals, the recommended daily intake is: magnesium 
280/350mg (w/m), potassium 3.1/3.5g (w/m), selenium 50/60μg (w/m), copper 0.9mg, zinc 
7/9mg (w/m), and calcium 800mg. 
These nutritional goals can be achieved in different ways e.g. choosing low-fat poultry 
and meat (≤4%), as well as low-fat (≤12%) and low-salt (≤1.5%) cold cuts, low-fat (≤ 1 %) 
milk and dairy (at least 500 ml/day) and 2-3 slices of low-fat and low-salt cheese daily; 
using vegetable oils and margarines instead of butter; consuming fish at least twice a week; 
consuming 5-6 portions of vegetables, fruits and berries daily (being equivalent to about 
500 grams/day [potato is not included]); consuming whole-grain products rich in fiber as 
part of all daily meals; using sugar sparingly; following regular frequency of meals; and 
keeping the daily alcohol consumption moderate, maximum 20 g/day (~2 alcohol units) in 
men and 10 g/day (~1 alcohol unit) in women. One alcohol unit is defined as 12 g of alcohol 
corresponding to the alcohol content in one bottle of beer (330 ml), one glass of wine (120 
ml) or one glass of spirits (40 ml). 
2.3.4 Current food consumption in Finland 
In Finland, the proportion of total fat in the diet has increased since 2007, being now 35E% 
in women and 36E% in men (Paturi et al., 2008; Raulio et al., 2013). The intake of SFA has 
constantly been more than recommended, and has even started to increase; the intake of 
SFA was 13.1-14E% in 2007 and 14.9-15.1E% in 2012 (women and men, respectively). In 
contrast, the intake of carbohydrates has decreased substantially (from 50.2 to 43.9E% in 
women and from 47.1 to 42.2E% in men), even though intake of sugar has remained at the 
same level (current intake of 10.0E% in women and 9.2E% in men). The smaller proportion 
of carbohydrates comes nowadays from bread and potato, and more from milk products. 
The intake of fiber was less than recommended among persons of working age (21g/day in 
women, 22g/day in men), but at the recommended level among the elderly when related to 
total energy intake (EI). Total EI from protein and alcohol were at the recommended level 
in both sexes, whereas the intake of salt has increased and is more than recommended 
(change from 6 to 6.5g/day in women, and from 8 to 8.9g/day in men). The intake of 
vitamins and essential minerals mainly meets the recommended levels; only the intakes of 
iron and folate among 25-64 years women, and intake of vitamin D among elderly women 
not using supplements were less than recommended. The whole report of the National 
FINDIET 2012 -survey has been available since December 2013 (Helldán et al., 2013). 
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2.4 COGNITIVE IMPAIRMENT: DIETARY RISK AND PROTECTIVE 
FACTORS 
2.4.1 Dietary lipids 
Dietary fats are a major source of energy (9 kcal/g) for the body (Otten et al., 2006; Mahan et 
al., 2008). Dietary fats are also essential for the digestion, absorption, and transport of the 
fat-soluble vitamins (A, D, E, and K) and phytochemicals such as carotenoids and 
lycopenes. Additionally, FAs function in cell signaling and alter the expression of specific 
genes involved in lipid and carbohydrate metabolism, and they may also serve as 
precursors or ligands for receptors that are important regulators of adipogenesis, 
inflammation, insulin action, and neurological function. 
Dietary lipids are mainly (~98%) in the form of triglycerides (glycerol esterified with 
three FA molecules), and the rest are in the form of phospholipids and sterols such as 
cholesterol (Otten et al., 2006; Mahan et al., 2008). FAs are rarely free in nature and almost 
always are linked to other molecules through their hydrophilic carboxylic acid head group 
(Mahan et al., 2008). FAs are classified according to the number of carbons, as well as the 
number and the position of the double bonds in the chain. Chain length and extent of 
saturation contribute to the melting temperature of a fat; in general, saturated fats are solid 
at the room temperature. Short-chain FAs contain 4-6, medium-chain FAs 8-14, and long-
chain FAs ≥16-20 carbons. In a SFA, all of the carbon binding sites not linked to another 
carbon are linked to hydrogen and are therefore saturated. There are no double bonds 
between carbons. Cis (hydrogen atoms are on the same side of the double bond) MUFAs 
contain only one double bond, and cis PUFAs at least two double bonds. TFAs are the 
common name for unsaturated FAs with the configuration of one hydrogen atom on 
opposite sides of the double bond. Only small amounts of fats are digested in the mouth 
with lingual lipase and in the stomach by gastric lipase, whereas fat digestion mostly takes 
place in the small intestine through pancreatic lipase (Mahan et al., 2008; Crupi et al., 2013). 
Short- and medium-chain FAs are absorbed via capillaries in the intestine directly into the 
blood, whereas longer-chain FAs are absorbed into enterocytes, which then re-esterify the 
free FAs. PUFAs include n-6 and n-3 FAs (n has been used in omega notation to refer to the 
placement of the first double bond counting from the methyl end; an alternative notation is 
ω), which humans cannot synthesize (Mahan et al., 2008). However, humans can synthesize 
linoleic acid (LA, 18:2n-6) to arachidonic acid (AA, 20:4n-6) and α-linolenic acid (18:3n-3) to 
eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) through a 
progressive series of desaturation and elongation steps occurring in the liver. Even though, 
most of these long-chain PUFAs must be obtained directly from diet, since the conversion 
of short-chain n-3 FAs to the long-chain forms (DHA) is quite inefficient (<5%) in humans 
(Crupi et al., 2013). 
The food sources of SFAs tend to be animal-based foods, including whole milk, cream, 
butter, cheese, and fatty meats (Otten et al., 2006; http://www.fineli.fi). MUFAs are found in 
high amounts in canola/rapeseed oil, olive oil, high-oleic sunflower oil, high-oleic safflower 
oil, and animal products (proving about 50% of dietary MUFAs), primarily meat fat. Foods 
rich in n-6 PUFAs include nuts, seeds, and vegetable oils, such as sunflower, safflower, 
corn, and soybean oils (Otten et al., 2006; http://www.fineli.fi). N-3 PUFAs are found in fish 
and in vegetable oils, such as flaxseed, canola/rapeseed, and soybean oils. EPA and DHA 
are present mainly in fish and seafood but also in other animal foods, such as meat and 
eggs (Meyer et al., 2003). With respect to the fish types, dark-meat fish (e.g. salmon, 
mackerel, sardine, herring, trout, and tuna) contains higher DHA and EPA (0.2-1.8 g) per 
serving than light-meat fish (e.g. cod, and haddock; 0.1-0.2 g) or shellfish (e.g. lobster, 
scallop, and shrimp; 0.1-0.4 g) (Kris-Etherton et al., 2002). The present n-6/n-3 ratio in 
Western diets is approximately 15-20:1, while the optimal ratio has been estimated to be 2:1-
4:1 (Crupi et al., 2013). The minimum need of essential FAs (LA and α-linolenic acid) is 3 
E%, of which at least 0.5 E% should be n-3 FAs (Nordic Council of Ministers, 2013; National 
15 
 
 
Nutrition Council, 2014). TFAs are found in foods such as margarines and vegetable 
shortenings subjected to partial hydrogenation (i.e. artificial addition of hydrogen atoms to 
unsaturated oils to form a stable, solid fat) and different bakery products and fried foods 
prepared using partially hydrogenated oils (Otten et al., 2006; Mahan et al., 2008). In 
addition, milk, butter and meats contain TFAs, but at lower levels. Margarines, baking 
shortenings, and frying fats have traditionally contained up to 40-50% TFA, whereas 
ruminant fats contain 1-8% TFA (Craig-Schmidt, 2006). The predominant trans isomer in 
ruminant fats is vaccenic acid (C18:1n11t) in contrast to the commercially hydrogenated 
vegetable fat in which the predominant isomers are elaidic acid (C18:1n-9t) and C18:1n10t. 
Cholesterol has an important role in steroid hormone and bile acid biosynthesis, and it is 
also an essential component of cell membranes (Otten et al., 2006). All tissues can 
synthesize enough cholesterol to meet their structural and metabolic needs. There is thus no 
evidence for a biological requirement for dietary cholesterol. Although no Estimate 
Average Requirement (EAR), Recommended Dietary Allowance (RDA), or Adequate 
Intake (AI) has been set for cholesterol, it is generally recommended that people maintain 
their dietary cholesterol intake as low as possible, while having a diet that is adequate in all 
of the required nutrients. There are large amounts of cholesterol in egg yolk, roe, and liver 
as well as in some other foods (http://www.fineli.fi). 
According to the diet–heart paradigm, consumption of SFA raises total cholesterol and 
low-density lipoprotein (LDL) cholesterol levels, increasing the risk of coronary heart 
disease (CHD). In contrast, PUFAs, and in particular vegetable oils, can reduce the risk of 
CHD (i.e. American Heart Association, http://www.heart.org). Moreover, clinical and 
epidemiological studies suggest that a higher intake of TFAs can be associated with an 
increased risk of CHD, cancer, and other chronic diseases (including type 2 DM and 
allergies) (Mahan et al., 2008). 
The relationships between dietary fats and blood lipid levels are not straightforward. For 
example, there is heterogeneity in circulating lipid concentrations in response to dietary 
PUFAs, and genetic factors may partly explain this phenomenon (Fontaine-Bisson et al., 
2007). An increase of 100 mg/day of dietary cholesterol has been predicted to result in a 
0.05-0.1 mmol/l increase in total serum cholesterol, of which about 80% is in the LDL-
cholesterol form (Otten et al., 2006). However, cholesterol absorption status is an important 
factor determining the responsiveness to dietary changes. In a recent study investigating 
the effects of a shift from a Western-type diet to a combined low-fat, low-
cholesterol/Mediterranean-type diet, a significant lowering of LDL-cholesterol was seen 
only in those participants with a low cholesterol absorption status (Wolff et al., 2011). The 
synthesis/absorption balance for cholesterol was postulated to be an intrinsic trait of the 
participants, and was not noticeably altered by the change in the diet. 
2.4.1.1 Fatty acids and cognition 
The long-term effects of dietary FAs for cognitive functions have been studied with 
somewhat varying results. Some studies have defined cognitive status with the focus on 
cognitive decline or MCI, while others have focused on evaluating the role of dietary fats 
on the level of cognitive performance in the non-demented or cognitively normal 
population. The main longitudinal population-based studies investigating the association 
between dietary fat intake and cognition are presented in Table 4. Most of the studies that 
have assessed changes in cognition prospectively have generally had short follow-up times, 
from 1.5 to 8.5 years, and only few studies completed recently have had follow-up times 
more than 10 years. Additionally, six studies have consisted of women only and three 
studies of men exclusively, thus generalization of the results to the whole population 
including both sexes needs to be done with caution. 
Dietary SFAs and/or trans-unsaturated FAs have been reported as risk factors for a 
cognitive decline in some (Morris et al., 2004; Devore et al., 2009a, Okereke et al., 2012), but 
not in all studies (Naqvi et al., 2011). It has been also proposed that a diet including high 
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amounts of copper, SFA and TFA could be related to a faster rate of cognitive decline 
(Morris et al., 2006a). However, also conflicting results exist at least for animal fats possibly 
due to small amounts of SFA consumed daily (Vercambre et al., 2009). Dietary cholesterol 
intake has not been associated with cognitive change in longitudinal studies (Morris et al., 
2004). In contrast, high MUFA intake has been associated with better cognitive performance 
or less cognitive decline in several studies (Morris et al., 2004; Solfrizzi et al., 2006a; Devore 
et al., 2009a; Vercambre et al., 2010; Naqvi et al., 2011; Okereke et al., 2012). Furthermore, a 
high PUFA intake has been reported to have beneficial effects on cognitive function in some 
(Solfrizzi et al., 2006a; Vercambre et al., 2010), but not in all studies (Solfrizzi et al., 2006b; 
Roberts et al., 2010a, Okereke et al., 2012), and even some opposite results exist, especially 
for n-6 PUFA (mainly linoleic acid) containing seed oils (Psaltopoulou et al., 2008). 
So far, epidemiological evidence, although inconclusive (Kalmijn et al., 1997a; Morris et 
al., 2005a; van de Rest et al., 2009; Roberts et al., 2010a), does point to a protective effect of 
dietary n-3 PUFA intake against poor cognition (van Gelder et al., 2007a; Beydoun et al., 
2008b; Vercambre et al., 2009; Kesse-Guyot et al,. 2011). Pure fish consumption has been 
associated positively with cognition in four studies (Morris et al., 2005a; van Gelder et al., 
2007a; Vercambre et al., 2009; Kim et al., 2013), two found borderline significant results 
(Kalmijn et al., 1997a; Kesse-Guyot et al., 2011), whereas the other three found no 
associations (Psaltopoulou et al., 2008; van de Rest et al., 2009; Gao et al., 2011). It has been 
also proposed that the benefits of seafood may depend on the type of seafood: it has been 
shown that consumption of tuna and dark-meat finfish at least once/week is related to 
better performance on verbal memory, whereas consumption of light-meat finfish or 
shellfish displayed no associations with cognition (Kim et al., 2013). Additionally, high 
dietary PUFA-SFA (Morris et al., 2004; Devore et al., 2009a) and n-3 to n-6 FA ratios 
(Beydoun et al., 2008b; Vercambre et al., 2009) have been related to smaller cognitive 
decline. Moreover, daily supplemental intake of n-3 PUFAs has been associated with a 
lower risk of cognitive decline in the Singapore Longitudinal Aging Studies (SLAS) among 
1475 Chinese ≥55 year old adults during a 1.5-year follow-up (Gao et al., 2011). 
In addition, dietary information assessed with food frequency questionnaires (FFQs), a 
few long-term follow-up studies have investigated FA levels by blood analyses i.e. studied 
the association between plasma and erythrocyte FA composition with cognition. In these 
prospective studies, higher levels of plasma and erythrocyte n-3 FAs have been related to a 
lessened decline in the speed-related (sensorimotor and complex speed) cognitive domains 
in the FACIT trial over 3 years (Dullemeijer et al., 2007), with a reduced risk of cognitive 
decline in the Etude du Vieillissement Artériel (EVA) study within 4 years (Heude et al., 
2003) or a decline in verbal fluency in the Atherosclerosis Risk in Communities (ARIC) 
study during a 6-year follow-up among hypertensive (Beydoun et al., 2008b) as well as 
dyslipidemic subjects (Beydoun et al., 2007). In the Three-City (3C) Study, higher plasma 
levels of EPA, but not DHA, was associated with lower gray matter atrophy of the right 
hippocampal/parahippocampal area and of the right amygdala; the latter being further 
related to smaller 4-year decline in semantic memory performances (Samieri et al., 2012). In 
the Birth cohort study from Scotland, cognitive benefits of high erythrocyte n-3 PUFA levels 
were seen only among the ApoE ε4 allele non-carriers (Whalley et al., 2008). However, in 
the Women’s Health Initiative Study of Cognitive Aging (WHISCA) over a median follow-
up of 5.9 years, no association was detected between red blood cell DHA + EPA levels and 
cognitive decline (Ammann et al., 2013). Furthermore, higher proportions of both stearic 
acid (a type of SFA, 18:0) and total n-6 PUFAs, and smaller ratios of n-3 to n-6 FAs and 
DHA to arachidonic acid (AA) have been associated with a greater risk of cognitive decline 
(Heude et al., 2003). Surprisingly, also a higher EPA concentration has been related to 
cognitive impairment in the Canadian Study of Health and Aging (CSHA) during a 5-year 
follow-up (Laurin et al., 2003). Moreover, greater palmitic acid (SFA) and AA (n-6 PUFA) 
concentrations and a lower amount of linoleic acid (n-6 PUFA) may increase the risk of a 
global cognitive decline (Beydoun et al., 2007). 
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2.4.1.2 Fatty acids and dementia/AD 
Table 5 provides information about the main longitudinal population-based studies having 
investigated the association between dietary fat intake and dementia/AD risk. Total fat 
intake has been reported as a risk factor for dementia/AD (Kalmijn et al., 1997b), especially 
among the ApoE ε4 allele carriers (Luchsinger et al., 2002), but also inconsistent results exist 
(Engelhart et al., 2002a; Morris et al., 2003a). Intakes of SFA and/or trans-FAs have been 
linked also to an increased risk of dementia/AD (Morris et al., 2003a), or there has been a 
tendency towards a higher risk for dementia/AD in some (Kalmijn et al., 1997b), but not in 
all studies (Engelhart et al., 2002a). Cholesterol intake has shown a tendency to increase the 
risk of dementia in one study (Kalmijn et al., 1997b), whereas the other two found no such 
association (Engelhart et al., 2002a; Morris et al., 2003a). 
In contrast, consumption of unsaturated fats like vegetable fats, MUFAs or n-6 PUFAs or 
high PUFA-SFA ratio (Morris et al., 2003a), or high total n-3 PUFA and DHA intake (Morris 
et al., 2003b) may decrease the risk of dementia/AD, although there is still doubt on this 
presumption (Engelhart et al., 2002a; Barberger-Gateau et al., 2007; Devore et al., 2009b); 
EPA intake has not been associated with dementia/AD (Morris et al., 2003b; Devore et al., 
2009b). Fish consumption has been associated in several prospective cohort studies with a 
reduced risk of dementia/AD (Kalmijn et al., 1997b), when consumed at least once a week 
(Barberger-Gateau et al., 2002; Morris et al., 2003b; Barberger-Gateau et al., 2007) or more 
than twice a week (Huang et al., 2005; Schaefer et al., 2006), even though also here some 
inconsistent results exist (Devore et al., 2009b). It has been also reported that this positive 
effect of fish may be more pronounced among the ApoE ε4 allele non-carriers (Huang et al., 
2005; Barberger-Gateau et al., 2007). Intakes of animal fat (Morris et al., 2003a) or meat 
(Barberger-Gateau et al., 2002; Barberger-Gateau et al., 2007) have shown no association 
with dementia/AD. 
Additionally, several long-term follow-up studies have investigated the association of 
FA levels measured with blood analyses to the risk of dementia/AD. In these prospective 
studies, a high plasma/serum DHA level has been related to a reduced risk of dementia/AD 
in the Framingham Heart Study over 9.1 years (Schaefer et al., 2006) and in the study of 
elderly American subjects during a 10-year follow-up (Kyle et al., 1999), but also 
inconsistent (Samieri et al., 2008, Kröger et al., 2009) and even a tendency towards reverse 
(Laurin et al., 2003) results exist. Furthermore, a high plasma EPA concentration has been 
associated with a decreased risk of dementia in the Three-City Study with a 4-year follow-
up (Samieri et al., 2008), but the other studies have found no association (Kyle et al., 1999; 
Schaefer et al., 2006, Kröger et al., 2009). Surprisingly, the high serum SFA level has also 
been associated with a decreased risk of AD in the Uppsala Longitudinal Study of Adult 
Men (ULSAM) over 35 years follow-up, whereas n-3 FAs showed no associations with 
dementia/AD (Rönnemaa et al., 2012). In contrast, high plasma n-6 to n-3 ratio and high AA 
to DHA ratio (Samieri et al., 2008) have been associated with an increased risk of dementia. 
However, the results concerning plasma total n-3 FAs have so far been unclear (Samieri et 
al., 2008; Kröger et al., 2009) or even confusing so that high plasma concentration of total n-
3 FAs could increase the risk of dementia (Laurin et al., 2003). 
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2.4.1.3 Supplementation with fatty acids and randomized controlled trials 
There have been several double-blind randomized controlled trials (RCTs) investigating the 
effects of n-3 FA supplements to cognitive endpoints in elderly persons (healthy/at increased 
vascular risk), but so far, they have shown inconsistent results. One RCT from the 
Netherlands involving 302 cognitively healthy individuals receiving either 1800 mg/d or 
400 mg/d EPA-DHA or placebo (sunflower oil containing mainly oleic acid, C18:1n-9) 
capsules for 26 weeks, found no overall effect of EPA and DHA supplementation on 
cognitive performance (van de Rest et al., 2008). In the Older People And n-3 Long-chain 
PUFAs (OPAL) RCT from the United Kingdom (n = 867) subjects assigned either to daily 
capsules of fish-oil providing 200mg EPA plus 500mg DHA or to placebo (olive oil rich in 
n-9 FAs) for 2 years also did not display any change in cognitive function (Dangour et al., 
2010a). In the SUpplementation with FOLate, vitamins B-6 and B-12 and/or OMega-3 FAs 
(SU.FOL.OM3) RCT conducted in France examined 1748 subjects with a history of MI, 
unstable angina, or ischemic stroke likewise found no significant main effects of EPA and 
DHA (600 mg) in a 2:1 ratio on cognitive function within 4 years (Andreeva et al., 2011). 
Conversely, one small American RCT involving 49 women randomized to receiving either 
DHA (800 mg/d), lutein (a common dietary carotenoid, 12 mg/d), a combination of DHA 
and lutein or placebo for 4 months, found that verbal fluency was improved in the DHA, 
lutein, and the combined treatment groups, and additionally in the combined treatment 
group, subjects’ memory scores and rate of learning were improved (Johnson et al., 2008). 
In the PREDIMED-NAVARRA RCT (n=268, at high vascular risk) an extra-virgin olive oil 
(EVOO)-rich MedDiet resulted in a better cognitive function (especially across fluency and 
memory tasks) and also MCI was less common in comparison with a control low-fat diet, 
whereas participants assigned to MedDiet+Nuts did not differ from controls after 6.5 years 
(Martínez-Lapiscina et al., 2013). Additionally, a randomized cross-over study from 
Sweden (n=38) found that daily supplementation of n-3 PUFA from fish oil (1000 mg fish 
oil, of which 600 mg was n-3 PUFA [EPA 300 mg, DHA 210 mg and 90 mg unspecified]) 
compared to non-oil based placebo over five weeks significantly improved cognitive 
functions (working memory capacity) in healthy subjects (Nilsson et al., 2012). 
Furthermore, a large (n = 1200) multidomain trial for primary prevention of cognitive 
decline in the elderly including exercise, nutrition, psychological counselling and 800mg 
DHA/d over 3 years is ongoing in France (Cole et al., 2010), and the results will become 
available in the near future. 
Further, several double-blind RCTs have been done in cognitively impaired or demented 
persons to clarify whether supplements can slow the rate of impairment. A 24-week RCT 
conducted at 19 clinical sites in the USA among 485 healthy subjects with mild memory 
complaints found that daily supplementation with 900 mg DHA improved learning and 
episodic memory function compared with placebo (50% corn oil and 50% soy oil), but did 
not achieve any changes in working memory or executive function (Yurko-Mauro et al., 
2010). One RCT (n=100) found that AD patients who took a preparation of essential FAs for 
4 weeks improved their short-term memory as compared with patients who consumed 
placebo (Yehuda et al., 1996). Additionally, OmegAD study consisting of 174 AD patients 
(whose conditions were stable while receiving acetylcholine esterase inhibitor treatment 
and who had a MMSE score of ≥15 points) obtained positive effects from 6 months’ 
supplementation with 1.7 g of DHA/d and 0.6 g of EPA/d on delayed word recall and 
attention, but only in individuals with very mild AD (MMSE >27 points and CDR of 0.5-1, 
n=32) (Freund-Levi et al., 2006). In a multi-country, multi-center RCT, the Souvenir I study 
(n=199), consumption of “medical food, Souvenaid” consisting of several different 
nutrients, including n-3 FAs (EPA and DHA), choline, and vitamins E, C and B12, improved 
memory performance as measured by delayed verbal recall testing among mild AD 
patients after 12 weeks (Scheltens et al., 2010). Recently, this finding has been confirmed 
and extended in the 24-week Souvenir II study (n=258), which used a defined 
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Neuropsychological Test Battery (NTB) memory domain composite score (from five 
neuropsychological memory tasks) (Scheltens et al., 2012). Furthermore the recent 6-month 
RCT from Australia found that verbal fluency was improved in the DHA supplemented 
group (1.55 g DHA + 0.40 g EPA/d; n=18) compared with the placebo group (n=15) in 
subjects with MCI (Sinn et al., 2012). Similarly, fish oil supplementation (1.3g DHA + 0.45g 
EPA/d; n=17) was related to improvement in memory function (particularly short-term and 
working memory, immediate verbal memory and delayed recall capability) compared with 
the placebo group (n=18) in a 12-month RCT from Malaysia among elderly people with 
MCI (Lee et al., 2013). Additionally, in a 12-weeks RCT from Italy conducted in elderly 
people with MCI, a significant improvement in the MMSE score and a positive trend in the 
semantic verbal fluency were seen among the combination-supplemented group (720mg 
DHA + 286mg EPA + 16mg vitamin E + 160mg soy phospholipids + 95mg tryptophan + 5mg 
melatonin; n=11) vs. the placebo group (n=14) (Rondanelli et al., 2012). In a 15-week RCT 
originating from Israel in non-demented elderly with memory complaints, verbal 
immediate recall was also significantly improved in the phosphatidylserine (PS)-DHA 
group (300mg PS and 79mg EPA+DHA, n=60) compared to the placebo group (n=62) 
(Vakhapova et al., 2010). Although these RCTs above have shown positive results, other 
RCTs have been more disappointing. In a 6-month RCT from Taiwan, mild to moderate AD 
patients (MMSE scores 10-26 and Clinical Dementia Rating (CDR) score of 1 or 2) and MCI 
patients randomized to receive n-3 PUFAs 1.8 g/d (1080 mg of EPA and 720 mg of DHA, 
n=17) or placebo (olive oil, n=12) showed that supplementation with n-3 PUFAs may 
improve global clinical function, but not cognitive function (Chiu et al., 2008). One recent 
RCT of DHA supplementation conducted in individuals with mild to moderate AD (MMSE 
scores 14-26) in 51 US clinical research sites of the AD Cooperative Study found no 
beneficial effect of supplementation with DHA 2g/d for 18 months (n=171) on either to the 
rate of cognitive and functional decline as compared to placebo (n=124) treatment (Quinn et 
al., 2010). 
Generally, no clear conclusions can be drawn for clinical practice because of the 
considerable heterogeneity in the RCT subjects, supplement types or dosages, assay 
techniques, outcome measures, and insufficient statistical power and/or treatment 
durations. However, it does seem that supplementation may be more effective when the 
disease is not yet advanced. 
2.4.2 Antioxidant vitamins and fruit polyphenols 
Oxidative stress represents an imbalance between biochemical processes leading to the 
production of reactive oxygen species (ROS), and those factors responsible for the removal 
of ROS (the antioxidant cascade) (Sayre et al., 2008). Oxidative stress is involved in several 
diseases and particularly in those subjects with an increased incidence due to advanced 
age. The central nervous system (CNS) is particularly vulnerable to oxidative stress, 
because of the high rate of O2 utilization, the relatively poor concentrations of antioxidants, 
and the high content of PUFAs - the biomacromolecules most susceptible to oxidation. 
Antioxidants form a complex network and work together to prevent oxidative damage to 
various cellular components, either by protecting against ROS formation, by removing 
them before they can damage vital components of the cell, or by repairing the damage once 
it has occurred (Sies, 1993). Since ROS undertake useful functions in the cells (i.e. redox 
signaling), the main role of antioxidants is not to remove ROS entirely but to maintain them 
at an optimum level (Rhee, 2006). 
Nowadays, many plants and fruits are considered to be a “functional food”, because 
they can protect from the onset or slow the progression of a disease when regularly 
consumed (Rossi et al., 2008). Functional food contains an abundance of essential 
antioxidant low molecular weight compounds, such as vitamins A (carotenoids), E 
(tocopherols), and C (ascorbic acid), and polyphenols. Polyphenols are the most abundant 
of these antioxidants in the diet. Their main dietary sources are fruits and plant-derived 
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beverages such as fruit juices, tea, coffee, red wine, cocoa, and beer (Scalbert and 
Williamson, 2000). Additionally, vegetables, dry legumes, and cereals contribute to the total 
polyphenol intake of ~1 g/d. In addition, minerals selenium, copper, zinc, and manganese 
can participate in antioxidant enzyme activities, and may reduce neuronal damage and 
death from oxidation-related reactions (Diplock, 1991). Three of the important antioxidant 
enzymes are superoxide dismutases, catalase and glutathione peroxidases (Sies, 1993). 
The main classes of polyphenols according to the nature of their carbon skeleton are 
flavonoids, phenolic acids and the less common stilbenes and lignans (Scalbert and 
Williamson, 2000). Flavonoids, present in colourful flowers and plants, comprise the largest 
- about 2/3 - group of polyphenols; more than 6,000 flavonoids are known (Jäger and Saaby, 
2011). On the basis of their molecular structure, flavonoids can in turn be divided into two 
groups: anthocyanins and anthoxanthins (Rossi et al., 2008). Anthocyanins - derivatives of 
anthocyanidins - are watersoluble pigments, responsible for the pigmentation of flowers 
and fruits, including the colour of red wine. There are also colourless anthoxanthins e.g. 
flavonols, flavones, flavanones, flavan-3-ols (flavanols), and isoflavones (Jäger and Saaby, 
2011). Anthocyanidins (cyanidin, delphinidin, malvidin, pelargonidin, peonidin, petunidin) 
are found in red wine, red onions, and red fruits such as cherries, strawberries, raspberries, 
red grapes and red/black currants (Scalbert and Williamson, 2000; Rossi et al., 2008; 
Bhagwat et al., 2011). Flavonols (quercetin, kaempferol, myricetin, isorhamnetin) are most 
abundant in onions, kale, leeks, broccoli and blueberries, while flavones (apigenin, luteolin) 
are found in celery, parsley, cabbage, and cauliflower. Flavanones (hesperetin, naringenin, 
eriodictyol) are found mainly in citrus fruits, flavan-3-ols (catechins, epicatechins, 
theaflavins, thearubigins) in green and black tea, purple grape juice, red wine, cocoa, 
apples, and berries, and isoflavones (genistein, daidzein) in soybeans. 
Phenolic acids, including caffeic acid (e.g. in coffee) and to a lesser extent ferulic acid 
(e.g. in wheat bran), account for about 1/3 of the total dietary polyphenols (Scalbert and 
Williamson, 2000). Caffeic acid is also found in the form of esters; the most frequently 
encountered caffeoyl ester is chlorogenic acid. Other phenolic acid derivatives are 
hydrolysable tannins – gallic acid in gallotannins (mango) or ellagic acid in ellagitannins 
(blackberry, raspberry, strawberry, wine and brandy aged in oak barrels). Stilbenes are not 
common in the diet; the main dietary source is resveratrol present in red wine, grape skin, 
and peanuts (Cornwell et al., 2004). Notable amounts of lignans are found in flaxseed, 
whole grain breads, vegetables, and tea. 
Vitamins E and C are both involved in cellular antioxidant defense by reducing the 
changes associated with cell degeneration due to chemical or physical insults (Martin et al., 
2002). Vitamin C (ascorbic acid, a water-soluble vitamin) is mainly found in fruits and 
vegetables, such as bell peppers, tomatoes, citrus fruits, strawberries, spinach, and 
cruciferous vegetables (e.g. broccoli and cabbages) (Otten et al., 2006; http://www.fineli.fi). 
In contrast, a high amount of vitamin E (a lipid-soluble vitamin) is found in vegetable oils 
such as sunflower- and rapeseed oils and spreads, unprocessed cereal grains (e.g. wheat-
germ), almonds and nuts, and egg yolk. Vitamin E has eight naturally occurring forms, or 
isomers: four tocopherols (α-, β-, γ-, and δ-tocopherols) and four tocotrienols (α-, β-, γ-, and 
δ- tocotrienols) (Brigelius-Flohé and Traber, 1999; Otten et al., 2006). The primary 
component of vitamin E in supplements is α-tocopherol whereas in the diet γ-tocopherol is 
more common. 
Carotenoids are a family of naturally occurring fat-soluble plant pigments and powerful 
antioxidants that are mainly obtained from deep yellow-, red-, and orange-coloured fruits 
and vegetables and green leafy vegetables in the human diet such as carrots, kale, tomato, 
spinach, broccoli, and watermelon (Otten et al., 2006; http://www.fineli.fi). The most 
prevalent carotenoids are α-carotene, β-carotene, lycopene, lutein, zeaxanthin, and β-
cryptoxanthin. 
Several longitudinal studies have investigated the relationship between dietary 
antioxidants and dementia/AD (Table 6), but they have found inconsistent results. A high 
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dietary intake of vitamins E and/or C has been associated in some studies with a reduced 
risk of dementia/AD (Morris et al., 2002a; Engelhart et al., 2002b; Morris et al., 2005b; 
Devore et al., 2010) and cognitive decline (Morris et al., 2002b; Morris et al., 2005b; 
Wengreen et al., 2007), as well as with better verbal memory (Péneau et al., 2011), but these 
findings are not uniform across studies (Kalmijn et al., 1997a; Paleologos et al. 1998; 
Commenges et al., 2000; Luchsinger et al., 2003; Laurin et al., 2004). Additionally, a higher 
intake of flavonoids received from fruits, vegetables, wine and tea (Commenges et al., 
2000), frequent drinking of fruit and vegetable juices (Dai et al., 2006), higher consumption 
of fruits and vegetables (Barberger-Gateau et al., 2007; Hughes et al., 2010), or intakes of 
dietary β-carotene and flavonoids among current smokers (Engelhart et al., 2002b), have 
been postulated to reduce the risk of dementia/AD. Further, a high consumption of 
vegetables, but not fruits, or of both vegetables and fruits has been linked to the smaller risk 
of cognitive decline (Kang et al., 2005; Morris et al., 2006b; Nooyens et al., 2011) and to a 
better executive function and memory (Sabia et al., 2009). However, the studies which have 
investigated intakes of dietary carotenes and/or flavonoids have produced also partly 
disappointing (Kalmijn et al., 1997a; Luchsinger et al., 2003; Laurin et al., 2004; Dai et al., 
2006; Devore et al., 2010) or even negative (Péneau et al., 2011) results. 
Supplemental intake of vitamins C and E either alone and/or together has been 
associated in some studies with a decreased risk of AD (Morris et al., 1998; Zandi et al., 
2004), VaD/mixed dementia (Masaki et al., 2000), cognitive impairment/decline (Paleologos 
et al., 1998; Morris et al., 2002b; Maxwell et al., 2005; Wengreen et al., 2007), or vascular 
cognitive impairment (VCI) (Maxwell et al., 2005) as well as with better cognitive function 
(Masaki et al., 2000; Grodstein et al., 2003), although these findings are not consistently 
repeated across studies (Laurin et al., 2002; Morris et al., 2002a; Luchsinger et al., 2003; 
Fillenbaum et al., 2005; Gray et al., 2008). Moreover, the use of multivitamins has been 
proposed to delay the risk of cognitive decline in some (Maxwell et al., 2005), but not in all 
studies (Morris et al., 2002b); no association has been shown with the risk of AD (Morris et 
al., 1998; Zandi et al., 2004; Maxwell et al., 2005). 
Studies of plasma/serum antioxidant concentrations in long-term follow-up studies have 
also been suggestive, although not decisive, in relation to cognitive performance. In these 
prospective studies, higher β-carotene serum levels have been related to a lower risk of 
cognitive decline among ApoE ε4 allele carriers as reported in the MacArthur Study of 
Successful Aging over 7 years (Hu et al., 2006), as well as in a Swiss study with a 22-year 
follow-up where those individuals with higher vitamin C and β-carotene plasma levels had 
a better semantic memory (Perrig et al., 1997). In the Nurses’ Health Study among elderly 
women, however, higher total plasma levels of carotenoids or tocopherols were not 
associated with a slower cognitive decline over 4-years (Kang and Grodstein, 2008). The 
middle tertile of plasma/serum γ-tocopherol per cholesterol unit was associated with a 
reduced risk of dementia during a 4-year follow-up in the Conselice Study of Brain Ageing 
from Italy (Ravaglia et al., 2008) and with a reduced risk of cognitive impairment in the 
Cardiovascular Risk Factors, Aging, and Dementia (CAIDE) study from Finland which had 
a duration of over 8 years (Mangialasche et al., 2013), whereas the Swedish Uppsala 
Longitudinal Study of Adult Men could detect no association between serum γ-tocopherol 
and the risk of dementia/AD during their 12-year follow-up (Sundelöf et al., 2009). In the 
Kungsholmen Project which lasted over 6 years, high plasma levels of total tocopherols, 
total tocotrienols, total vitamin E, and β-tocopherol individually, were associated with a 
reduced risk of AD (Mangialasche et al., 2010). Additionally, in the CAIDE study, elevated 
serum levels of γ-tocopherol, β-tocotrienol and total tocotrienols have been associated with 
a reduced risk of cognitive impairment (Mangialasche et al., 2013). The other forms of 
plasma/serum vitamin E (notably α-tocopherol) have revealed no association with 
cognition (Perrig et al., 1997; Dunn et al., 2007; Ravaglia et al., 2008; Sundelöf et al., 2009; 
Mangialasche et al., 2010). Additionally, RCTs have provided conflicting findings about the 
efficacy of vitamin E in the prevention and treatment of individuals with MCI or AD 
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(Farina et al., 2012) as well as about the efficacy of the other antioxidant supplements 
(vitamin C, β-carotene) on cognitive function (Jia et al., 2008). 
The variable results from studies of antioxidant intake and cognitive function are likely a 
result of differences in study design, difficulties in the definition and measurement of 
cognitive function, errors in the measurement of dietary intake, or confounding by factors 
related to both antioxidant intake and cognitive function. Further, the health effects of 
specific antioxidant vitamins may be difficult to identify in observational studies because 
the common sources (e.g. fruits, vegetables and vitamin supplements) are also sources of 
other beneficial vitamins, minerals and other compounds. Antioxidants from food are 
always invariably consumed with other nutrients in a certain proportion (reflecting long-
term intake), whereas supplemental antioxidants are consumed at a very high dose either 
with or without other substances (generally for a shorter duration), thus leading to 
differences in absorption or biological activity between antioxidants from food and 
supplements. Further, supplement users are generally a select group of individuals with 
either health problems (Bender et al., 1992) or greater health-seeking behaviours (Kirk et al., 
1999), and the composition of vitamin supplements can be very different from the dietary 
sources, e.g. vitamin E supplements contain mostly α-tocopherol. 
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FA
, 
tr
an
s 
fa
t 
an
d 
D
H
A
. 
C
om
bi
ne
d 
in
ta
ke
 o
f 
va
ri
ou
s 
vi
ta
m
in
 E
 f
or
m
s 
m
ig
ht
 b
e 
m
or
e 
im
po
rt
an
t 
th
an
 α
-t
oc
op
he
ro
l 
al
on
e 
in
 t
he
 p
ro
te
ct
iv
e 
re
la
tio
ns
 w
ith
 
co
g
n
it
iv
e 
d
ec
lin
e 
an
d
 A
D
. 
K
an
g 
et
 a
l. 
(2
00
5)
 
N
ur
se
s’
 H
ea
lt
h 
st
ud
y 
U
S
A
 
n 
=
 1
3 
38
8 
M
ea
n 
ag
e 
at
 c
og
ni
tiv
e 
in
te
rv
ie
w
: 
74
 y
rs
 
10
0%
 w
om
en
 
Fo
llo
w
-u
p:
 1
0 
to
 1
6 
yr
s 
A
 F
FQ
: 
15
 f
ru
its
 a
nd
 3
0 
ve
ge
ta
bl
es
 
A
ge
, 
ed
uc
at
io
n,
 B
P,
 c
ho
le
st
er
ol
, 
D
M
, 
C
H
D
, 
ho
rm
on
e 
th
er
ap
y,
 a
ge
 
at
 m
en
op
au
se
, 
B
M
I,
 s
m
ok
in
g,
 u
se
 
of
 a
nt
id
ep
re
ss
an
ts
 a
nd
 N
S
A
ID
s,
 
al
co
ho
l i
nt
ak
e,
 P
A,
 t
ot
al
 E
I,
 m
en
ta
l 
he
al
th
 a
nd
 v
ita
lit
y,
 a
nd
 v
ita
m
in
 
su
pp
le
m
en
ta
tio
n.
 
In
ta
ke
 o
f 
cr
uc
ife
ro
us
 v
eg
et
ab
le
s 
w
as
 
as
so
ci
at
ed
 w
ith
 b
et
te
r 
co
g
n
it
iv
e 
p
er
fo
rm
an
ce
. 
Fu
rt
he
r,
 t
ot
al
 v
eg
et
ab
le
 in
ta
ke
, 
in
 p
ar
tic
ul
ar
 in
ta
ke
s 
of
 g
re
en
 le
af
y 
or
 
cr
uc
ife
ro
us
 v
eg
et
ab
le
s,
 w
as
 a
ss
oc
ia
te
d 
w
ith
 
le
ss
 c
og
n
it
iv
e 
d
ec
lin
e.
 
In
ta
ke
 o
f 
fr
ui
ts
 w
as
 n
ot
 a
ss
oc
ia
te
d 
w
ith
 
co
gn
iti
on
 o
r 
co
gn
iti
ve
 d
ec
lin
e.
 
 
Ta
bl
e 
6 
to
 b
e 
co
nt
in
ue
d 
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  Ta
bl
e 
6.
 (
co
nt
in
ue
d)
 M
ai
n 
lo
ng
itu
di
na
l s
tu
di
es
 e
xa
m
in
in
g 
th
e 
as
so
ci
at
io
n 
be
tw
ee
n 
di
et
ar
y 
an
ti
ox
id
an
t 
in
ta
ke
 a
nd
 c
og
ni
tio
n.
 
 A
u
th
or
s 
S
tu
d
y 
p
op
u
la
ti
on
 a
n
d
 
fo
ll
ow
-u
p
 
A
ss
es
sm
en
t 
of
 d
ie
ta
ry
 
an
ti
ox
id
an
t 
in
ta
ke
 
C
ov
ar
ia
te
s 
O
u
tc
om
e 
an
d
 r
es
u
lt
s 
M
or
ri
s 
et
 a
l. 
(2
00
6b
) 
C
H
A
P 
U
S
A
 
n 
=
 3
71
8 
M
ea
n 
ag
e:
 7
4 
yr
s 
62
%
 w
om
en
 
Fo
llo
w
-u
p:
 6
 y
rs
 
A
 1
39
-i
te
m
 F
FQ
: 
28
 
ve
ge
ta
bl
es
 a
nd
 2
1 
fr
ui
ts
 
(a
nd
 u
se
 o
f 
vi
ta
m
in
 
su
pp
le
m
en
ts
) 
A
ge
, 
se
x,
 r
ac
e,
 e
du
ca
tio
n,
 
co
gn
iti
ve
 a
ct
iv
iti
es
, 
PA
, 
al
co
ho
l 
in
ta
ke
, 
an
d 
in
te
ra
ct
io
ns
 o
f 
ag
e*
se
x,
 e
du
ca
tio
n*
se
x,
 
ra
ce
*e
du
ca
tio
n,
 t
im
e*
ea
ch
 
co
va
ri
at
e,
 t
im
e*
ra
ce
*e
du
ca
tio
n.
 
H
ig
h 
ve
ge
ta
bl
e 
bu
t 
no
t 
fr
ui
t 
co
ns
um
pt
io
n 
w
as
 
as
so
ci
at
ed
 w
ith
 a
 s
lo
w
er
 r
at
e 
of
 c
og
n
it
iv
e 
d
ec
lin
e.
 
D
ai
 e
t 
al
. 
(2
00
6)
 
K
am
e 
Pr
oj
ec
t 
W
as
hi
ng
to
n,
 U
S
A
 
n 
=
 1
58
9 
(6
3 
A
D
) 
M
ea
n 
ag
e:
 7
2 
yr
s 
54
%
 w
om
en
 
Fo
llo
w
-u
p:
 >
6.
3 
yr
s 
A
 F
FQ
 
A
ge
, 
se
x,
 e
du
ca
tio
n,
 P
A
, 
B
M
I,
 
ba
se
lin
e 
C
A
S
I 
sc
or
e,
 o
lfa
ct
io
n 
di
ag
no
st
ic
 g
ro
up
, 
to
ta
l E
I,
 in
ta
ke
s 
of
 S
FA
s,
 M
U
FA
s,
 P
U
FA
s,
 a
nd
 
vi
ta
m
in
s 
C
 a
nd
 E
 a
nd
 β
-c
ar
ot
en
e,
 
A
po
E,
 s
m
ok
in
g,
 a
lc
oh
ol
 a
nd
 t
ea
 
dr
in
ki
ng
, 
an
d 
su
pp
le
m
en
ta
tio
n 
of
 
vi
ta
m
in
s 
C
, 
E 
an
d 
m
ul
tiv
ita
m
in
. 
Fr
eq
ue
nt
 (
at
 le
as
t 
3 
tim
es
/a
 w
ee
k)
 d
ri
nk
in
g 
of
 
fr
ui
t 
an
d 
ve
ge
ta
bl
e 
ju
ic
es
 w
as
 a
ss
oc
ia
te
d 
w
ith
 
a 
de
cr
ea
se
d 
ri
sk
 o
f 
A
D
, 
pa
rt
ic
ul
ar
ly
 a
m
on
g 
th
e 
A
po
E 
ε4
 c
ar
ri
er
s.
 
D
ie
ta
ry
 in
ta
ke
s 
of
 v
ita
m
in
s 
E 
an
d 
C
, 
an
d 
β-
ca
ro
te
ne
 w
er
e 
no
t 
re
la
te
d 
to
 t
he
 r
is
k 
of
 A
D
. 
B
ar
be
rg
er
-G
at
ea
u 
et
 
al
. 
(2
00
7)
 
3C
 s
tu
dy
 
Fr
an
ce
 
n 
=
 8
08
5 
(2
81
 d
em
en
tia
, 
18
3 
A
D
) 
A
ge
: 
≥
 6
5 
yr
s 
Fo
llo
w
-u
p:
 3
.5
 y
rs
 
A
 b
ri
ef
 F
FQ
 
A
ge
, 
se
x,
 e
du
ca
tio
n,
 c
ity
, 
in
co
m
e,
 
m
ar
ita
l s
ta
tu
s,
 A
po
E 
ε4
, 
D
M
, 
an
d 
B
M
I.
 
D
ai
ly
 c
on
su
m
pt
io
n 
of
 f
ru
its
 a
nd
 v
eg
et
ab
le
s 
w
as
 a
ss
oc
ia
te
d 
w
ith
 a
 d
ec
re
as
ed
 r
is
k 
of
 a
ll 
ca
us
e 
d
em
en
ti
a.
 
W
en
gr
ee
n 
et
 a
l. 
(2
00
7)
 
C
ac
he
 C
ou
nt
y 
S
tu
dy
 
on
 M
em
or
y,
 H
ea
lth
 
an
d 
A
gi
ng
 
U
S
A
 
n 
=
 3
63
2 
M
ea
n 
ag
e:
 7
5 
yr
s 
57
%
 w
om
en
 
Fo
llo
w
-u
p:
 7
.2
 y
rs
 
A
 1
41
-i
te
m
 F
FQ
 (
an
d 
us
e 
of
 v
ita
m
in
 a
nd
 m
in
er
al
 
su
pp
le
m
en
ts
) 
A
ge
, 
se
x,
 e
du
ca
tio
n,
 A
po
E 
ε4
, 
sm
ok
in
g,
 a
lc
oh
ol
 u
se
, 
PA
, 
B
M
I,
 
hi
st
or
y 
of
 D
M
, 
M
I,
 a
nd
 s
tr
ok
e,
 
in
ta
ke
s 
of
 o
th
er
 a
nt
io
xi
da
nt
s,
 t
im
e 
va
ri
ab
le
s,
 a
nd
 in
te
ra
ct
io
ns
 
be
tw
ee
n 
tim
e 
va
ri
ab
le
s 
an
d 
an
tio
xi
da
nt
 v
ar
ia
bl
e 
of
 in
te
re
st
. 
H
ig
he
r 
an
tio
xi
da
nt
 in
ta
ke
 (
in
c.
 v
ita
m
in
s 
C
, 
an
d 
E,
 a
nd
 c
ar
ot
en
e 
fr
om
 f
oo
d 
or
 f
ro
m
 f
oo
d 
+
 
su
pp
le
m
en
ts
) 
w
as
 r
el
at
ed
 t
o 
be
tt
er
 c
og
n
it
iv
e 
p
er
fo
rm
an
ce
 a
nd
 s
lo
w
er
 c
og
n
it
iv
e 
d
ec
lin
e;
 
hi
gh
 d
ie
ta
ry
 v
ita
m
in
 C
 in
ta
ke
, 
or
 n
ot
ab
ly
 
co
m
bi
ne
d 
in
ta
ke
 w
ith
 d
ie
ta
ry
 v
ita
m
in
 E
 
se
em
ed
 e
sp
ec
ia
lly
 b
en
ef
ic
ia
l. 
 
Ta
bl
e 
6 
to
 b
e 
co
nt
in
ue
d 
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  Ta
bl
e 
6.
 (
co
nt
in
ue
d)
 M
ai
n 
lo
ng
itu
di
na
l s
tu
di
es
 e
xa
m
in
in
g 
th
e 
as
so
ci
at
io
n 
be
tw
ee
n 
di
et
ar
y 
an
ti
ox
id
an
t 
in
ta
ke
 a
nd
 c
og
ni
tio
n.
 
 A
u
th
or
s 
S
tu
d
y 
p
op
u
la
ti
on
 a
n
d
 
fo
ll
ow
-u
p
 
A
ss
es
sm
en
t 
of
 d
ie
ta
ry
 
an
ti
ox
id
an
t 
in
ta
ke
 
C
ov
ar
ia
te
s 
O
u
tc
om
e 
an
d
 r
es
u
lt
s 
S
ab
ia
 e
t 
al
. 
(2
00
9)
 
W
hi
te
ha
ll 
II
 s
tu
dy
 
U
ni
te
d 
K
in
gd
om
 
 
n 
=
 5
12
3 
M
ea
n 
ag
e:
 4
4 
yr
s 
(e
ar
ly
 
m
id
lif
e)
/5
6 
yr
s 
(m
id
lif
e)
 
28
%
 w
om
en
 
Fo
llo
w
-u
p:
 1
7 
yr
s 
A
 q
ue
st
io
nn
ai
re
 o
n 
lif
es
ty
le
 f
ac
to
rs
 (
e.
g.
 
co
ns
um
pt
io
n 
of
 f
ru
its
 a
nd
 
ve
ge
ta
bl
es
) 
at
 e
ar
ly
 
m
id
lif
e 
an
d 
at
 m
id
lif
e.
 
A
ge
, 
se
x,
 a
nd
 s
oc
io
ec
on
om
ic
 
po
si
tio
n.
 
C
on
su
m
pt
io
n 
of
 f
ru
its
 a
nd
 v
eg
et
ab
le
s 
le
ss
 
th
an
 t
w
ic
e 
a 
da
y 
at
 m
id
lif
e 
w
as
 a
ss
oc
ia
te
d 
w
it
h 
po
or
 e
xe
cu
ti
ve
 f
u
n
ct
io
n
 a
n
d
 m
em
or
y 
at
 la
te
-l
ife
. 
H
ug
he
s 
et
 a
l. 
(2
01
0)
 
H
A
R
M
O
N
Y 
st
ud
y 
S
w
ed
en
 
 
n 
=
 3
77
9 
tw
in
s 
(3
55
 
de
m
en
tia
, 
24
0 
A
D
)  
M
ea
n 
ag
e:
 4
8 
yr
s 
62
%
 w
om
en
 
Fo
llo
w
-u
p:
 >
30
 y
rs
 
A
 2
3-
ite
m
 q
ue
st
io
nn
ai
re
 
A
ge
, 
se
x,
 e
du
ca
tio
n,
 s
m
ok
in
g,
 
al
co
ho
l c
on
su
m
pt
io
n,
 P
A,
 B
M
I,
 
an
gi
na
 p
ec
to
ri
s,
 t
ot
al
 f
oo
d 
in
ta
ke
 
in
 c
om
pa
ri
so
n 
to
 o
th
er
s,
 a
nd
 
m
ar
ita
l s
ta
tu
s.
 
H
ig
he
r 
fr
ui
t 
an
d 
ve
ge
ta
bl
e 
co
ns
um
pt
io
n 
at
 
m
id
lif
e 
w
as
 a
ss
oc
ia
te
d 
w
ith
 r
ed
uc
ed
 r
is
k 
of
 
d
em
en
ti
a  
(b
y 
27
%
) 
an
d 
A
D
 (
by
 4
0%
),
 
es
pe
ci
al
ly
 a
m
on
g 
w
om
en
 a
nd
 t
ho
se
 w
it
h 
an
gi
na
 p
ec
to
ri
s 
in
 m
id
lif
e.
 
D
ev
or
e 
et
 a
l. 
(2
01
0)
 
R
ot
te
rd
am
 s
tu
dy
 
Th
e 
N
et
he
rl
an
ds
 
n 
=
 5
39
5 
(4
65
 d
em
en
tia
, 
36
5 
A
D
)  
M
ea
n 
ag
e:
 6
8 
yr
s 
59
%
 w
om
en
 
Fo
llo
w
-u
p:
 9
.6
 y
rs
 
H
om
e 
in
te
rv
ie
w
 (
a 
m
ea
l-
ba
se
d 
ch
ec
kl
is
t)
 a
nd
 a
 
17
0-
ite
m
 F
FQ
 a
t 
th
e 
cl
in
ic
. 
A
ge
, 
ed
uc
at
io
n,
 A
po
E 
ε4
, 
to
ta
l E
I,
 
al
co
ho
l i
nt
ak
e,
 s
m
ok
in
g,
 B
M
I,
 a
nd
 
su
pp
le
m
en
t 
us
e 
(m
ul
tiv
ita
m
in
s,
 
vi
ta
m
in
s 
E 
an
d 
C
, 
β-
ca
ro
te
ne
, 
fla
vo
no
id
s,
 o
r 
n-
3 
FA
s.
 
H
ig
he
r 
di
et
ar
y 
vi
ta
m
in
 E
 in
ta
ke
 w
as
 a
ss
oc
ia
te
d 
w
ith
 a
 lo
w
er
 lo
ng
-t
er
m
 r
is
k 
of
 d
em
en
ti
a/
A
D
. 
D
ie
ta
ry
 in
ta
ke
s 
of
 v
ita
m
in
 C
, 
β-
ca
ro
te
ne
, 
an
d 
fla
vo
no
id
s 
w
er
e 
no
t 
as
so
ci
at
ed
 w
ith
 t
he
 
de
m
en
tia
/A
D
 r
is
k.
 
N
oo
ye
ns
 e
t 
al
. 
(2
01
1)
 
D
oe
tin
ch
em
 C
oh
or
t 
S
tu
dy
 
Th
e 
N
et
he
rl
an
ds
 
n 
=
 2
61
3 
A
ge
: 
43
-7
0 
yr
s 
51
%
 w
om
en
 
Fo
llo
w
-u
p:
 u
p 
to
 1
2 
yr
s 
A
 1
78
-i
te
m
 F
FQ
 
A
ge
, 
se
x,
 e
du
ca
tio
n,
 t
ot
al
 E
I,
 
in
ta
ke
 o
f 
ot
he
r 
fr
ui
ts
, 
ve
ge
ta
bl
es
, 
le
gu
m
es
, 
an
d 
ju
ic
es
, 
ba
se
lin
e 
co
gn
iti
ve
 f
un
ct
io
n,
 P
A,
 s
m
ok
in
g,
 
S
B
P,
 u
se
 o
f 
B
P-
lo
w
er
in
g 
m
ed
ic
at
io
n,
 s
er
um
 H
D
L-
ch
ol
es
te
ro
l, 
w
ai
st
 c
ir
cu
m
fe
re
nc
e,
 
co
ff
ee
 c
on
su
m
pt
io
n,
 v
ita
lit
y,
 a
nd
 
m
en
ta
l h
ea
lth
. 
H
ig
he
r 
ve
ge
ta
bl
e 
in
ta
ke
 w
as
 r
el
at
ed
 t
o 
lo
w
er
 
ba
se
lin
e  
in
fo
rm
at
io
n
 p
ro
ce
ss
in
g
 s
p
ee
d
 a
nd
 
w
or
se
 c
og
n
it
iv
e 
fl
ex
ib
il
it
y,
 b
ut
 t
o 
sm
al
le
r 
de
cl
in
e 
in
 in
fo
rm
at
io
n 
pr
oc
es
si
ng
 s
pe
ed
 a
nd
 
g
lo
b
al
 c
og
n
it
iv
e 
fu
n
ct
io
n
 a
t 
fo
llo
w
-u
p.
 H
ig
h 
in
ta
ke
s 
of
 c
ab
ba
ge
, 
m
us
hr
oo
m
s,
 r
oo
t 
ve
ge
ta
bl
es
 a
nd
 n
ut
s 
w
er
e 
re
la
te
d 
to
 b
et
te
r 
ba
se
lin
e 
co
gn
iti
ve
 f
un
ct
io
n 
an
d/
or
 s
m
al
le
r 
co
g
n
it
iv
e 
d
ec
lin
e.
 T
ot
al
 in
ta
ke
s 
of
 f
ru
its
, 
le
gu
m
es
 a
nd
 j
ui
ce
s 
w
er
e 
no
t 
as
so
ci
at
ed
 w
ith
 
ba
se
lin
e 
or
 c
ha
ng
e 
in
 c
og
n
it
iv
e 
fu
n
ct
io
n
. 
 
Ta
bl
e 
6 
to
 b
e 
co
nt
in
ue
d 
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  Ta
bl
e 
6.
 (
co
nt
in
ue
d)
 M
ai
n 
lo
ng
itu
di
na
l s
tu
di
es
 e
xa
m
in
in
g 
th
e 
as
so
ci
at
io
n 
be
tw
ee
n 
di
et
ar
y 
an
ti
ox
id
an
t 
in
ta
ke
 a
nd
 c
og
ni
tio
n.
 
 A
u
th
or
s 
S
tu
d
y 
p
op
u
la
ti
on
 a
n
d
 
fo
ll
ow
-u
p
 
A
ss
es
sm
en
t 
of
 d
ie
ta
ry
 
an
ti
ox
id
an
t 
in
ta
ke
 
C
ov
ar
ia
te
s 
O
u
tc
om
e 
an
d
 r
es
u
lt
s 
Pé
ne
au
 e
t 
al
. 
(2
01
1)
 
S
U
.V
I.
M
A
X
 2
 s
tu
dy
 
Fr
an
ce
 
n 
=
 2
53
3 
A
ge
: 
45
-6
0 
yr
s 
45
%
 w
om
en
 
Fo
llo
w
-u
p:
 1
3 
yr
s 
R
ep
ea
te
d 
(a
t 
le
as
t 
si
x)
 
24
-h
 d
ie
ta
ry
 r
ec
or
ds
 
A
ge
, 
se
x,
 e
du
ca
tio
n,
 B
M
I,
 
in
te
rv
en
tio
n 
gr
ou
p,
 t
ot
al
 E
I,
 P
A
, 
al
co
ho
l u
se
, 
sm
ok
in
g,
 d
ep
re
ss
iv
e 
sy
m
pt
om
s,
 a
nd
 in
ta
ke
s 
of
 f
oo
d 
(v
eg
et
ab
le
 f
at
, 
an
im
al
 f
at
, 
an
d 
fis
h)
, 
an
d 
sp
ec
ifi
c 
nu
tr
ie
nt
s 
(S
FA
, 
n-
3 
FA
s,
 a
nd
 n
-6
 F
A
s)
. 
H
ig
he
r 
in
ta
ke
s 
of
 f
ru
its
 a
nd
 v
eg
et
ab
le
s,
 f
ru
it
s 
al
on
e,
 v
ita
m
in
 C
-r
ic
h 
fr
ui
ts
 a
nd
 v
eg
et
ab
le
s,
 a
nd
 
vi
ta
m
in
s 
C
 a
nd
 E
 w
er
e 
re
la
te
d 
to
 b
et
te
r 
ve
rb
al
 
m
em
or
y.
 I
n 
co
nt
ra
st
, 
hi
gh
er
 in
ta
ke
s 
of
 f
ru
its
 
an
d 
ve
ge
ta
bl
es
, 
ve
ge
ta
bl
es
 a
lo
ne
, 
an
d 
β-
ca
ro
te
ne
-r
ic
h 
fr
ui
ts
 a
nd
 v
eg
et
ab
le
s 
w
er
e 
re
la
te
d 
to
 p
oo
re
r 
ex
ec
u
ti
ve
 f
u
n
ct
io
n
 (
i.e
. 
po
or
er
 r
es
ul
t 
on
 t
he
 f
or
w
ar
d 
di
gi
t 
sp
an
 t
es
t)
. 
 A
D
 =
 A
lz
he
im
er
’s
 d
is
ea
se
; 
A
po
E 
=
 A
po
lip
op
ro
te
in
 E
; 
B
M
I 
=
 b
od
y 
m
as
s 
in
de
x;
 B
P 
=
 b
lo
od
 p
re
ss
ur
e;
 3
C
 =
 T
hr
ee
-C
it
y 
co
ho
rt
 s
tu
dy
; 
C
A
S
I 
=
 C
og
ni
tiv
e 
A
bi
lit
ie
s 
S
cr
ee
ni
ng
 I
ns
tr
um
en
t;
 C
H
A
P 
=
 C
hi
ca
go
 H
ea
lt
h 
an
d 
A
gi
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2.4.3 Coffee, tea and caffeine 
Coffee is widely consumed globally; it is the preferred drink (after water) in Europe and in 
the USA (Grigg, 2002). According to international statistics, the Finns have the highest per 
capita coffee consumption in the world with 12.0 kg in year 2007, followed by Norwegians 
(9.9 kg) and Danes (8.7 kg) (World Resources Institute). Earlier in the 1970’s and 1980’s, the 
coffee consumption numbers in Finland varied between 10-14.3 kg/y. There are over 70 
different coffee species which have been described, of these Coffea Arabica (arabica) and C. 
canephora (robusta) are the most important (Butt and Sultan, 2011). 
A cup of coffee is rich in biologically active substances such as niacin/nicotinic acid, 
trigonelline, quinolinic acid, tannic acid, pyrogallic acid, and caffeine (Dórea and da Costa, 
2005). Additionally, coffee contains notable amounts of antioxidants of the 
hydroxycinnamic acids family (caffeic, chlorogenic, coumaric, ferrulic and sinapic acids). In 
a 200 ml cup of coffee, the amount of chlorogenic acid (CGA) can range from 70-350 mg, 
and caffeic acid from 35-175 mg (Higdon and Frei, 2006). Further, several micronutrients 
are found in coffee, including magnesium (~7 mg/240ml cup), potassium (~116 mg/240ml 
cup), nicotinic acid (1-3 mg/cup) and vitamin E (0.2 mg of both α- and γ-tocopherol in one 
cup). 
Caffeine - a purine alkaloid (1,3,7-trimethylxanthine) - is present in many dietary 
sources, i.e., in coffee, tea, cocoa beverages, candy bars, and soft drinks (Nehlig, 1999). The 
amount of caffeine ranges rather widely between these various foods, with coffee 
representing a major source of intake (71–220 mg caffeine/150 ml). In tea, the content of 
caffeine is 32–42 mg/150 ml, in cola 15–32 mg/150 ml and in cocoa 4 mg/150 ml. The content 
of caffeine per coffee cup varies largely also according to the serving size (usually 50–190 
ml), the preparation method (boiled, filtered, percolated, espresso, instant), and the type of 
the coffee used (Arabica or Robusta as the main commercial species). Depending on the 
preparation method, the caffeine content of a cup of coffee ranges from 0.6–3.3 mg/ml for 
espresso, 0.7–1.1 mg/ml for boiled or filtered coffee and 0.2–0.6 mg/ml (up to as much as 1.0 
mg/ml) in instant coffee. Arabica is the most widely consumed type of coffee throughout 
the world, in most countries representing 70%–100% (100% in Finland and Sweden) of all 
the coffee consumed. However, the average content of caffeine is about twice as high in 
Robusta as in Arabica coffee (1.6-2.4 % of dry weight vs. 0.9-1.2 %). Thus, in a standard 150 
ml cup, the content of caffeine can range from 131–220 mg/cup for Robusta and from 71–
120 mg/cup for Arabica coffee. In Finland, the standard size of coffee cup is considered to 
be about 125 ml, i.e. also smaller caffeine amounts/cup (http://www.kahvi.net/index. 
php?k=110913). 
Caffeine is a mild central nervous system (CNS) stimulant, and it provides benefits such 
as enhanced energy, mental alertness, vigilance, mood and psychomotor function (Nehlig, 
2010). However, the effect of caffeine on memory and learning is somewhat ambiguous i.e. 
ineffective, improved or impaired effects have been reported. Caffeine’s effect on attention 
is also unclear, even though in demanding tasks, caffeine has been shown to be beneficial. 
Usually moderate coffee/caffeine consumption (3-4 cups/d providing 300-400 mg of 
caffeine) has no adverse effects in healthy adults. However, in some studies, caffeine has 
caused unfavourable effects on BP. It has been reported that 200-300 mg of caffeine 
equivalent to 2-3 cups of coffee/d might increase SBP by 3-14 mmHg and DBP by 4-13 
mmHg among normotensive individuals (Nurminen et al., 1999), and on average by ~8 
mmHg in SBP and ~6 mmHg in DBP among hypertensive persons for ≥3 h (Mesas et al., 
2011); the evidence for long-term effects on BP is inconclusive. High levels of caffeine may 
also have adverse effects e.g. during pregnancy causing possibly fetal growth restriction 
(Higdon and Frei, 2006). The lethal dose of caffeine has been estimated at 100-200 mg/kg of 
body weight, and ingestion of 15-30 mg/kg has resulted in significant toxicity. Caffeine 
overdose may cause several symptoms including agitation, delirium, seizures, dyspnea, 
cardiac arrhythmias, myoclonus, nausea, vomiting, hyperglycemia and hypokalemia. 
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Coffee consumption may also increase serum total and LDL cholesterol concentration 
(Urgert and Katan, 1997; Higdon and Frei, 2006). The cholesterol-raising factors have been 
found to be due to the coffee oil components, diterpenes, cafestol (major responsible factor) 
and kahweol, which are mostly removed from coffee by paper filters. Robustas contain no 
kahweol and less cafestol than Arabicas, thus intake levels of diterpenes could be reduced 
by increasing the proportion of Robustas in coffee blends. In the Scandinavian boiled, 
Turkish and French press (cafetiere) coffees, the amounts of cafestol and kahweol are 
relatively high (6-12 mg/cup), while in filtered, percolated and instant coffees, the levels of 
these diterpenes are much lower (0.2-0.6 mg/cup). 
Tea, a product made from leaf and the buds of the tea plant Camellia sinensis, is the 
second most commonly consumed drink (after water) in most parts of Asia, in nearly all the 
countries of the former Soviet Union and in North Africa (Grigg, 2002); per capita mean 
consumption has been reported to be 120 ml/day (Cabrera et al., 2006). Teas are classified 
into three major types depending on the manufacturing process: non-fermented green tea, 
semi-fermented oolong tea, and fermented black and red (Pu-Erh) teas. Approximately 76–
78% of the tea produced and consumed is black tea, 20–22% is green tea, and less than 2% is 
oolong tea. Black tea is consumed principally in Europe, North America and North Africa 
(except Morocco), green tea in China, Japan, Korea and Morocco, and oolong tea in China 
and Taiwan. In the USA, 80% of the tea consumed is black iced tea. 
Tea leaves are a rich source of polyphenols: flavan-3-ols, which are commonly referred to 
as catechins and gallic acid (Cabrera et al., 2006; Ferruzzi, 2010). In green tea, the major 
flavonoids are the monomer catechins – epigallocatechin-gallate (EGCG, 7-74 mg/g), 
epigallocatechin (EGC, 0-55 mg/g), epicatechin-gallate (ECG, 1-41 mg/g) and epicatechin 
(EC, 0.1-17 mg/g); lower levels of their epimeric forms include catechin (C, 0-8 mg/g), 
gallocatechin (GC), catechin-gallate (CG), and gallocatechin-gallate (GCG). Additionally, 
green tea contains proteins, amino acids (such as theanine), carbohydrates, xanthic bases 
(caffeine, theophylline), vitamins (B, C, E) and minerals (manganese, chromium, selenium, 
zinc). During the fermentation process, catechins undergo enzymatic transformation into 
polyphenolic compounds. Thus in black and oolong tea, the polymerized catechins - 
theaflavins, theasinensins and thearubigins - predominate. These complex polyphenols 
contribute to the characteristic orange-red-brown colour and flavour of black tea. In 
contrast, theanine appears to antagonize some of the undesirable effects of caffeine e.g. its 
tendency to raise BP, while enhancing its positive cognitive effects (Bryan, 2008). 
Ten longitudinal studies have investigated the association between coffee, tea and/or 
caffeine intake and cognition, but produced rather inconsistent results (Table 7). Daily 
coffee drinking has been associated with a decreased risk of AD (Lindsay et al., 2002), and 
with the least 10-year cognitive decline (van Gelder et al., 2007b), but there are also 
numerous inconsistent results (Ng et al., 2008; Laitala et al., 2009; Gelber et al., 2011). 
Instead, caffeine intake has been related to a smaller change in a complex motor speed (van 
Boxtel et al., 2003) or among men to a lower odds of having any of the lesion types at 
autopsy (Gelber et al., 2011), and among women either with less decline in verbal cognitive 
functioning and in visuospatial memory (Ritchie et al., 2007) or with a reduced risk of 
cognitive decline/impairment (Santos et al., 2010); however there are several studies 
reporting no association with cognitive decline/dementia (van Boxtel et al., 2003; Ritchie et 
al., 2007; Gelber et al., 2011). Regular tea drinking has been associated with a reduced risk 
of cognitive decline (Ng et al., 2008), but not with a reduced risk of dementia/AD (Laurin et 
al., 2004; Dai et al., 2006). Clearly, more research is needed to elucidate the dose-response 
relationship between coffee/tea consumption and cognition. Furthermore, biological 
evidence clarifying the relationship between coffee/caffeine use and neural degeneration 
will be required before one could consider instigating a public health program promoting 
caffeine intake. 
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2.4.4 Plant extracts and spices 
Several plant extracts and spices have been postulated to be protective against cognitive 
impairment and dementia, but results vary between studies. Ginkgo biloba - medicinal 
products derived from the maidenhair tree - are some of the most widely used plant 
products (Birks and Grimley Evans, 2009). Ginkgo biloba consists of flavonoids, terpenoids, 
and terpene lactones (ginkgolides and bilobalide). In some trials, Ginkgo biloba has 
appeared to be more effective than placebo, but its clinical efficacy in the treatment of 
cerebral dysfunction is unclear (Birks and Grimley Evans, 2009; Weinmann et al., 2010). 
The turmeric (Curcuma longa) plant - a perennial herb belonging to the ginger family - 
has been used in traditional Chinese medicine for thousands of years (Shishodia et al., 2005; 
Ringman et al., 2005). Turmeric’s most active component, curcumin - a polyphenolic yellow 
pigment - was identified in 1815. Curcumin makes up 2-5% of the turmeric-spice and it is 
used as a spice in Indian curries. Later, modern science has proposed that curcumin has a 
potentially beneficial role in AD/neuropathology by exerting anti-amyloidogenic, anti-
oxidative, anti-inflammatory, cholesterol-lowering, and hemostatic properties. 
Additionally, many other plant extracts and phytochemicals such as ginseng, sinapic 
acid, Japanese remedy yokukansan, saffron, rosmarinic acid, sage, lemon balm, lavender 
(Howes and Perry, 2011) and aged garlic extract (Ray et al., 2011) have been studied as 
potential AD-preventive agents, but their effectiveness is still more or less inconclusive. 
2.4.5 Alcohol 
The impact of alcohol on cognition is not entirely clear: different outcomes, beverages, 
drinking patterns (e.g. binge drinking, i.e. drinking large quantities of alcohol in a single 
session), and follow-up times, or possible interactions with other lifestyle-related or genetic 
factors can confer considerable variability on to the results. Generally, heavy drinking and 
alcohol abuse have been related to an increased risk of dementia, but light-to-moderate 
alcohol consumption has been suggested to be a protective factor against dementia/AD 
(Peters et al., 2008; Panza et al., 2009); a U- or J-shaped curve may best describe the 
relationship. The protective effects are more likely with wine consumption and in the 
absence of the ApoE ε4 allele. Resveratrol, a naturally occurring polyphenol found mainly 
in the skin of red grapes (Vitis vinifera) and red wine, has been found to reduce β-secretase 
activity, the generation of the reactive oxygen intermediates (ROIs), and the aggregation of 
Aβ-peptide, thus possessing a neuroprotective potential (Vingtdeux et al., 2008; Richard et 
al., 2011). Nonetheless, the current evidence of moderate alcohol consumption in 
preventing cognitive impairment/decline is only suggestive (Peters et al., 2008; Panza et al., 
2009). 
In the evidence report prepared for Agency for Healthcare Research and Quality 
(AHRQ), the level of evidence for light-to-moderate alcohol consumption to act as a 
protective factor for AD was estimated as low (Williams et al., 2010). There is currently no 
indication that individuals who abstain from alcohol consumption would benefit from 
starting to use alcohol. RCTs would be difficult to justify ethically in this area. 
2.4.6 Vitamin B12, folate and vitamin D 
Both vitamin B12 (cobalamin) and folate/folic acid (vitamin B9) - water-soluble vitamins - are 
involved in a common metabolic pathway supplying essential methyl groups for DNA and 
protein synthesis (Vogel et al., 2009). Vitamin B12 is necessary for the conversion of 
homocysteine (Hcy) to methionine, and a deficiency in either vitamin B12 or folate leads to 
an increase in total serum Hcy level due to reduced methylation reactions; elevated 
methylmalonic acid (MMA) levels may also be evidence of vitamin B12 deficiency. Hcy has 
a neurotoxic effect that could lead to cell death or neurologic and psychiatric disturbances 
such as AD (Kivipelto et al., 2009). The recommended dietary allowance (RDA) of vitamin 
B12 is ~2-3 μg/d among adults; a typical Western diet consists of 3-30 μg vitamin B12/d, and 
liver is an excellent dietary source (Dali-Youcef and Andrès, 2009; http://www.fineli.fi). 
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Nonetheless, B12 deficiency is frequent among elderly people with a prevalence of around 
20%; the main causes are pernicious anemia and dietary B12 malabsorption or deficiency e.g. 
due to strict vegetarianism (Dali-Youcef and Andrès, 2009; Vogel et al., 2009). Folate 
deficiency is also rather common among aged people and is usually caused by dietary 
deficiency, diminished absorption or increased utilization (Malouf and Grimley Evans, 
2008). The RDA of folate is 300 μg/d among adults, and rich sources are animal protein, 
leafy vegetables, fruits, mushrooms and yeast (Malouf and Grimley Evans, 2008; 
http://www.fineli.fi). 
Several longitudinal studies have investigated the relationship between Hcy and 
cognition and these have reported mainly positive results (Wald et al., 2011). In the 
prospective studies, high Hcy levels have been associated with an increased risk of 
dementia and AD in the Framingham study over an 8-year period (Seshadri et al., 2002), in 
the Conselice Study of Brain Aging (CSBA) with a 4-year follow-up (Ravaglia et al., 2005), 
in the Kungsholmen Project with a 6.7-year follow-up (Kivipelto et al., 2009), in the 
Cardiovascular Risk Factors, Aging, and Dementia (CAIDE) study over a 7.4-year period 
(Hooshmand et al., 2010) and in the Prospective  Population Study of Women in 
Gothenburg with a 35-year follow-up (Zylberstein et al., 2011). Additionally, a high Hcy 
level has been related to a decline in recall memory in the Veterans Affairs Normative 
Aging Study over a 3-year period (Tucker et al., 2005), to an increased risk of cognitive 
impairment in the Sacramento Area Latino Study on Aging during a 4.5-year follow-up 
(Haan et al., 2007) and to worse cognitive performance (i.e. poorer performance in global 
cognition, episodic memory, executive functions and verbal expression) in the CAIDE 
study over a 7-year period (Hooshmand et al., 2012). Additionally, in the Oxford Healthy 
Aging Project, low serum concentrations of holotranscobalamin and high MMA or Hcy 
levels reflecting low vitamin B12 status were related to a more rapid cognitive decline 
during a 10-year follow-up; in contrast folate exhibited no association (Clarke et al., 2007). 
Further, higher total folate intake (from diet and supplements) has been associated with a 
decreased risk of AD in an American study during a 6.1-year follow-up (Luchsinger et al., 
2007). In the Vienna Transdanube Aging Study (VITA), higher serum folate levels at 
baseline as well as the self-reported combined use of folic acid and vitamin B12 for more 
than one year were associated with a lower conversion rate from MCI to dementia (Blasko 
et al., 2012). In the VITA study, higher serum folate levels were also associated with less 
extensive medial temporal lobe atrophy, and higher homocysteine levels with 
moderate/severe global brain atrophy. 
B12 deficiency appears to be more common among patients with chronic neurologic 
disorders (Dali-Youcef and Andrès, 2009). However to date, there is no clear evidence from 
RCTs that supplementation with vitamin B12 or folate can improve cognitive decline or 
dementia, although it may normalize homocysteine levels (Malouf and Grimley Evans, 
2008; Dali-Youcef and Andrès, 2009; Dangour et al., 2010b; Ford and Almeida, 2012). It is 
possible that there is a “critical time window” when supplementation is most effective. An 
interesting approach to delay/prevent cognitive decline has been shown only in a few RCT. 
The 3-year FACIT trial reported positive cognitive effects (in memory and information-
processing speed) of folate treatment (800μg/d) among healthy elderly subjects with high 
plasma levels of Hcy and normal serum levels of vitamin B12 at screening (Durga et al., 
2007). Additionally, in the 2-year VITACOG trial, B vitamins (0.8mg folate, 0.5mg vitamin 
B12, 20mg vitamin B6) slowed the cognitive and clinical decline in subjects with MCI 
(benefits in global cognition and in episodic and semantic memories), in particular in those 
with elevated Hcy levels (de Jager et al., 2012). Further RCTs will be needed to examine the 
benefits of treatment in the conversion from MCI to dementia. 
Low levels of fat-soluble steroid hormone, vitamin D, are common in adults and are 
associated with skeletal and non-skeletal, age-associated diseases (Annweiler et al., 2009; 
Dickens et al., 2011). Animal studies have linked vitamin D status to cognitive dysfunction 
and dementia, but in humans the association is not yet clearly established. Recently, the 
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EPIDOS study with a 7-year follow-up reported an association between vitamin D 
deficiency and non-Alzheimer-dementia among older women (Annweiler et al., 2011), but 
to date, no large RCTs have examined the effect of vitamin D supplements on cognitive 
decline or dementia. In Finland, the recommended intake of vitamin D for adults <60 years 
is 10μg/d; supplementation is advised from the beginning of October till the end of March 
only if the recommended intake is not supplied with diet. For persons >60 years, a 
supplementation of 20μg/d is though recommended year-round (National Nutrition 
Council, 2014); rich sources are fish, milk and spreads (http://www.fineli.fi). 
2.4.7 Dietary patterns and related factors 
In recent years, analytical procedures using composite dietary patterns (DPs) capturing 
dimensions of nutrition that may be missed by single nutrients or foods have emerged to 
examine the relationship between diet and cognition. DP attempts to capture the 
complicated interactions and cumulative effects of a diet; when additional information e.g. 
on cooking styles and origins of the aliments are known, even more thorough results can be 
achieved. 
The traditional diet-scoring systems include the Mediterranean Diet (MEDI) score, which 
is characterized by a high intake of vegetables, legumes, fruits, nuts and cereals, high intake 
of unsaturated FAs (olive oil), but low intake of SFAs, a moderately high intake of fish, a 
low-to-moderate intake of dairy products (in the form of cheese or yogurt), a low-to-
moderate intake of red meat, poultry and eggs, and a regular but moderate amount of 
alcohol, primarily in the form of wine and generally with meals (Willett et al., 1995). A scale 
indicating the degree of adherence to the MEDI has been constructed with the use of the 
sex-specific median as the cut-off value: a higher score indicates stricter adherence to the 
MEDI (Trichopoulou et al., 2003). Furthermore, comprehensive diet-quality indexes like a 
healthy eating index (HEI), which combines multiple aspects of a diet in relation to dietary 
guidelines into a single score, have been used also to classify and describe DPs. 
The use of diet-scoring systems confers undeniable advantages in understanding the role 
of diet in chronic diseases (Sofi et al., 2010; Gu and Scarmeas, 2011). However, the 
epidemiological evidence obtained from longitudinal studies about the relationship 
between a MEDI/HEI/DP (including several dietary components) and cognition is limited 
and partly divergent (Table 8). Higher adherence to the MEDI has been associated either 
significantly or with a tendency towards reduced risks of cognitive decline/MCI (Scarmeas 
et al., 2006; Scarmeas et al., 2009a; Tangney et al., 2011), of a slower decline on the MMSE 
(Féart et al., 2009), and of reduced risk of MCI progression to AD (Scarmeas et al., 2009a), 
albeit these have not been uniformly confirmed across the studies for either MEDI in 
relation to cognitive function (Psaltopoulou et al., 2008) or to MCI (Roberts et al., 2010b; 
Cherbuin and Anstey, 2012) or for HEI/MEDI in relation to the cognitive change (Tangney 
et al., 2011; Vercambre et al., 2012; Samieri et al., 2013a). Furthermore, higher adherence to 
the MEDI has been linked in the Washington Heights-Inwood Columbia Aging Project 
(WHICAP) to a decreased risk of developing AD during a follow-up of 4 to 5 years 
(Scarmeas et al., 2006; Scarmeas et al., 2009b) as well as to a lower mortality from AD 
(Scarmeas et al., 2007); the Three-City (3C) study, the Mayo Clinic Study of Aging, or the 
Women’s Health Study (WHS) found no association of the MEDI with dementia/AD risk 
(Féart et al., 2009; Roberts et al., 2010b), or with several cognitive tests (excluding the 
MMSE) (Féart et al., 2009), or with trajectory of cognitive performance/averaged cognition 
(Samieri et al., 2013b). Additionally, a DP characterized by frequent consumption of n-3 
PUFAs and antioxidants (Barberger-Gateau et al., 2007), a DP reflecting a diet rich in n-3 
and n-6 PUFAs, vitamin E, and folate, but lower SFA and vitamin B12 intake (Gu et al., 
2010), as well as a Japanese DP characterized by high intakes of soybeans/soybean 
products, green/other vegetables, algae, and milk/dairy products, and by a low intake of 
rice (Ozawa et al., 2013) have been associated with a lower dementia/AD/VaD risk. In the 
Quebec Longitudinal Study on Nutrition and Successful Aging (NuAge) from Canada, 
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higher adherence to a prudent DP (vegetables, fruits, fish, poultry, and lower-fat dairy 
products) was associated with less cognitive decline among low socioeconomic position 
(SEP) individuals over 3 years of follow-up (Parrott et al., 2013). Additionally, higher 
adherence to a Western DP (meats, potatoes, processed foods, and higher-fat dairy 
products) was associated with worse overall performance and greater cognitive decline in 
low-educated persons. Additionally, a recent RCT of 124 participants with elevated BP, 
subjects on the Dietary Approaches to Stop Hypertension (DASH)-style diet (i.e. high 
intake of plant foods, fruits, vegetables, fish, poultry, whole grains, low-fat dairy products, 
and nuts, and low intake of red meat, sodium, sweets, and sugar-sweetened beverages) 
exhibited greater neuro-cognitive improvements when compared to normal subjects (Smith 
et al., 2010). Since hypertension has been associated with an increased risk of AD (Launer et 
al., 2000; Kivipelto et al., 2001b; Kivipelto et al., 2002; Whitmer et al., 2005), it is biologically 
plausible that the DASH-diet could also reduce the risk of AD. 
One important reason for the differences in results between studies on DPs and 
cognition is probably related to population differences. Since population-specific medians 
are used to estimate adherence to DPs, the DPs and the levels of adherence to DPs may not 
be entirely comparable between countries and populations. Interestingly, several studies in 
different countries have linked higher MEDI adherence to lower all-cause mortality 
(Knoops et al., 2004; Mitrou et al., 2007; Sjögren et al., 2010; Buckland et al., 2011; 
McNaughton et al., 2012; Zazpe et al., 2014). 
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ud
y 
A
us
tr
al
ia
 
n 
=
 1
52
8 
(1
0 
M
C
I,
 
19
 C
D
R
 0
.5
, 
37
 a
ny
-
M
C
D
) 
A
ge
: 
60
-6
4 
yr
s 
51
%
 w
om
en
 
Fo
llo
w
-u
p:
 4
 y
rs
 
A
 2
15
-i
te
m
 F
FQ
 (
an
d 
co
ok
in
g 
m
et
ho
ds
, 
se
rv
in
g 
si
ze
s,
 a
nd
 c
om
m
en
ts
 a
bo
ut
 e
at
in
g 
ha
bi
ts
).
 
M
ED
I 
sc
or
e 
(w
ith
 t
he
 m
et
ho
do
lo
gy
 u
se
d 
by
 
S
ca
rm
ea
s 
et
 a
l.,
 2
00
6)
. 
A
ge
, 
se
x,
 e
du
ca
tio
n,
 A
po
E 
ε4
, 
B
M
I,
 P
A
, 
st
ro
ke
, 
D
M
, 
hy
pe
rt
en
si
on
, 
an
d 
to
ta
l E
I.
 
M
ED
I 
w
as
 n
ot
 a
ss
oc
ia
te
d 
w
ith
 t
he
 r
is
k 
fo
r 
M
C
I.
 
 
Ta
bl
e 
8 
to
 b
e 
co
nt
in
ue
d 
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  Ta
bl
e 
8.
 (
co
nt
in
ue
d)
 M
ai
n 
lo
ng
itu
di
na
l s
tu
di
es
 e
xa
m
in
in
g 
th
e 
as
so
ci
at
io
n 
be
tw
ee
n 
co
m
po
si
te
 d
ie
ta
ry
 p
at
te
rn
s 
an
d 
co
gn
iti
on
. 
 Au
th
or
s 
S
tu
d
y 
p
op
u
la
ti
on
 
an
d
 f
ol
lo
w
-u
p
 
A
ss
es
sm
en
t 
of
 D
P
 (
e.
g
. 
M
ED
I/
h
ea
lt
h
y 
d
ie
t 
in
ta
ke
) 
C
ov
ar
ia
te
s 
O
u
tc
om
e 
an
d
 r
es
u
lt
s 
V
er
ca
m
br
e 
et
 a
l. 
(2
01
2)
 
W
A
C
S
 
U
S
A
 
 
n 
=
 2
50
4 
(w
ith
 ≥
2 
co
gn
iti
ve
 
as
se
ss
m
en
ts
) 
A
ge
: 
≥
 6
5 
yr
s 
10
0%
 w
om
en
 (
w
it
h 
pr
ev
al
en
t 
va
sc
ul
ar
 
di
se
as
e/
≥
3 
co
ro
na
ry
 
ri
sk
 f
ac
to
rs
) 
Fo
llo
w
-u
p:
 5
.4
 y
rs
 
A
 1
16
-i
te
m
 F
FQ
. 
M
ED
I 
sc
or
e 
(s
ca
le
 o
f 
0-
9 
po
in
ts
):
 9
 f
oo
d 
ca
te
go
ri
es
 in
cl
ud
in
g 
ve
ge
ta
bl
es
, 
le
gu
m
es
, 
fr
ui
ts
, 
ce
re
al
s,
 f
is
h,
 m
ea
t,
 d
ai
ry
 p
ro
du
ct
s,
 M
U
FA
-S
FA
 
ra
tio
, 
an
d 
al
co
ho
l i
nt
ak
e.
 
A
n
 a
lt
er
n
at
e 
M
ED
I 
sc
or
e 
(m
ax
. 
sc
or
e 
55
, 
w
ith
 
hi
gh
er
 s
co
r e
s 
in
di
ca
tin
g 
hi
gh
er
 a
dh
er
en
ce
; 
w
ith
 
th
e 
m
et
ho
do
lo
gy
 u
se
d 
by
 T
an
gn
ey
 e
t 
al
.,
 2
01
1)
. 
A
ge
, 
ed
uc
at
io
n,
 m
ar
ita
l s
ta
tu
s,
 
to
ta
l E
I,
 P
A,
 u
se
 o
f 
m
ul
tiv
ita
m
in
 
su
pp
le
m
en
ts
, 
sm
ok
in
g 
st
at
us
, 
B
M
I,
 p
os
tm
en
op
au
sa
l h
or
m
on
e 
us
e,
 u
se
 o
f 
dr
ug
s 
(a
sp
ir
in
, 
N
S
A
ID
) 
>
10
 d
ay
s 
in
 t
he
 p
re
vi
ou
s 
m
on
th
,  
de
pr
es
si
on
, 
D
M
, 
hy
pe
rt
en
si
on
, 
ca
rd
io
va
sc
ul
ar
 
pr
of
ile
 a
t 
ba
se
lin
e,
 
hy
pe
rl
ip
id
em
ia
, 
ra
nd
om
iz
at
io
n 
as
si
gn
m
en
t 
fo
r 
vi
ta
m
in
s 
E 
an
d 
C
, 
be
ta
-c
ar
ot
en
e 
an
d 
fo
la
te
. 
In
 w
om
en
 w
it
h 
pr
e-
ex
is
tin
g 
va
sc
ul
ar
 
di
se
as
e 
or
 r
is
k 
fa
ct
or
s,
 a
dh
er
en
ce
 t
o 
th
e 
M
ED
I 
w
as
 n
ot
 a
ss
oc
ia
te
d 
w
ith
 
su
bs
eq
ue
nt
 5
-y
ea
r 
co
g
n
it
iv
e 
ch
an
g
e 
fo
r 
th
e 
gl
ob
al
 c
om
po
si
te
, 
TI
C
S
, 
ve
rb
al
 m
em
or
y,
 o
r 
ca
te
go
ry
 
flu
en
cy
 s
co
re
s .
 
S
am
ie
ri
 e
t 
a l
. 
(2
01
3a
) 
N
ur
se
s’
 
H
ea
lth
 s
tu
dy
 
U
S
A
 
n 
=
 1
60
58
 (
w
ith
 ≥
1 
co
gn
iti
ve
 
as
se
ss
m
en
t)
 
A
ge
: 
≥
 7
0 
yr
s 
 
10
0%
 w
om
en
  
Fo
llo
w
-u
p:
 ~
 6
 y
rs
 
A
 1
16
-i
te
m
 F
FQ
 (
at
 le
as
t 
on
e 
co
m
pl
et
io
n)
. 
A
n
 a
lt
er
n
at
e 
M
ED
I 
sc
or
e 
(s
ca
le
 o
f 
0-
9 
po
in
ts
, 
w
ith
 h
ig
he
r 
sc
or
es
 in
di
ca
tin
g 
hi
gh
er
 a
dh
er
en
ce
):
 9
 
co
m
po
ne
nt
s  
in
c.
 v
eg
et
ab
le
s,
 f
ru
its
, 
le
gu
m
es
, 
w
ho
le
 g
ra
in
s,
 n
ut
s,
 f
is
h,
 r
ed
 a
nd
 p
ro
ce
ss
ed
 m
ea
ts
, 
m
od
er
at
e 
al
co
ho
l i
nt
ak
e,
 a
nd
 M
U
FA
-S
FA
 r
at
io
. 
Lo
ng
-t
er
m
 M
ED
I 
ex
po
su
re
 w
as
 e
st
im
at
ed
 b
y 
av
er
ag
in
g 
al
l r
ep
ea
te
d 
m
ea
su
re
s 
of
 d
ie
t 
(>
13
yr
s)
. 
A
ge
, 
ed
uc
at
io
n,
 lo
ng
-t
er
m
 t
ot
al
 
EI
 a
nd
 P
A
, 
B
M
I,
 s
m
ok
in
g,
 
de
pr
es
si
on
, 
m
ul
tiv
ita
m
in
 u
se
, 
D
M
, 
hy
pe
rt
en
si
on
, 
hy
pe
rc
ho
le
st
er
ol
em
ia
, 
M
I.
 
Lo
ng
-t
er
m
 M
ED
I 
ad
he
re
nc
e 
w
as
 
as
so
ci
at
ed
 w
ith
 a
 m
od
er
at
el
y 
be
tt
er
 
g
lo
b
al
 c
og
n
it
iv
e 
p
er
fo
rm
an
ce
 a
n
d
 
ve
rb
al
 m
em
or
y  
bu
t 
no
t 
w
it
h 
co
g
n
it
iv
e 
ch
an
g
e.
 O
f 
th
e 
co
m
po
ne
nt
s,
 h
ig
he
r 
lo
ng
-t
er
m
 
ve
ge
ta
bl
e 
in
ta
ke
 w
as
 r
el
at
ed
 t
o 
le
ss
 
de
cl
in
e 
in
 g
lo
ba
l c
og
ni
tio
n,
 a
nd
 a
 
hi
gh
er
 M
U
FA
-S
FA
 r
at
io
 t
o 
le
ss
 d
ec
lin
e 
in
 g
lo
ba
l c
og
ni
tio
n 
an
d 
ve
rb
al
 
m
em
or
y.
 F
ur
th
er
, 
gr
ea
te
r 
in
ta
ke
 o
f 
ve
ge
ta
bl
es
, 
fis
h 
an
d 
nu
ts
 w
er
e 
as
so
ci
at
ed
 w
ith
 h
ig
he
r 
m
ea
n 
co
gn
iti
ve
 f
un
ct
io
n.
 
 
Ta
bl
e 
8 
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 b
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co
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  Ta
bl
e 
8.
 (
co
nt
in
ue
d)
 M
ai
n 
lo
ng
itu
di
na
l s
tu
di
es
 e
xa
m
in
in
g 
th
e 
as
so
ci
at
io
n 
be
tw
ee
n 
co
m
po
si
te
 d
ie
ta
ry
 p
at
te
rn
s 
an
d 
co
gn
iti
on
. 
 A
u
th
or
s 
S
tu
d
y 
p
op
u
la
ti
on
 
an
d
 f
ol
lo
w
-u
p
 
A
ss
es
sm
en
t 
of
 D
P
 (
e.
g
. 
M
ED
I/
h
ea
lt
h
y 
d
ie
t 
in
ta
ke
) 
C
ov
ar
ia
te
s 
O
u
tc
om
e 
an
d
 r
es
u
lt
s 
O
za
w
a 
et
 a
l. 
(2
01
3)
 
Th
e 
H
is
ay
am
a 
S
tu
dy
 
Ja
pa
n 
 
n 
=
 1
00
6 
(2
71
 
de
m
en
tia
, 
14
4 
A
D
, 
88
 V
aD
, 
39
 o
th
er
) 
A
ge
: 
60
-7
9 
yr
s 
(m
ea
n 
68
 y
rs
) 
57
%
 w
om
en
 
Fo
llo
w
-u
p:
 m
ed
ia
n 
15
 y
rs
 
A
 7
0-
ite
m
 F
FQ
. 
O
f 
th
e 
7 
di
ff
er
en
t 
D
Ps
 e
xt
ra
ct
ed
, 
D
P
1
 w
as
 
ch
ar
ac
te
ri
ze
d 
by
 h
ig
h 
in
ta
ke
s 
of
 s
oy
be
an
s 
an
d 
so
yb
ea
n 
pr
od
uc
ts
, 
gr
ee
n 
an
d 
ot
he
r 
ve
ge
ta
bl
es
, 
al
ga
e,
 a
nd
 m
ilk
 a
nd
 d
ai
ry
 p
ro
du
ct
s,
 a
s 
w
el
l a
s 
by
 
a 
lo
w
 in
ta
ke
 o
f 
ri
ce
. 
D
Ps
 w
er
e 
de
ri
ve
d 
by
 u
si
ng
 a
 
re
du
ce
d 
ra
nk
 r
eg
re
ss
io
n 
w
ith
 7
 n
ut
ri
en
ts
 (
S
FA
, 
M
U
FA
, 
PU
FA
, 
vi
ta
m
in
 C
, 
po
ta
ss
iu
m
, 
ca
lc
iu
m
, 
an
d 
m
ag
ne
si
um
) 
as
 r
es
po
ns
iv
e 
va
ri
ab
le
s 
an
d 
19
 f
oo
ds
 
an
d 
fo
od
 g
ro
up
s 
as
 in
de
pe
nd
en
t 
va
ri
ab
le
s.
 
A
ge
, 
se
x,
 e
du
ca
tio
n,
 D
M
, 
hy
pe
rt
en
si
on
, 
to
ta
l c
ho
le
st
er
ol
, 
st
ro
ke
, 
B
M
I,
 s
m
ok
in
g 
ha
bi
ts
, 
to
ta
l E
I.
 
H
ig
he
r 
ad
he
re
nc
e 
to
 a
 D
P1
 w
as
 
as
so
ci
at
ed
 w
ith
 a
 r
ed
uc
ed
 r
is
k 
of
 a
ll-
ca
us
e 
d
em
en
ti
a,
 A
D
 a
n
d
 V
aD
. 
S
am
ie
ri
 e
t 
al
. 
(2
01
3 b
) 
W
H
S
 
U
S
A
 
n 
=
 6
17
4 
(w
ith
 1
-2
 
co
gn
iti
ve
 
as
se
ss
m
en
ts
) 
A
ge
: 
≥
 6
5 
yr
s 
10
0%
 w
om
en
 
Fo
llo
w
-u
p:
 5
.6
 y
rs
 
A
 1
31
-i
te
m
 F
FQ
. 
A
n
 a
lt
er
n
at
e 
M
ED
I 
sc
or
e 
(s
ca
le
 o
f 
0-
9 
po
in
ts
, 
w
ith
 h
ig
he
r 
sc
or
es
 in
di
ca
tin
g 
hi
gh
er
 a
dh
er
en
ce
):
 9
 
co
m
po
ne
nt
s 
in
c.
 v
eg
et
ab
le
s,
 f
ru
its
, 
le
gu
m
es
, 
w
ho
le
 g
ra
in
s,
 n
ut
s,
 f
is
h,
 r
ed
 a
nd
 p
ro
ce
ss
ed
 m
ea
ts
, 
m
od
er
at
e 
al
co
ho
l i
nt
ak
e,
 a
nd
 M
U
FA
-S
FA
 r
at
io
. 
 
A
ge
, 
ra
nd
om
iz
at
io
n 
as
si
gn
m
en
t,
 
ra
ce
, 
ed
uc
at
io
n,
 a
nn
ua
l i
nc
om
e,
 
to
ta
l E
I,
 a
lc
oh
ol
 in
ta
ke
, 
ex
er
ci
se
, 
B
M
I,
 c
ur
re
nt
 s
m
ok
in
g,
 D
M
, 
de
pr
es
si
on
, 
hy
pe
rt
en
si
on
, 
hy
pe
rc
ho
le
st
er
ol
em
ia
, 
po
st
m
en
op
au
sa
l h
or
m
on
e 
us
e,
 
in
iti
al
 c
og
ni
tiv
e 
sc
or
e,
 a
nd
 t
im
e 
in
te
rv
al
 b
et
w
ee
n 
th
e 
as
se
ss
m
en
ts
. 
Th
e 
al
te
rn
at
e 
M
ED
I 
sc
or
e 
w
as
 n
ot
 
as
so
ci
at
ed
 w
ith
 t
ra
je
ct
or
ie
s 
of
 
re
p
ea
te
d
 c
o
g
n
it
iv
e 
sc
or
es
, 
ov
er
al
l 
g
lo
b
al
 c
og
n
it
io
n
 o
r 
ve
rb
al
 
m
em
or
y 
at
 o
ld
er
 a
ge
s.
 O
f 
th
e 
co
m
po
ne
nt
s,
 h
ig
he
r 
M
U
FA
-S
FA
 r
at
io
 
w
as
 r
el
at
ed
 t
o 
be
tt
er
 t
ra
je
ct
or
ie
s 
of
 
gl
ob
al
 c
og
ni
tio
n 
an
d 
ve
rb
al
 m
em
or
y,
 
an
d 
gr
ea
te
r 
w
ho
le
 g
ra
in
 in
ta
ke
 w
ith
 
be
tt
er
 a
ve
ra
ge
d 
gl
ob
al
 c
og
ni
tio
n.
 
 
Ta
bl
e 
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to
 b
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co
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ue
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  Ta
bl
e 
8.
 (
co
nt
in
ue
d)
 M
ai
n 
lo
ng
itu
di
na
l s
tu
di
es
 e
xa
m
in
in
g 
th
e 
as
so
ci
at
io
n 
be
tw
ee
n 
co
m
po
si
te
 d
ie
ta
ry
 p
at
te
rn
s 
an
d 
co
gn
iti
on
. 
 A
u
th
or
s 
S
tu
d
y 
p
op
u
la
ti
on
 
an
d
 f
ol
lo
w
-u
p
 
A
ss
es
sm
en
t 
of
 D
P
 (
e.
g
. 
M
ED
I/
h
ea
lt
h
y 
d
ie
t 
in
ta
ke
) 
C
ov
ar
ia
te
s 
O
u
tc
om
e 
an
d
 r
es
u
lt
s 
Pa
rr
ot
t 
et
 a
l. 
(2
01
3)
 
N
uA
ge
 
C
an
ad
a 
 
n 
=
 1
09
9 
A
ge
: 
68
-8
4 
yr
s 
Fo
llo
w
-u
p:
 3
 y
rs
 
A
 7
8-
ite
m
 F
FQ
. 
P
ru
d
en
t 
D
P
: 
ve
ge
ta
bl
es
, 
fr
ui
ts
, 
le
gu
m
es
, 
fa
tt
y 
fis
h,
 p
ou
ltr
y,
 a
nd
 lo
w
er
-f
at
 d
ai
ry
 p
ro
du
ct
s.
 
W
es
te
rn
 D
P
: 
m
ea
ts
, 
po
ta
to
es
, 
w
hi
te
 b
re
ad
, 
ba
ke
d 
go
od
s,
 p
ro
ce
ss
ed
 m
ea
ts
, 
hi
gh
er
-f
at
 d
ai
ry
 
pr
od
uc
ts
, 
an
d 
sa
lty
 s
na
ck
s.
 
EI
, 
ag
e,
 s
ex
, 
PA
, 
us
ag
es
 o
f 
m
ed
ic
at
io
n,
 v
ita
m
in
 s
up
pl
em
en
ts
 
an
d 
na
tu
ra
l h
ea
lth
 p
ro
du
ct
s,
 
so
ci
al
 e
ng
ag
em
en
t,
 d
ep
re
ss
io
n,
 
pe
rc
ei
ve
d 
he
al
th
 s
ta
tu
s,
 
sm
ok
in
g,
 w
ai
st
 c
ir
cu
m
fe
re
nc
e,
 
B
M
I,
 h
yp
er
te
ns
io
n,
 D
M
2,
 S
B
P,
 
in
co
m
e,
 e
du
ca
tio
n,
 o
cc
up
at
io
n 
an
d 
th
ei
r 
in
te
ra
ct
io
ns
 w
ith
 t
im
e.
 
Th
e 
m
ag
ni
tu
de
 a
nd
 c
ha
ra
ct
er
is
tic
s 
of
 
th
e 
di
et
-c
og
ni
tio
n 
re
la
ti
on
sh
ip
 
de
pe
nd
ed
 o
n 
in
di
vi
du
al
’s
 S
EP
. 
 
H
ig
he
r 
ad
he
re
nc
e 
to
 a
 p
ru
de
nt
 D
P 
w
as
 a
ss
oc
ia
te
d 
w
ith
 le
ss
 c
og
n
it
iv
e 
d
ec
lin
e 
am
on
g 
lo
w
 S
EP
-p
er
so
ns
. 
H
ig
he
r 
ad
he
re
nc
e 
to
 a
 W
es
te
rn
 D
P 
w
as
 r
el
at
ed
 t
o 
w
or
se
 o
ve
ra
ll 
p
er
fo
rm
an
ce
 a
nd
 m
or
e 
co
gn
iti
ve
 
de
cl
in
e 
in
 lo
w
-e
du
ca
te
d 
pe
rs
on
s.
 
 A
D
 =
 A
lz
he
im
er
’s
 d
is
ea
se
; 
A
po
E 
=
 A
po
lip
op
ro
te
in
 E
; 
B
M
I 
=
 b
od
y 
m
as
s 
in
de
x;
 B
V
R
T 
=
 B
en
to
n 
Vi
su
al
 R
et
en
ti
on
 T
es
t;
 3
C
 =
 T
hr
ee
-C
it
y 
co
ho
rt
 s
tu
dy
; 
C
C
I 
=
 C
ha
rl
so
n 
co
m
or
bi
di
ty
 in
de
x;
 C
D
R
 =
 C
lin
ic
al
 D
em
en
ti
a 
R
at
in
g;
 C
H
A
P 
=
 C
hi
ca
go
 H
ea
lt
h 
an
d 
A
gi
ng
 P
ro
je
ct
; 
C
H
D
 =
 c
or
on
ar
y 
he
ar
t 
di
se
as
e;
 D
M
 =
 
di
ab
et
es
 m
el
lit
us
; 
D
P 
=
 d
ie
ta
ry
 p
at
te
rn
; 
EI
 =
 e
ne
rg
y 
in
ta
ke
; 
FC
S
R
T 
=
 F
re
e 
an
d 
C
ue
d 
S
el
ec
ti
ve
 R
em
in
di
ng
 T
es
t;
 F
FQ
 =
 f
oo
d 
fr
eq
ue
nc
y 
qu
es
ti
on
na
ir
e;
 
G
D
S
 =
 G
er
ia
tr
ic
 D
ep
re
ss
io
n 
S
ca
le
; 
H
EI
-2
00
5 
=
 H
ea
lt
hy
 E
at
in
g 
In
de
x-
20
05
; 
IS
T 
=
 I
sa
ac
s 
S
et
 T
es
t;
 M
C
I 
=
 m
ild
 c
og
ni
ti
ve
 i
m
pa
ir
m
en
t;
 M
C
D
 =
 m
ild
 
co
gn
iti
ve
 d
is
or
de
r;
 M
ED
I 
=
 M
ed
it
er
ra
ne
an
 D
ie
t;
 M
I 
=
 m
yo
ca
rd
ia
l i
nf
ar
ct
io
n;
 M
M
S
E 
=
 M
in
i-
M
en
ta
l S
ta
te
 E
xa
m
in
at
io
n;
 M
U
FA
 =
 m
on
ou
ns
at
ur
at
ed
 f
at
ty
 
ac
id
; 
N
S
A
ID
 =
 n
on
-s
te
ro
id
al
 a
nt
i-
in
fla
m
m
at
or
y 
dr
ug
; 
N
uA
ge
 =
 Q
ue
be
c 
Lo
ng
it
ud
in
al
 S
tu
dy
 o
n 
N
ut
ri
tio
n 
an
d 
S
uc
ce
ss
fu
l A
gi
ng
; 
PA
 =
 p
hy
si
ca
l a
ct
iv
ity
; 
PA
TH
 =
 P
er
so
na
lit
y 
an
d 
To
ta
l 
H
ea
lt
h 
Th
ro
ug
h 
Li
fe
 s
tu
dy
; 
PU
FA
 =
 p
ol
yu
ns
at
ur
at
ed
 f
at
ty
 a
ci
d;
 S
B
P 
=
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Additionally, dietary factors and DPs are related to several factors and behaviours which 
may also influence the risk of cognitive impairment and dementia. Lower education (Akbaraly 
et al., 2009) and socioeconomic status (Simsek et al., 2013) have been postulated to affect dietary 
behaviours, and lower education is also a known risk factor for dementia and AD (Lindsay et 
al., 2002; Ngandu et al., 2007). It has been also proposed that DPs tend to be less healthy in 
smokers (McClure et al., 2009), and that midlife smoking (Whitmer et al., 2005), in particular 
heavy smoking (Tyas et al., 2003; Rusanen et al., 2011), increases the risk of dementia and/or 
AD. It has been also speculated that smoking is a risk factor for dementia and AD particularly 
among the ApoE ε4 carriers (Rusanen et al., 2010). 
High caloric intake has been related to an increased risk of cognitive impairment and 
dementia among men (Creavin et al., 2012) as well as to AD among the ApoE ε4 allele carriers 
(Luchsinger et al., 2002). Furthermore, an increase in both the number of unhealthy behaviours 
(e.g. smoking, alcohol abstinence, low PA, and low fruit and vegetable consumption) and in 
their duration has been linked to poorer cognition (poor executive function and memory) in 
later life (Sabia et al., 2009). In contrast, an active lifestyle in terms of intellectual, social, and 
physical engagement might protect to some degree against the onset of dementia/AD and 
cognitive impairment (Lindsay et al., 2002; Fratiglioni et al., 2004; Rovio et al., 2005; Scarmeas et 
al., 2009b; Håkansson et al., 2009; Craik et al., 2010; Paillard-Borg et al., 2012). 
With regard to the association between dietary factors and cognition, in many respects the 
long-term relationship remains unclear. The literature has many conflicting results, perhaps 
since very few studies have dietary data available from midlife. In addition, research on diet 
and cognition usually is concerned with single dietary components and not so much data is 
available on DPs. Studies of diet and dementia-related diseases raise also very complicated 
methodological challenges, such as selection of an appropriate dietary assessment method 
(Table 3), a residual confounding effect, and a publication bias. The general trend is that dietary 
factors related to CVDs or CBVDs also have some association with cognitive functioning, 
although the mechanisms may be more complex than the vascular pathway. Although some 
positive and negative associations between different dietary components and cognition have 
already been found, the data so far are not sufficiently convincing to enable one to issue general 
dietary recommendations focusing solely on cognition, and thus a high priority is to achieve a 
better understanding of which dietary factors can contribute to the maintenance of cognitive 
ability. 
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3 Aims of the study 
The present doctoral thesis aimed at obtaining a comprehensive understanding of the influence 
of dietary factors on cognitive performance, MCI and dementia. Special attention was directed 
to the possible effects of dietary fat intake, coffee consumption and the adherence to a healthy 
diet in relation to different cognitive outcomes, as well as to possible interactions between 
environmental and genetic risk factors. The set of studies has been conducted in a large 
population-based sample of individuals who have been followed on average from 14 up to 21 
years. This provided a unique opportunity to examine the relationships between midlife 
risk/protective factors and the late-life cognitive outcomes. The general hypothesis was that 
healthy dietary choices might reduce the risk of dementia. 
 
The specific aims were: 
 
1. To investigate how dietary fat consumption at midlife would be related to the 
development of MCI and to the performance on various neuropsychological tests in a non-
demented population (Study I). 
 
2. To study whether dietary fat consumption at midlife would be related to the development 
of dementia and AD in late-life (Study II). 
 
3. To investigate whether coffee and/or tea consumption at midlife would be related to the 
development of dementia/AD in late-life (Study III). 
 
4. To assess whether a healthy diet at midlife could protect against dementia/AD later in life 
(Study IV). 
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4 Participants and methods 
4.1 STUDY POPULATION 
The present thesis is based on the Cardiovascular Risk Factors, Aging and Incidence of 
Dementia (CAIDE) study carried out in Eastern Finland. The participants of the CAIDE study 
were derived from population-based independent random samples that were first studied in 
1972, 1977, 1982 or 1987 (midlife visit) within the framework of the North Karelia Project and 
the Finnish part of Monitoring Trends of Determinants in CArdiovascular Disease 
(FINMONICA) study (Puska et al., 1979; Puska et al., 1983; Vartiainen et al., 1994). These 
original two studies were conducted to evaluate the risk factors, morbidity and mortality from 
CVDs. In 1972 and 1977, a random sample of 6.6% of the population born in 1913-1947 and 
living in Kuopio and North Karelia provinces in Eastern Finland was drawn. In 1982 and 1987, 
the sample included people aged 25-64 years and was stratified so that in both areas at least 250 
subjects were chosen from each sex and 10-year age group. This procedure was used to comply 
with the international World Health Organization (WHO) Multinational MONItoring of trends 
and determinants in Cardiovascular disease (MONICA) project protocol (WHO MONICA 
Project Principal Investigators, 1988). The participation rates in these baseline surveys were 
high, ranging from 77% to 96% (Vartiainen et al., 1994). 
A random sample of 2000 individuals on average 50 years old (range 39-64 years) was invited 
to participate in the re-examination conducted within the CAIDE study (Kivipelto et al., 2001a). 
Those eligible still alive and living in or close to the towns of Kuopio or Joensuu, were 65-79 
years old in 1997. Altogether 1449 (72.5 %) persons agreed to participate in the first phase of the 
re-examination (screening phase) in 1998. However, 40 persons who were screened, and 
referred for further evaluation in the second phase, refused to continue in the study. Thus, after 
an average follow-up of 21 years, a total of 1409 (70.5 %) participants completed the re-
examination with a complete cognitive assessment. The flow chart (Figure 2) presents the 
formation of the CAIDE study population. The CAIDE study was approved by the local ethics 
committee, and written informed consent was obtained from all participants before enrolment 
in the study in 1998. 
4.2 MIDLIFE (BASELINE) EXAMINATION 
The survey methods used during the midlife visits (baseline) were carefully standardized and 
complied with international recommendations. They also followed the WHO MONICA 
protocol in 1982 and 1987 (WHO MONICA Project Principal Investigators, 1988), and were 
comparable with the methods used in 1972 and 1977 (Vartiainen et al., 1994). 
4.2.1 Dietary assessment 
In brief, at baseline an exhaustive structured questionnaire (on average 135 items) was mailed to 
the participants prior to their visit and this was returned to the survey site. The self-
administered questionnaire contained sections on health-related behaviours (dietary habits, 
alcohol consumption, leisure-time and work-related PA and smoking), health status and 
medical history, including cerebrovascular and cardiovascular events and conditions diagnosed 
by a physician. Each survey questionnaire had approximately 20 multiple-choice questions 
about dietary habits. Most of these questions were qualitative or frequency-based, but the 
consumptions of milk, sour milk, eggs, coffee, tea, and sugar in tea/coffee were assessed 
quantitatively. Additionally, the usual daily number of bread slices consumed and the type of 
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spread used was inquired during the examination in a standardized way. The amount of spread 
was also asked: standard-sized bread slices with different amounts of spread per bread (0, 2.5, 
5, 10, or 15 g) were shown as examples. Fat intake from milk, sour milk and spreads was 
calculated and used as an indicator of total fat intake. In the analyses, the net amount of spreads 
was used; it was calculated as “gross amount of spreads * fat content“. Further, PUFAs, MUFAs 
and SFAs derived from spreads were calculated from these data. For the milk and sour milk, 
amounts of various fatty acids were calculated according to the information received from 
national milk company. PUFAs (2.5% of the FAs) were calculated as “milk fat * 0.025”, MUFAs 
(22.5% of the FAs) as “milk fat * 0.225”, and SFAs (62.5% of the FAs) as “milk fat * 0.625”. In 
study I, dietary fat intakes were dichotomized (two lowest tertiles = low intake vs. highest tertile 
= high intake), whereas in study II, dietary fat intakes from spreads and milk products were 
categorized into quartiles. The questions concerning alcohol consumption varied somewhat 
between different baseline sampling and late-life years. In study I, late-life alcohol consumption 
was used in the analyses as follows: 1) at least once a month, 2) less than once a month, 3) not 
using alcohol. In study IV (years 1982 and 1987), weekly alcohol consumption at midlife was 
inquired for beer, wine, spirits and so-called long drinks, and the total weekly alcohol intake 
(grams/week) was defined as follows: a bottle of beer containing 12.5 grams of alcohol, a glass 
of wine 12 g, a drink of spirits 12 g, and a long drink 14.5 g. 
4.2.2 Other assessments 
Leisure-time PA was assessed on the questionnaire as follows: “How often do you participate in 
leisure time PA that lasts at least 20-30 minutes and causes breathlessness and sweating?” There 
were six response categories: 1) daily, 2) 2-3 times a week, 3) once a week, 4) 2-3 times a month, 
5) a few times a year, 6) not at all. For the current analyses, the original categories were 
dichotomized into groups: 1) persons who participated in leisure-time PA at least twice a week 
(= active), and 2) persons who participated in leisure-time PA less than twice a week (= 
sedentary). Work-related PA including occupational and commuting PA was not used as a 
confounder in this thesis. Smoking was classified as ever/never smoker (Studies I-III) or as 
current/former/non-smoker (Study IV). 
At the survey site, measurement of BP, height and weight was also included, the two latter 
mentioned also enabling the calculation of BMI – weight (in kilograms) divided by height (in 
meters) squared. Furthermore, venous blood specimens were taken to determine serum 
cholesterol profiles. In 1972 and 1977, serum total cholesterol level was determined from frozen 
serum samples by using the Liebermann–Burchard method vs. in 1982 and 1987 from fresh 
serum samples by using an enzymatic method (CHOD-PAP Monotest, Boehringer, Mannheim, 
Germany). The enzymatic assay yielded values that were 2.4 % lower than those measured by 
the Liebermann–Burchard method; thus, the values for total cholesterol level from the 1972 and 
1977 surveys were corrected accordingly. All cholesterol levels were determined at the same 
central laboratory, and the laboratory data were standardized against national and international 
reference laboratories. 
4.3 LATE-LIFE EXAMINATION 
Survey methods in 1998 were identical to those applied in the previous surveys. Information on 
each subject’s medical status was updated and the history of cardio/cerebrovascular 
events/conditions (i.e. MI, stroke or DM) (yes/no), the use of cholesterol-lowering drugs as well 
as a questionnaire related to psychosocial factors were added. Blood leukocyte samples were 
analyzed to determine ApoE genotype. The standard phenol-chloroform technique was used to 
extract DNA; ApoE genotypes were analyzed by polymerase chain reaction and HhaI digestion, 
as described previously (Tsukamoto et al., 1993). For the analyses, ApoE genotypes were 
grouped into ApoE ε4 carriers (ε2/ε4, ε3/ε4, and ε4/ε4) and non-carriers (ε2/ε2, ε2/ε3, and 
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ε3/ε3). Among the participants (n = 1409) of the study, approximately one third (n = 489, 34.7 %) 
were ApoE ε4 carriers, and the remainder (n = 885, 62.8 %) non-carriers. In 1998, the depressive 
symptoms were measured with Beck depression scale (Beck et al., 1961). 
4.3.1 Measurement of cognitive functions 
In the late-life examination in 1998, cognitive functions were investigated in three phases 
(figure 2): 
1) Screening phase: all participants were evaluated using the following cognitive tests: 
 Mini Mental State Examination (MMSE) as a measure of global cognitive function 
(Folstein et al., 1975) 
 Immediate word recall tests for episodic memory (Nyberg et al., 1997; Heun et al., 1998); 
the mean number of correct words was calculated from three different 10 word lists 
 Category fluency test for semantic memory (Borkowski et al., 1967); the score was the 
number of correct animal names generated in 60 seconds 
 Purdue Peg Board task (Tiffin, 1968) and letter-digit substitution test for psychomotor 
speed (Wechsler, 1944); the sum of the normalized scores in these tests divided by two 
was calculated 
 Stroop colour-word test for executive functioning (Stroop, 1935); the difference was 
calculated between the time used for naming the colour of the ink in which 
incongruously named colour words are printed, and the time used for naming coloured 
rectangles 
 Prospective memory task (Einstein et al., 1997); at the beginning of the test-session, the 
subject was asked to remind the investigator, that he/she must sign a paper at the end of 
the test session. The score in the test was categorized as remembering without reminder 
(score=4), remembering with one reminder (score=3), remembering with two reminders 
(score=2), or not remembering (score=1). 
 Subjective memory rating (Bennett-Levy 1980); as a mean result of 22 questions all 
ranging from 1 (highest) to 4 (lowest). 
 
2) Clinical phase: subjects with ≤ 24 points on MMSE underwent a thorough cardiovascular and 
neurological examination by a physician, and a detailed neuropsychological evaluation by a 
neuropsychologist. A review board (comprising of the study physician, the study 
neuropsychologist and a senior neurologist) ascertained the preliminary diagnoses based on all 
available information. Subjects judged to have possible dementia were invited to phase 3 of the 
examination. 
 
3) Differential diagnostic phase included brain magnetic resonance imaging (MRI), blood tests, 
chest radiograph, electrocardiogram, and cerebrospinal fluid (CSF) analysis. All data 
accumulated from phases 1 and 2 were carefully re-assessed by the review board before the 
final diagnosis was established. Altogether 61 individuals were diagnosed with dementia, and 
48 of those had AD. In addition, 82 subjects received a diagnosis of MCI, and 1266 were 
categorized as normal controls. 
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Figure 2. Formation of the CAIDE study population. 
 
4.3.2 Diagnosis of MCI, dementia and AD 
The diagnosis of dementia was based on DSM-IV criteria (American Psychiatric Association, 
1994), and probable and possible ADs were diagnosed according to NINCDS-ADRDA criteria 
(McKhann et al., 1984). Patients with AD displayed generalized and/or medial temporal lobe 
atrophy, and none had significant vascular pathology on MRI. Isolated, minor lacunae or 
moderate white matter changes were not considered as exclusion criteria for AD. AD patients 
scored four or less on the Hachinski Ischemia Scale (Hachinski et al., 1975). VaD diagnosis was 
based on the NINDS-AIREN criteria (Román et al., 1993). Consensus criteria were used to 
diagnose other dementia types: frontotemporal dementia (FTD) (Neary et al., 1998), dementia 
with Lewy bodies (DLB) (McKeith et al., 1996), and alcohol-related dementia (Oslin et al., 1998). 
Dementia diagnoses for non-participants were derived from patient records of the local 
hospitals and primary health care centres. 
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Participants were classified as having MCI using a modified version of the Mayo Clinic AD 
Research Criteria (Petersen et al., 1999). These included: 1) memory complaint by patient, family 
or physician; 2) normal activities of daily living; 3) normal global cognitive function as judged 
by physician; 4) objective impairment of memory or other areas of cognitive functioning as 
evidenced by scores > 1.5 standard deviations (SD) below the age-appropriate mean; 5) Clinical 
Dementia Rating (CDR) score of 0.5; and 6) absence of dementia. 
4.4 STATISTICAL METHODS 
All statistical analyses were conducted using SPSS for Windows, version 11.5, 14.0 or 21 (SPSS 
Inc., Chicago, Illinois, USA) software. Additionally in study IV, version 17 of the PASW 
statistics was used in the finalized analyses. The differences between persons with MCI and 
cognitively normal persons, demented and non-demented, as well as between non-participants 
and participants of the follow-up study (including comparisons between women and men 
among participants), were investigated with independent samples t-test and chi square (Χ2) -
test. 
Multiple logistic regression analyses with adjustments for the main confounders were used 
to calculate Odds Ratios (ORs) with 95 % Confidence Intervals (CIs) for MCI (study I), dementia 
(studies II, III, IV), and AD (studies II, III, IV). In studies III and IV, the main analyses included 
only dementia and AD diagnoses from the study to ensure diagnostic accuracy, although the 
analyses were reran also including the dementia cases found in the follow-up non-participants 
from the medical records. In study II, the results shown in detail included also the non-
participants, because it was wished to include as many demented individuals as possible in the 
analyses. Analyses of covariance (ANCOVA) with Bonferroni adjustments for multiple 
comparisons were used to analyse differences in several cognitive functions according to the 
midlife fat intake (study I) and in MMSE according to the adherence to a healthy diet (study IV). 
The effect modification by ApoE ε4 (studies I, II, III) or sex (studies I, III) was investigated first 
by including the interaction terms into the analyses, and then carrying out analyses stratified by 
ApoE ε4/sex. In the second study, we also investigated the odds of dementia/AD in each effect 
modifier*exposure subgroup (ApoE ε4*fat intake) by creating variables including all the 
possible groupings. The level of significance was p ≤ 0.05 in all analyses. 
4.5 METHODOLOGICAL ISSUES OF THE SUB-STUDIES 
In the statistical analyses of this doctoral thesis, the 1972, 1977, 1982, and 1987 cohorts were 
combined. However, in study IV only the sub-samples first enrolled in either 1982 or 1987 were 
used, because for those subjects more extensive dietary information was available. 
4.5.1 Study I 
The first study focused on persons without dementia. Differences between individuals with 
MCI and cognitively normal persons were analysed with independent samples t-tests and Χ2 -
tests. The association between midlife dietary fat intake and MCI was investigated with 
multiple logistic regression analyses (two models). For cognitive functions, ANCOVA were 
applied with similar adjustments as for MCI. Those individuals who had dementia (n = 68) were 
excluded from the analyses. Dietary fat intakes i.e. intakes of total fat from milk products and 
spreads, SFAs, PUFAs and MUFAs derived from milk and spreads, and PUFA-SFA ratio (milk 
products and spreads) were dichotomized (two lowest tertiles = low intake vs. highest tertile = 
high intake), and the lowest category was used as the reference group (Table 9). Information 
concerning fats in cooking and baking in the household were also dichotomized: using 
vegetable oil or margarine vs. butter or butter–oil mixture. Additionally, in 1987, the frequency 
of fish consumption (n = 152) was investigated, and dichotomized into those who had eaten fish 
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at least twice a week vs. less. The first analyses were conducted by adjusting for midlife age, sex, 
education, follow-up time and other subtypes of fats. In model 2, further adjustments were 
made also for ApoE ε4 carrier status and midlife vascular risk factors including smoking, SBP, 
serum total cholesterol, and BMI. Further analyses controlled additionally either for midlife 
leisure-time PA, alcohol consumption, or vascular disorders at late-life including MI, stroke and 
DM. 
 
Table 9. Categories for different types of fats used in Study I. 
 
Type of fat Low High 
Total fat (from milk products and spreads) 0-38.0 g/day >38.0 g/day 
SFA from spreads 0-21.6 g/day >21.6 g/day 
MUFA from spreads 0-11.3 g/day >11.3 g/day 
PUFA from spreads 0-2.1 g/day >2.1 g/day 
PUFA-SFA ratio (milk products and spreads) 0-0.05 >0.05 
 
Abbreviations: MUFA = monounsaturated fatty acid; PUFA = polyunsaturated fatty acid; SFA = 
saturated fatty acid. 
 
4.5.2 Study II 
In the second study, we examined the role of midlife dietary fat intake on the subsequent 
development of dementia/AD; the dementia diagnoses of the non-participants derived from 
patient records of the local hospitals and primary health care centers were included. Fat intake 
from milk, sour milk and spreads was calculated and used as an indicator of total fat intake. 
Furthermore, PUFAs, MUFAs and SFAs derived from spreads were calculated from these data. 
For the logistic regression analyses, dietary fat intakes from spreads and milk products (milk 
and sour milk) were categorized into quartiles (Table 10), and the lowest quartile served as the 
reference group. Analyses were adjusted for midlife age, gender, education, follow-up time, 
milk fat and other subtypes of fats from spreads (model 1). Further analyses (model 2) 
controlled also for midlife vascular risk factors including smoking status (smoker/non-smoker), 
SBP (as continuous), cholesterol (as continuous), and BMI (as continuous), ApoE ε4 carrier 
status (carrier/non-carrier), the history of vascular disorders (inquired at the re-examination) 
including MI (yes/no), stroke (yes/no), and DM (yes/no). 
 
Table 10. Categories for different types of fats used in Study II. 
 
Type of fat 1st quartile 
(g/day) 
2nd quartile 
(g/day) 
3rd quartile 
(g/day) 
4th quartile 
(g/day) 
Total fat (from milk products and spreads) 0-18.6 18.7-30.2 30.3-46.6 >46.6 
Fat from milk products (milk/sour milk) 0-4.8 4.9-9.4 9.5-17.2 >17.2 
Fat from spread 0-12.5 12.6-22.5 22.6-35.0 >35.0 
 SFA from spreads 0-4.1 4.2-8.3 8.4-15.8 >15.8 
 MUFA from spreads 0-3.7 3.8-6.2 6.3-9.9 >9.9 
 PUFA from spreads 0-0.4 0.5-0.8 0.9-2.9 >2.9 
 
Abbreviations: MUFA = monounsaturated fatty acid; PUFA = polyunsaturated fatty acid; SFA = 
saturated fatty acid. 
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4.5.3 Study III 
The third study focused on evaluating the associations between midlife coffee/tea consumption 
and the development of dementia/AD later in life. The consumptions of coffee and tea were 
assessed quantitatively at the midlife examination. In this study, the following question was 
used: “How many cups of coffee do you drink daily?” to assess the level of coffee consumption; 
one cup of coffee equals 1.25 dl. According to the responses, the participants were categorized 
into three coffee drinking categories: consumers of 0-2 cups (low, n = 223), 3–5 cups (moderate, 
n = 641) and >5 cups (high, n = 542) per day. Information about the type of coffee was collected 
only in the year 1987 (filtered coffee n = 129, boiled coffee n = 63, instant coffee n = 6), but due to 
the small sample size no further analyses could be done. Subsequently, the question concerning 
tea consumption was dichotomized into those not drinking tea (0 cup/day) vs. those drinking 
tea (≥1 cup/day). Logistic regression models were used to analyze independent effect of coffee 
or tea drinking to the risk of dementia and AD so that the lowest category served as the 
reference group. The analyses were first adjusted for midlife age, sex, education, follow-up time 
and community of residence (model 1). Additional adjustments were made also for midlife 
smoking, SBP, serum total cholesterol, BMI, and PA (model 2), as well as for the ApoE ε4 allelic 
status, the presence of late-life MI/stroke/DM, and Beck depressive scale (Model 3). In addition, 
analyses for dementia were rerun including also diagnoses from the patient records for the non-
participants in the follow-up (models 1 and 2). 
4.5.4 Study IV 
The fourth study examined the long-term effects of DPs on the subsequent development of 
dementia/AD. The analyses were restricted to those participants that were first included in 1982 
or 1987, since the information about dietary habits was more extensive (Table 11).  
 
Table 11. Dietary questions included in the midlife healthy-diet index. 
 
Question Answering options 
Beneficial components 
How often have you eaten vegetables or root vegetables 
(not potato) as such, grated or fresh during last week (7 days)? 
1) never 
2) during 1-2 days/week 
3) during 3-5 days/week 
4) during 6-7 days/week 
How often have you eaten fresh or frozen berries or fruits during 
last week (7 days)? 
1) never 
2) during 1-2 days/week 
3) during 3-5 days/week 
4) during 6-7 days/week 
How many slices of bread do you use daily? (Asked at the study site) Open 
How often do you consume fish? 
(This question only from year 1987.) 
1) once/day 
2) almost every day 
3) couple of times/week 
4) once/week 
5) once or twice/month 
6) rarely or never 
How many cups of coffee do you drink typically during one day? Open 
Monounsaturated fatty acids (MUFAs) from milk products and 
spreads (Consumption about spreads was asked at the study site) 
Open 
Polyunsaturated fatty acids (PUFAs) from milk products and 
spreads (Consumption about spreads was asked at the study site) 
Open 
 Table 11 to be continued 
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Table 11. (continued) Dietary questions included in the midlife healthy-diet index. 
 
Question Answering options 
Detrimental/unhealthy components 
How often do you consume sausage foods? 1) ≥ once/day 
2) almost every day 
3) couple of times/week 
4) once/week 
5) once or twice/month 
6) rarely or never 
How many eggs (boiled, fried) do you eat normally during one week? Open 
How often do you eat candies? 1) never 
2) ≤ once/week 
3) couple of times/week 
4) ≥ once/day 
How often do you drink sweet (sugary) soft drinks? 1) never  
2) ≤ once/week 
3) couple of times/week 
4) ≥ once/day 
How many sugar lumps and teaspoonfuls of granulated sugar do 
you use when drinking one cup of coffee or tea? 
Open 
How often do you consume salty fish? 
(This question only from year 1982.) 
1) ≥ once/day 
2) almost every day 
3) couple of times/week 
4) once/week 
5) once or twice/month 
6) rarely or never 
Saturated fatty acids (SFAs) from milk products and spreads 
(Consumption about spreads was asked at the study site) 
Open 
Other components 
How many glasses of alcohol (typical measure) or bottles have you 
been drinking during last week? (If you have not drunk any alcohol, 
mark 0.) 
 
Beer (IV A or III) ________ bottles 
Long drinks ________ bottles 
Spirits ________ measures (~ 4cl) 
Wine ________ glasses 
How often do you add salt in your food on the dining table? 1) almost never 
2) usually, when the food is not salty 
enough 
3) almost always before tasting 
Type of fats used in cooking 1) vegetable oil/margarine 
2) butter/butter-oil mixture 
Type of fats used in baking 1) vegetable oil/margarine 
2) butter/butter-oil mixture 
 
For calculating the midlife healthy-diet index (HDI), the method was modified from that 
Trichopoulou et al. (2003) used for the construction of the MEDI score. The composition of the 
CAIDE midlife HDI is shown in table 12. A value of 0 or 1 was assigned to each of the 18 food 
groups, using mainly sex-specific medians as cutoffs: one point/variable was given, when 
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consumption of the beneficial components was at or above the sex-specific median level, and 
for detrimental components when the consumption was below the sex-specific median level. 
Beneficial components included vegetables and roots, berries and fruits, bread, fish (the 1987 
sample only), coffee drinking, and MUFAs and PUFAs from milk products and spreads 
(consumption about spreads was inquired at the study site). Unhealthy components included 
sausage foods, eggs, candies, sweet soft drinks, sugar lumps in coffee/tea, salty fish (the 1982 
sample only), and SFAs from milk products and spreads. For alcohol drinking, a value of 1 was 
assigned to persons with moderate alcohol consumption and a value of 0 to persons not 
consuming alcohol or consuming abundantly (moderate and abundant were defined with sex-
specific median values among drinkers). With respect to the use of salt on the dining table, a 
value of 1 was given to persons who were not adding salt to the meals and a value of 0 to the 
other categories (i.e. adding salt when the food is not salty enough or almost always before 
tasting). Finally, we also included fats used for cooking and baking in the household into our 
HDI: using vegetable oil or margarine was assigned a value of 1 and butter or a butter-oil 
mixture a value of 0. There were some missing values for some of the food groups (0–19 persons 
with missing values apart from the variable ‘fat used in baking’, where there were 51 missing 
values). Those with missing values were given 0.5 points for that respective food group. After 
adding up the points of every food category, the total HDI was estimated that could range 
theoretically from 0 (minimal adherence to healthy diet) to 17 (maximal adherence). The HDI 
was dichotomized based on median values: 0–8 points (low adherence to healthy diet) and >8 
points (high adherence to healthy diet). 
 
Table 12. Formation of the CAIDE midlife healthy-diet index. 
 
Food consumption Points a 
Men Women 
Beneficial components 1 point, if… 1 point, if… 
 Vegetables and roots ≥1 time/week ≥3 times/week 
 Berries and fruits ≥1 time/week ≥3 times/week 
 Bread >5 slices/day >3 slices/day 
 Fish (in subsample only) b ≥once/week ≥once/week 
 Coffee >4 cups/day >3 cups/day 
 MUFA from milk products and spreads >11.2 g/day >6.13 g/day 
 PUFA from milk products and spreads >2.06 g/day >1.04 g/day 
Detrimental/unhealthy components   
 Sausage foods ≤twice/month <once/month 
 Eggs (boiled, fried) <2/week <2/week 
 Candies never never 
 Sweet soft drinks never never 
 Sugar lumps in tea and coffee <6 lumps/day <2 lumps/day 
 Salty fish (in subsample only) b <once/month <once/month 
 SFA from milk products and spreads c <19.5 g/day <10.2 g/day 
Alcohol drinking d moderately (1-60 g/week) moderately (1-23.9 g/week) 
Use of salt on the dining table not adding salt to meals not adding salt to meals 
Type of fats used for cooking vegetable oil or margarine vegetable oil or margarine 
Type of fats used for baking vegetable oil or margarine vegetable oil or margarine 
 
Total score indicating low vs. high adherence to healthy diet: 0–8 points vs. >8 points. 
Table 12 to be continued. 
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Table 12. (continued) 
 
a One point for each variable was given, if a person had a consumption level at or above the sex-
specific median level for the beneficial component, and below the sex-specific median for 
detrimental components. For variables where medians were not used, 1 point was given for a 
favorable consumption pattern. For alcohol drinking, moderate drinking was defined as drinking 
below the sex-specific median among drinkers. Both non-drinkers and heavy drinkers had 0 points. 
b In the calculation of the HDI, information on salty fish consumption was available for subjects 
included in 1982 and fish consumption for subjects included in 1987. Therefore, there were 17 items 
available for each subject. 
c For example, 5 g of spread (margarine containing 60% fat) contains 1.2 g MUFAs, 0.9 g PUFAs, 
and 0.7 g SFAs (values may vary depending on product), and 1 glass (2 dl) of semi-skimmed milk 
(1.5% fat) contains 0.7 g MUFAs, 0.1 g PUFAs, and 2.1 g SFAs. 
d One glass of wine or 1 shot of liquor contains on average 12 g of alcohol, 1 bottle of beer contains 
12.5 g and 1 bottle of long drink contains 14.5 g of alcohol. 
Abbreviations: CAIDE = Cardiovascular risk factors, Aging and Incidence of Dementia study; HDI = 
healthy-diet index; MUFA = monounsaturated fatty acid; PUFA = polyunsaturated fatty acid; SFA = 
saturated fatty acid. 
 
 
 
The independent effect of a healthy diet on the risk of dementia and AD was investigated with 
multiple logistic regression analyses, so that the group with low adherence to a healthy diet 
served as the reference group. The analyses were controlled first for age, sex, education, follow-
up time, community of residence, and ApoE ε4 carrier status (model 1). Model 2 was adjusted 
additionally for cardiovascular risk factors including midlife SBP, serum total cholesterol, BMI, 
and the presence of late-life MI/stroke/DM. Model 3 was adjusted additionally for midlife 
leisure-time PA and smoking. For MMSE, analysis of covariance (ANCOVA) was applied with 
similar adjustments as for dementia and AD. Bonferroni adjustments were used for multiple 
comparisons. For the non-participants, logistic regression analyses were done to the appropriate 
extent (model 1 was adjusted for age, sex, education, and community of residence; model 2 was 
adjusted additionally for midlife SBP, serum total cholesterol and BMI, and model 3 was 
adjusted additionally for midlife leisure-time PA and smoking). 
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5 Results 
5.1 GENERAL CHARACTERISTICS OF THE CAIDE POPULATION 
Of the 2000 individuals invited to the re-examination in 1998, altogether 1449 (72.5 %) came to 
the screening visit (Figure 2) (average follow-up 21 years). 1409 individuals (70.5 %) 
participated in the complete re-examination. A total of 61 (4.3 %) persons were diagnosed with 
dementia, out of which 48 had AD. The dementia diagnoses of the non-participants (subjects 
who did not attend or complete the re-examination) were derived from patient records of the 
local hospitals and primary health care centers. The total number of persons with dementia 
increased to 117 (5.9 % of the total sample of 2000 persons), of which 76 (3.8 % of the total 
population) had AD. There were 82 (5.8 %) participants who were diagnosed as having MCI. 
The mean age (SD) of the population at the midlife examination was 50.6 (6.0) years, and the 
mean age at late-life examination was 71.6 (4.1) years. There were 1250 women (62.5 %), and 750 
men (37.5 %). Half of the population sampled lived in or close to the town of Kuopio and half 
lived in or close to the town of Joensuu. 
5.1.1 Participants and non-participants 
The non-participants in the late-life survey differed from the participants in that they were 
older and less educated (Table 13). The non-participants also had had worse vascular risk factor 
profiles at midlife, with higher SBP, DBP, total cholesterol level, and BMI. The proportion of 
smokers also tended to be somewhat higher among the non-participants. Additionally, the total 
fat intake and the consumption of SFAs and MUFAs were higher, whereas consumption of tea 
was lower among the non-participants. Dementia was more prevalent among the non-
participants compared to the participants. 
5.1.2 Women and men 
Among the participants, women were slightly older than men at the time of late-life 
examination (Table 14). Instead, the mean education was higher in the men. At midlife, the total 
fat intake and the consumption of SFAs, MUFAs and PUFAs from milk, sour milk and spreads 
were all higher in the men. Men tended to drink more coffee at midlife than women, but there 
were no differences in tea drinking habits between sexes. Smoking and alcohol drinking at least 
once/month were more common among men than women. SBP, total cholesterol and BMI were 
similar regardless of sex, but DBP was higher in the men. Men were more often physically 
active in their leisure-time. The occurrence of dementia, AD, and MCI was similar among 
women and men, as were the occurrences of stroke and DM. However, there were twice as 
many men who had suffered a MI than women. Women had higher scores on the Beck 
depression scale in late-life compared to men. 
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Table 13. General characteristics of the CAIDE population. 
 
  All 
n = 2000 
Participants 
n = 1409 
Non-participants 
n = 591 
p *) 
Demographic characteristics 
Age, years Midlife 50.6 (6.0) 50.4 (6.0) 51.2 (5.9) <0.01 
Latelife 71.6 (4.1) 71.3 (4.0) 72.4 (4.1) <0.01 
Sex, n (%) Women 1250 (62.5) 875 (62.1) 375 (63.5) 0.57 
Men 750 (37.5) 534 (37.9) 216 (36.5) 
Community, n (%) Kuopio 1000 (50.0) 691 (49.0) 309 (52.3) 0.19 
Joensuu 1000 (50.0) 718 (51.0) 282 (47.7) 
Education, years 8.3 (3.4) 8.6 (3.5) 7.5 (3.0) <0.01 
Midlife dietary factors 
Total fat, g/d 36.3 (26.8) 35.1 (26.0) 39.1 (28.3) <0.01 
SFA, g/d 20.9 (17.5) 20.2 (16.9) 22.7 (18.6) <0.01 
MUFA, g/d 10.7 (8.0) 10.4 (7.8) 11.5 (8.5) <0.01 
PUFA, g/d 3.0 (4.5) 2.9 (4.4) 3.1 (4.7) 0.41 
Coffee drinking, cups/d 4.9 (2.4) 4.8 (2.4) 5.0 (2.3) 0.11 
Tea drinking, cups/d 0.8 (1.2) 0.8 (1.2) 0.6 (1.2) <0.01 
Alcohol drinking, n (%) < once/month 1047 (52.4) 723 (51.3) 324 (54.8) 0.53 
≥ once/month 417 (20.9) 295 (20.9) 122 (20.6) 
Midlife lifestyle factors 
SBP, mmHg 146.0 (20.6) 144.3 (19.8) 150.2 (21.7) <0.01 
DBP, mmHg 89.9 (11.1) 89.2 (10.9) 91.7 (11.3) <0.01 
Total cholesterol, mmol/l 6.8 (1.2) 6.7 (1.2) 7.0 (1.3) <0.01 
BMI, kg/m2 26.8 (4.0) 26.6 (3.7) 27.2 (4.5) <0.01 
Smokers, n (%) 886 (44.3) 605 (42.9) 281 (47.5) 0.06 
Leisure-time physical 
activitya, n (%) 
Active 781 (39.1) 558 (39.6) 223 (37.7) 0.61 
Sedentary 1154 (57.7) 812 (57.6) 342 (57.9) 
Late-life cognitive impairment 
Dementia, n (%) 117 (5.9) 68 (4.8) 49 (8.3) <0.01 
AD, n (%) 76 (3.8) 51 (3.6) 25 (4.2) 0.44 
 
*) p-value is for the difference between participants and non-participants. T-test was used for 
continuous, and chi square test for categorical variables. 
The values are means (standard deviations [SDs]) unless otherwise stated. 
a Physically active at leisure-time indicates exercise at least twice a week, while physically 
sedentary/inactive indicates exercise less than twice a week. 
Abbreviations: AD = Alzheimer’s disease; BMI = body mass index; DBP = diastolic blood pressure; 
MUFA = monounsaturated fatty acid; PUFA = polyunsaturated fatty acid; SBP = systolic blood 
pressure; SFA = saturated fatty acid. Total fat, SFA, MUFA and PUFA are calculated from milk, sour 
milk and spreads. 
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Table 14. General characteristics of the CAIDE participants (n = 1409) according to sex. 
 
  Women 
n = 875 
Men 
n = 534 
p *) 
Demographic characteristics 
Age, years Midlife 50.5 (6.1) 50.0 (5.8) 0.12 
Latelife 71.5 (4.1) 70.9 (3.9) <0.01 
Community, n (%) Kuopio 418 (47.8) 273 (51.1) 0.22 
Joensuu 457 (52.2) 261 (48.9) 
Education, years 8.5 (3.2) 8.9 (3.8) 0.04 
Follow-up time, years 20.9 (4.9) 20.8 (4.9) 0.71 
ApoE ε4, n (%) Carriers 289 (33.0) 200 (37.5) 0.10 
Non-carriers 563 (64.3) 322 (60.3) 
Midlife dietary factors 
Total fat, g/d 27.4 (17.8) 47.7 (31.8) <0.01 
SFA, g/d 15.8 (11.7) 27.4 (21.1) <0.01 
MUFA, g/d 8.1 (5.3) 14.1 (9.6) <0.01 
PUFA, g/d 2.2 (3.1) 4.1 (5.8) <0.01 
Coffee drinking, cups/d 4.7 (2.1) 5.0 (2.8) 0.07 
Tea drinking, cups/d 0.8 (1.2) 0.8 (1.3) 0.81 
Alcohol drinking, n (%) < once/month 524 (59.9) 199 (37.3) <0.01 
≥ once/month 108 (12.3) 187 (35.0) 
Midlife lifestyle factors 
SBP, mmHg 144.6 (20.7) 143.6 (18.3) 0.36 
DBP, mmHg 88.5 (10.7) 90.4 (11.2) <0.01 
Total cholesterol, mmol/l 6.8 (1.3) 6.7 (1.1) 0.10 
BMI, kg/m2 26.6 (4.0) 26.5 (3.1) 0.61 
Smokers, n (%) 200 (22.9) 405 (75.8) <0.01 
Leisure-time physical activitya, n (%) Active 317 (36.2) 241 (45.1) <0.01 
Sedentary 526 (60.1) 286 (53.6) 
Late-life clinical characteristics 
Dementia, n (%) 35 (4.0) 26 (4.9) 0.44 
AD, n (%) 29 (3.3) 19 (3.6) 0.79 
MCI, n (%) 55 (6.3) 27 (5.1) 0.36 
MI, n (%) 91 (10.4) 116 (21.7) <0.01 
Stroke, n (%) 57 (6.5) 42 (7.9) 0.35 
DM, n (%) 49 (5.6) 42 (7.9) 0.10 
Beck depression scale 10.4 (6.7) 8.6 (6.4) <0.01 
 
*) p-value is for the difference between women and men. T-test was used for continuous, and chi 
square test for categorical variables. The values are means (SDs) unless otherwise stated. 
a Physically active at leisure-time indicates exercise at least twice a week, while physically 
sedentary/inactive indicates exercise less than twice a week. 
Abbreviations: AD = Alzheimer’s disease; BMI = body mass index; DBP = diastolic blood pressure; 
DM = diabetes mellitus; HDI = healthy-diet index; MCI = mild cognitive impairment; MI = 
myocardial infarction; MUFA = monounsaturated fatty acid; PUFA = polyunsaturated fatty acid; SBP 
= systolic blood pressure; SFA = saturated fatty acid. Total fat, SFA, MUFA and PUFA are calculated 
from milk, sour milk and spreads. 
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5.1.3 MCI 
The participants diagnosed as having MCI were older than controls at the time of the late-life 
examination (Table 15). They were less educated, had higher serum total cholesterol level at 
midlife, a tendency to have higher midlife SBP, as well as a lower intake of PUFAs from milk, 
sour milk and spreads compared to cognitively normal persons. As expected, the MCI group 
had poorer late-life cognitive functioning in all of the measured domains - global cognitive 
functioning, episodic, semantic and prospective memories, psychomotor speed and executive 
functioning. 
5.1.4 Dementia 
Participants with dementia were older than controls at the time of the late-life examination 
(Table 15). They were also less educated, were more often ApoE ε4 carriers, and had higher 
midlife values of SBP, DBP, serum total cholesterol, and BMI compared to cognitively normal 
subjects. The occurrences of MI and stroke were higher among the group with dementia than 
among controls, as was the presence of depressive symptoms. As expected, the dementia group 
had the poorest performance in cognitive tests. 
5.1.5 Adherence to healthy diet 
Individuals with low midlife adherence to a healthy diet were less educated as compared to the 
high adherence group (Table 16). The low adherence group also had higher DBP and BMI, they 
were more often sedentary, and were more often diagnosed with dementia/AD later in life. 
Altogether 59.0 % of the non-participants in the CAIDE 1998 re-examination belonged to the 
group with a low adherence to a healthy diet compared to 53.7 % of the participants; however, 
the difference was not statistically significant (p = 0.29). 
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Table 15. General characteristics of CAIDE participants (n=1409) according to cognition in 1998. 
 
  Normal 
n = 1266 
Clinical MCI 
n = 82 
Demented 
n = 61 
p 1) p 2) 
Demographic characteristics 
Age, years Midlife 50.1 (6.0) 51.7 (5.8) 53.4 (4.8) 0.02 <0.01 
Latelife 71.0 (3.9) 72.8 (4.1) 74.5 (3.9) <0.01 <0.01 
Sex, n (%) Women 785 (62.0) 55 (67.1) 35 (57.4) 0.36 0.47 
Men 481 (38.0) 27 (32.9) 26 (42.6) 
Community, n (%) Kuopio 600 (47.4) 49 (59.8) 42 (68.9) 0.03 <0.01 
Joensuu 666 (52.6) 33 (40.2) 19 (31.1) 
Education, years 8.8 (3.5) 6.8 (2.4) 6.7 (2.6) <0.01 <0.01 
Follow-up time, years 20.9 (5.0) 21.1 (4.8) 21.1 (4.4) 0.73 0.71 
ApoE ε4, n (%) Carriers 427 (33.7) 31 (37.8) 31 (50.8) 0.44 <0.01 
Non-carriers 810 (64.0) 49 (59.8) 26 (42.6) 
Midlife dietary factors 
Total fat, g/d 34.9 (26.2) 38.2 (23.9) 36.1 (24.8) 0.26 0.72 
SFA, g/d 20.0 (17.0) 23.0 (16.0) 20.0 (16.1) 0.12 0.99 
MUFA, g/d 10.4 (7.9) 11.0 (6.8) 10.6 (7.7) 0.49 0.77 
PUFA, g/d 3.0 (4.5) 2.3 (2.9) 3.4 (4.9) 0.06 0.50 
Coffee drinking, cups/d 4.8 (2.4) 4.8 (2.3) 4.8 (2.9) 0.93 0.91 
Tea drinking, cups/d 0.8 (1.2) 0.9 (1.3) 1.0 (1.6) 0.47 0.35 
Alcohol drinking, 
n (%) 
< once/month 652 (51.5) 40 (48.8) 31 (50.8) 0.30 0.29 
≥ once/month 257 (20.3) 21 (25.6) 17 (27.9) 
Midlife lifestyle factors 
SBP, mmHg 143.4 (19.4) 148.4 (23.2) 155.4 (20.7) 0.06 <0.01 
DBP, mmHg 89.0 (10.8) 90.6 (11.0) 92.3 (12.2) 0.19 0.02 
Total cholesterol, mmol/l 6.7 (1.2) 7.2 (1.2) 7.1 (1.0) <0.01 <0.01 
BMI, kg/m2 26.5 (3.7) 27.1 (3.6) 27.9 (3.9) 0.12 <0.01 
Smokers, n (%) 548 (43.3) 29 (35.4) 28 (45.9) 0.16 0.69 
Leisure-time physical 
activitya, n (%) 
Active 502 (39.7) 37 (45.1) 19 (31.1) 0.29 0.16 
Sedentary 729 (57.6) 42 (51.2) 41 (67.2) 
Late-life cognitive functioning 
Global cognitive function (MMSE) 26.3 (1.9) 22.6 (1.4) 20.8 (3.1) <0.01 <0.01 
Episodic memory 5.1 (1.2) 4.2 (1.2) 3.0 (1.5) <0.01 <0.01 
Semantic memory 20.4 (5.9) 16.8 (4.7) 13.0 (5.3) <0.01 <0.01 
Psychomotor speed 0.12 (0.80) -0.5 (0.6) -1.1 (1.0) <0.01 <0.01 
Executive functioning (Stroop) 39.4 (20.5) 50.0 (34.4) 52.0 (41.9) 0.01 0.04 
Prospective memory 2.7 (0.8) 2.2 (0.8) 1.7 (0.8) <0.01 <0.01 
Late-life clinical characteristics 
MI, n (%) 172 (13.6) 16 (19.5) 19 (31.1) 0.11 <0.01 
Stroke, n (%) 80 (6.3) 7 (8.5) 12 (19.7) 0.35 <0.01 
DM, n (%) 78 (6.2) 7 (8.5) 6 (9.8) 0.37 0.15 
Beck depression scale 9.6 (6.5) 10.2 (7.9) 12.3 (7.5) 0.52 0.02 
p1) is for the difference between cognitively normal persons and MCI, p2) for the difference between cognitively 
normal persons and demented. T-test was used for continuous, and chi square test for categorical variables. 
The values are means (SDs) unless otherwise stated. 
a Physically active at leisure-time indicates exercise at least twice a week, while physically sedentary/inactive 
indicates exercise less than twice a week. Abbreviations: BMI = body mass index; DBP = diastolic blood 
pressure; MCI = mild cognitive impairment; MMSE = Mini Mental State Examination; MUFA = monounsaturated 
fatty acid; PUFA = polyunsaturated fatty acid; SBP = systolic blood pressure; SFA = saturated fatty acid. 
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Table 16. Demographic and clinical characteristics by healthy-diet index for participants in the 1982 
and 1987 midlife examination (n=525). 
 
Characteristics  Low adherence 
(0-8 points) 
n = 289 
High adherence 
(> 8 points) 
n = 236 
p *) 
Demographics 
Age, years Midlife 56.9 (4.1) 57.2 (3.9) 0.37 
Latelife 71.1 (3.8) 71.1 (3.9) 0.85 
Sex, n (%) Women 181 (62.6) 143 (60.6) 0.63 
Men 108 (37.4) 93 (39.4) 
Community, n (%) Kuopio 140 (48.4) 108 (45.8) 0.54 
Joensuu 149 (51.6) 128 (54.2) 
Follow-up time, years 14.2 (2.4) 14.0 (2.5) 0.24 
Education, years 7.7 (3.0) 8.8 (3.7) <0.01 
Midlife vascular factors 
SBP, mmHg 149.4 (22.1) 147.4 (19.9) 0.28 
DBP, mmHg 88.7 (12.0) 86.3 (11.0) 0.02 
Total cholesterol, mmol/l 6.7 (1.2) 6.6 (1.3) 0.30 
BMI, kg/m2 27.9 (4.6) 27.1 (4.0) 0.04 
Leisure-time physical 
activitya, n (%) 
Active 106 (39.6) 117 (52.7) <0.01 
Sedentary 162 (60.4) 105 (47.3) 
Smokingb, n (%) 
 
 
Current smoker 50 (18.1) 42 (18.3) 0.97 
Former smoker 59 (21.4) 47 (20.5) 
Never smoker 167 (60.5) 140 (61.1) 
Late-life clinical characteristics 
Dementia, n (%) 21 (7.3) 8 (3.4) 0.05 
AD, n (%)c 10 (4.9) 1 (0.6) 0.01 
MCI, n (%)c 14 (7.2) 7 (4) 0.18 
MI, n (%)c 28 (13.5) 26 (14.5) 0.78 
Stroke, n (%)c 14 (6.8) 13 (7.3) 0.85 
DM, n (%)c 15 (7.2) 11 (6.2) 0.69 
ApoE ε4, n (%)c Carriers 63 (30.6) 64 (36.2) 0.25 
Non-carriers 143 (69.4) 113 (63.8) 
 
*) p-value is for the difference between persons with a high and low adherence to healthy diet. T-
test was used for continuous, and chi square test for categorical variables. The values are means 
(SDs) unless otherwise stated. 
a Physically active at leisure-time indicates exercise at least twice a week, while physically 
sedentary/inactive indicates exercise less than twice a week. 
b Current smoker = has smoked within a year; former smoker = has smoked >1 year ago; never 
smoker = has never smoked. 
c Data for late-life clinical characteristics including MI, stroke and DM as well as for late-life AD, MCI 
and ApoE are shown only for participants (n = 385). 
Abbreviations: BMI = body mass index; DBP = diastolic blood pressure; MCI = mild cognitive 
impairment; MI = myocardial infarction; SBP = systolic blood pressure. 
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5.2 DIETARY FATS AND MCI (STUDY I) 
High total fat intake at midlife was associated with an increased risk of MCI (Figure 3a). 
Persons with high midlife SFA intake from milk, sour milk and spreads had more than a two-
fold risk of MCI compared to those persons with a low SFA intake (Figure 3b). The intakes of 
PUFA (Figure 3c) or MUFA (Figure 3d) or PUFA-SFA ratio (model 2: OR 0.91, 95 % CI 0.53-
1.56) did not differ between the high vs. low intake groups. There was no relation between 
choice of fats (vegetable oil/margarine vs. butter/butter-oil mixture) in cooking (OR 1.20, 95 % 
CI 0.72-2.00) or in baking (OR 1.06, 95 % CI 0.61-1.82) in the household and the risk of MCI. 
These results were not modified after controlling additionally for midlife leisure-time PA, 
alcohol consumption, or vascular disorders at late-life (MI, stroke, DM). The frequency of fish 
consumption was also investigated in 1987, but further analyses were restricted due to the too 
small number of persons (n = 152). 
In the analyses stratified by sex, abundant SFA intake was associated with an increased risk 
(model 2: OR 3.20, 95 % CI 1.13-9.06), and higher PUFA intake with a decreased risk of MCI (OR 
0.26, 95 % CI 0.07-0.90) only among women. In the analyses stratified by the ApoE ε4, total fat 
intake was associated with an increased risk of MCI only among ApoE ε4 non-carriers (OR 2.05, 
95 % CI 1.07-3.93), whereas SFA intake was associated with an increased risk of MCI only 
among ApoE ε4 carriers (OR 5.06, 95 % CI 1.35-18.94). No significant interactions were detected 
between sex or ApoE and dietary fat intake. 
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Figure 3. Association between dietary fats and mild cognitive impairment (MCI). 
 
Values are Odds Ratios (ORs) with 95 % Confidence Intervals (CIs); CIs are shown in the figure with 
black bars. * p ≤ 0.05. Adjusted for age, sex, education, follow-up time, other subtypes of fats 
(except for total fat intake), ApoE ε4 carrier status and midlife vascular factors (systolic blood 
pressure, body mass index, total cholesterol, smoking). 
Abbreviations: MUFA = monounsaturated fatty acid; PUFA = polyunsaturated fatty acid; SFA = 
saturated fatty acid. 
 
5.3 DIETARY FATS AND COGNITIVE FUNCTIONS (STUDY I) 
The association between midlife dietary fat intake and different domains of cognitive 
functioning was investigated among participants without dementia in 1998. Subjects with a 
high total fat intake at midlife performed significantly worse in domains of global cognitive 
function and psychomotor speed in late-life than the persons with lower intake (Table 17). 
Abundant SFA intake from milk, sour milk and spreads at midlife was associated with poorer 
global cognitive function and prospective memory. High PUFA intake tended to be associated 
with better semantic memory, higher PUFA-SFA ratio with better performance on psychomotor 
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speed and executive function, and frequent fish consumption (i.e. at least twice per week) with 
better global cognitive function (p = 0.09) and semantic memory (p = 0.06). Performance on 
psychomotor speed was additionally worse among those persons who had chosen butter or 
butter-oil mixture in baking (p = 0.03) or in cooking (p for trend = 0.07) at midlife than among 
those persons using vegetable oil or margarine. In addition, frequent fish consumption tended 
to be associated with better global cognitive function (p for trend = 0.09) and semantic memory 
(p for trend = 0.06). After controlling additionally for midlife leisure-time PA, alcohol 
consumption, or vascular disorders at late-life, the effect of all fat types on cognitive function 
remained virtually the same. When the analyses were stratified by sex, the results were 
primarily significant among women. The analyses stratified by ApoE showed no clear pattern 
of association between midlife fat intake and different cognitive domains. 
 
 
Table 17. Association of midlife fat intake with cognitive functioning in late-life. 
 
Fat intake Global 
cognitive 
function 
(MMSE) 
Episodic 
memory 
Semantic 
memory 
Psychomotor 
speed 
Executive 
function 
(Stroop) 
Prospective 
memory 
Total fat 
 Low (0-38.0 g) 26.2 (0.1) 5.0 (0.04) 20.3 (0.2) 0.10 (0.03) 39.8 (0.8) 2.7 (0.03) 
 High (>38.0 g) 25.9 (0.1) 4.9 (0.1) 20.0 (0.3) -0.02 (0.04) 41.0 (1.1) 2.6 (0.04) 
 p 0.05 0.19 0.32 0.02 0.37 0.18 
SFA from milk and spreads 
 Low (0-21.6 g) 26.2 (0.1) 5.0 (0.05) 20.4 (0.2) 0.08 (0.03) 39.3 (0.9) 2.7 (0.04) 
 High (>21.6 g) 25.8 (0.1) 4.9 (0.1) 19.7 (0.4) 0.02 (0.05) 42.0 (1.5) 2.6 (0.1) 
 p 0.03 0.30 0.12 0.35 0.18 0.05 
PUFA from milk and spreads 
 Low (0-2.1 g) 26.0 (0.1) 5.0 (0.05) 19.9 (0.2) 0.04 (0.03) 39.9 (0.9) 2.7 (0.04) 
 High (>2.1 g) 26.1 (0.1) 4.9 (0.1) 20.8 (0.3) 0.1 (0.04) 40.8 (1.3) 2.7 (0.05) 
 p 0.59 0.29 0.07 0.20 0.60 0.88 
PUFA-SFA ratio (milk and spreads) 
 Low (0-0.05 g) 26.0 (0.1) 5.0 (0.04) 20.1 (0.2) 0.04 (0.03) 40.9 (0.8) 2.7 (0.03) 
 High (>0.05 g) 26.1 (0.1) 4.9 (0.1) 20.3 (0.3) 0.1 (0.04) 38.6 (1.1) 2.7 (0.04) 
 p 0.31 0.48 0.64 0.09 0.09 0.56 
MUFA from milk and spreads 
 Low (0-11.3 g) 26.1 (0.1) 5.0 (0.05) 20.4 (0.2) 0.09 (0.03) 39.7 (0.9) 2.7 (0.04) 
 High (>11.3 g) 26.0 (0.1) 4.9 (0.1) 19.7 (0.4) 0.01 (0.05) 41.2 (1.5) 2.7 (0.1) 
 p 0.61 0.45 0.17 0.23 0.45 0.77 
 
Values are adjusted mean scores (standard errors) from analyses of covariance (ANCOVA). Groups 
that differ from each other are marked with bold font. Bonferroni adjustment was used for multiple 
comparisons. p-values ≤ 0.05 are shown with bold font. 
In cognitive tests used, the higher result means better performance, except for the Stroop test, 
where the best performance is the least amount of time used. 
Adjusted for age, sex, education, follow-up time, other subtypes of fats from milk products and 
spreads (analyses for total fat adjusted only for age, sex, education and follow-up time), ApoE ε4 
carrier status, and midlife vascular factors (systolic blood pressure, body mass index, total 
cholesterol, smoking). 
Abbreviations: MUFA = monounsaturated fatty acid; PUFA = polyunsaturated fatty acid; SFA = 
saturated fatty acid. 
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5.4 DIETARY FATS AND DEMENTIA (STUDY II) 
Subjects with moderate (2nd quartile) total fat intake at midlife were less likely to have 
dementia (OR 0.43, 95 % CI 0.23-0.80) after controlling for age, sex, education and follow-up 
time (model 1) compared with subjects of low total fat intake; for AD, a trend was seen (OR 
0.52, 95 % CI 0.26-1.08). After further adjustments for ApoE, midlife vascular risk factors, and 
the history of vascular diseases (model 2), the results were somewhat attenuated (OR 0.43, 95 % 
CI 0.18-1-03 for dementia, and OR 0.52, 95 % CI 0.20-1.36 for AD). Higher total fat intake (3rd 
and 4th quartiles), fat intake separately from milk products or total fat intake from spreads was 
not significantly associated with dementia or AD. 
 
5.4.1 Fatty acids from spreads 
A moderate (2nd quartile) PUFA intake from spreads was associated with a decreased risk of 
dementia (model 2: Figure 4a), but not of AD (Figure 4b). However, higher (3rd quartile) PUFA 
intake from spreads was associated with a decreased risk of dementia (OR 0.51, 95 % CI 0.27-
0.94) as well as AD (OR 0.36, 95 % CI 0.16-0.82), when controlled for age, sex, education, follow-
up time and other subtypes of fat from spreads and milk (model 1). After further adjustments 
(model 2), these associations were no longer significant. 
Moderate (2nd quartile) MUFA intake from spreads was also associated with a decreased 
risk of dementia (model 1: OR 0.51, 95 % CI 0.29-0.92), even though after further adjustments, 
the CIs became wider and statistical significance was lost. For AD, a borderline significant 
association was seen in model 1 (OR 0.53, 95 % CI 0.27-1.04) only. In contrast, moderate (2nd 
quartile) SFA intake from spreads was associated with an increased risk of dementia (Figure 4c) 
and AD (Figure 4d), even after all the adjustments (model 2). Higher (3rd or 4th quartile) SFA 
intake did not significantly affect the risk of dementia or AD. 
 
 
 
a) 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
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Figure 4. Association between dietary fats from spreads and dementia/Alzheimer’s disease (AD). 
 
Values are Odds Ratios (ORs) with 95 % Confidence Intervals (CIs). * p ≤ 0.05 when compared to 
the reference group (low intake of fats). Adjusted for age, sex, education, follow-up time, other 
subtypes of fat from spreads and milk, ApoE ε4 carrier status, midlife vascular factors (systolic blood 
pressure, body mass index, total cholesterol, smoking), and history of vascular diseases (myocardial 
infarction, stroke, diabetes mellitus). Abbreviations: MUFA = monounsaturated fatty acid; PUFA = 
polyunsaturated fatty acid; SFA = saturated fatty acid. 
Categorization of PUFA from spreads: Q1=0-0.4g/d, Q2=0.5-0.8g/d, Q3=0.9-2.9g/d, Q4=>2.9g/d. 
Categorization of SFA from spreads: Q1=0-4.1g/d, Q2=4.2-8.3g/d, Q3=8.4-15.8g/d, Q4=>15.8g/d. 
 
 
The combined effects of ApoE genotype and fat intake on dementia risk were investigated by 
including groupings of fat intake*ApoE ε4 allele status in the logistic regression models (Figure 
5). Compared to ApoE ε4 non-carriers with low PUFA or MUFA intakes (first quartiles), ApoE 
ε4 carriers with low PUFA and MUFA intake had an increased risk of dementia, respectively 
(PUFA: OR 3.00, 95 % CI 1.15–7.83; MUFA: OR 3.67, 95 % CI 1.46–9.20). Additionally, the risk of 
dementia was increased among ApoE ε4 carriers with moderate to high SFA intake (2nd 
quartile: OR 6.91, 95 % CI 2.33–20.49; 3rd quartile: OR 2.84, 95 % CI 0.77–10.44; 4th quartile: OR 
7.41, 95 % CI 1.35–40.77). There was no significant association between fat intake and the risk of 
dementia among ApoE ε4 non-carriers. For AD, the results were similar to those for dementia 
(Figure 5). However, no significant interactions were detected between ApoE and PUFA, 
MUFA or SFA intakes. 
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Figure 5. Combined effects of ApoE ε4 carrier status and midlife PUFA, MUFA and SFA consumptions 
in spreads and the risk of dementia (a) and Alzheimer’s disease (AD) (b).  
 
       ApoE ε4 non-carriers         ApoE ε4 carriers         
 
Adjusted for age, sex, education, follow-up time, other subtypes of fat from spreads and milk, ApoE 
ε4, and midlife systolic blood pressure, body mass index, cholesterol, smoking and late-life history 
of myocardial infarction, stroke and diabetes. * p < 0.05, ** p < 0.01 when compared to reference 
group (1st fat quartile and ApoE ε4 non-carrier). 
Abbreviations: MUFA = monounsaturated fatty acid; PUFA = polyunsaturated fatty acid; SFA = 
saturated fatty acid. 
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5.5 COFFEE AND/OR TEA DRINKING AND DEMENTIA (STUDY III) 
At midlife, nearly half of the participants (45.6%) had a moderate (3–5 cups) daily consumption 
of coffee, 38.5% consumed high (> 5 cups) amounts of coffee, and 15.9% consumed low (0–2 
cups) amounts of coffee. The majority of the participants (60.5%) did not drink tea, and four 
fifths of tea drinkers consumed 1–2 cups per day. The low coffee consumption group was 
somewhat older at the midlife examination (51.1 vs. 50.5 vs. 49.8 years, p = 0.02) and more 
educated (9.6 vs. 8.9 vs. 7.9 years, p < 0.001) compared to the moderate or high coffee 
consumption groups. There were fewer men in the moderate coffee consumption group than 
among low or high coffee consumption groups (29.3 vs. 47.5 vs. 43.9%, p < 0.001). At midlife, the 
high coffee consumers had the highest serum total cholesterol levels (6.9 vs. 6.4 vs. 6.7 mmol/l, p 
< 0.001) and the highest frequency of smoking (50.9 vs. 45.3 vs. 35.5%, p < 0.001). At late-life, the 
low coffee consumers had the highest occurrence of dementia (6.7 vs. 2.7 vs. 5.4%, p = 0.01) and 
AD (5.0 vs. 2.2 vs. 4.3%, p = 0.05), and the highest scores on the Beck depression scale (11.0 vs. 9.0 
vs. 10.0, p = 0.002) compared with moderate or high coffee consumers. 
Moderate coffee drinking (3-5 cups/d) at midlife was associated with a decreased risk of 
dementia by 65% (Figure 6a) and AD by 64% (Figure 6b) in the analyses adjusted for 
sociodemographic factors, midlife vascular factors and leisure-time PA (model 2). There was no 
dose-response effect of coffee drinking on dementia/AD risk reduction. When non-participants 
were included in the analyses, moderate coffee drinkers exhibited a decreased risk of 
subsequently developing dementia by 60% (OR 0.40, 95 % CI 0.24-0.69) compared to the low 
coffee consumers. 
Tea consumption (drinking ≥ 1 cup of tea/day vs. not drinking) had no associations with 
dementia/AD (model 2: OR 1.04, 95% CI 0.59–1.84 for dementia, OR 0.91, 95% CI 0.48–1.71 for 
AD, and OR 1.27, 95% CI 0.84–1.91 for all the demented). There were no significant 
multiplicative interactions between the ApoE genotype and coffee/tea drinking for the risk of 
dementia, but the coffee – dementia relation was more pronounced among ApoE ε4 carriers. 
When the analyses were stratified according to the ApoE ε4 carrier status, then the ORs for 
dementia among moderate coffee consumers compared to low consumers was 0.32 (95% CI 
0.11–0.92) among the ApoE ε4 carriers and 0.44 (95% CI 0.12–1.55) among the non-carriers 
(model 2). For AD, no effect modification was found by the ApoE ε4 carrier status. 
Similarly, there were no significant multiplicative interactions between sex and coffee/tea 
drinking with respect to the risk of dementia and AD, but the coffee – dementia association 
tended to be more pronounced in men. In the analyses stratified by sex, ORs for dementia 
among moderate coffee consumers was 0.27 (95% CI 0.08-0.89) among men and 0.51 (95% CI 
0.17-1.52) among women (model 2). Additionally, the risk of dementia was significantly lower 
among men with high coffee consumption (OR 0.36, 95 % CI 0.13-0.97) compared to men with 
low coffee consumption. No sex-related differences were observed for AD. 
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Figure 6. Association between coffee drinking and dementia/Alzheimer’s disease (AD). 
 
Values are Odds Ratios (ORs) with 95 % Confidence Intervals (CIs). * p ≤ 0.05. Adjusted for midlife 
age, sex, education, follow-up time, community of residence, midlife vascular factors (systolic blood 
pressure, body mass index, serum total cholesterol, smoking), and leisure-time physical activity. 
 
5.6 HEALTHY-DIET INDEX AND DEMENTIA (STUDY IV) 
The composition of the CAIDE midlife healthy-diet index is shown in table 12. In our 
population, scores ranged from 2 to 14.5; no participants had the lowest (0) or highest (17) 
possible scores. 
Subjects with a high adherence to a healthy diet had better global cognitive functioning than 
those with a low adherence to a healthy diet [model 3: mean MMSE (standard error, SE) 26.2 
(0.2) vs. 25.6 (0.2), respectively, p = 0.02]. Additionally, those participants who ate the healthiest 
had an 88% decreased risk of dementia and a 92% decreased risk of AD compared with 
individuals whose diet was least healthy (Figure 7). Adjustments for various confounders did 
not change the results. When non-participants were included in the analyses, the subjects in the 
high-adherence to a healthy diet group showed a tendency towards a decreased risk of 
dementia as compared with the low-adherence group (model 1: OR 0.5, 95% CI 0.23–1.27; model 
2: OR 0.27, 95% CI 0.07–1.00; model 3: OR 0.28, 95% CI 0.07–1.09). 
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Figure 7. Association between midlife healthy diet and dementia/Alzheimer’s disease (AD) among 
the CAIDE participants. 
 
Values are Odds Ratios (ORs) with 95 % Confidence Intervals (CIs). * p ≤ 0.05. Adjusted for midlife 
age, sex, education, follow-up time, community of residence, ApoE ε4 carrier status, midlife vascular 
factors (systolic blood pressure, body mass index, serum total cholesterol), presence of late-life 
myocardial infarction/stroke/diabetes mellitus, midlife leisure-time physical activity and smoking. 
HDI= healthy-diet index. 
 
77 
 
 
6 Discussion 
6.1 MAIN FINDINGS AND COMPARISONS TO OTHER STUDIES 
6.1.1 Dietary fats and cognition 
The present doctoral thesis revealed that dietary fat intake at midlife was related to dementia 
and AD later in life. In general, compared to lower fat intake, moderate consumption of fats 
from spreads and milk products was protective against developing dementia. In particular, the 
type of fat being consumed was important. A moderate intake of unsaturated fats (PUFAs and 
MUFAs) from spreads was related to a decreased dementia risk two decades later, while a 
moderate intake of SFAs increased the risk of dementia and AD. 
Midlife dietary fat intake was also related to cognitive performance in individuals without 
dementia. A higher total fat and SFA intake at midlife increased the risk of developing MCI two 
decades later. They were also related to poorer global cognition, psychomotor speed, and 
prospective memory. Additionally, the subjects who chose butter or butter-oil mixture instead 
of vegetable oil or margarine for baking or cooking had a poorer psychomotor speed two 
decades later. In contrast, a higher consumption of PUFAs and a higher PUFA-SFA ratio tended 
to be associated with better semantic memory, psychomotor speed and executive functioning. 
These results are in agreement with previous and recently-published similar studies (Table 4, 
Table 5). Conflicting findings have been reported in a number of shorter-term follow-up studies 
(<10 years), which are usually prone to bias due to sub-clinical dementia. Inconsistencies 
between studies may also be due to different dietary assessment methodologies (Table 3), and 
different outcome definitions (i.e. a variety of cognitive test batteries have been used to evaluate 
cognitive performance). In this doctoral thesis, fat intake was assessed by a semi-quantitative 
FFQ. 
In the early 1970s in the North Karelia area, 2/3 of the total fat intake was derived from milk 
and milk products including butter, whereas in the 1980s their proportion of the total fat intake 
declined especially due to an increase in meat and cheese consumption (Pietinen et al., 1989). 
Since most of the participants in the CAIDE study had their midlife visit in 1972 (n=493) or 1977 
(n=531), i.e. in “buttery-time”, and smaller amount of participants had their midlife visit in 
either 1982 (n=222) or in 1987 (n=163), these changes are less likely to have influenced the 
results. TFA intake was not investigated in the CAIDE project. In Finland, it was high 
consumption of SFAs (particularly from spreads and dairy products) and low consumption of 
unsaturated fats that had been identified already during the 1970s as the main components of 
an unhealthy diet. Margarines, baking shortenings, and frying fats have traditionally contained 
up to 40-50% TFA, whereas ruminant fats such as butter contain only 1-8% TFA (Craig-Schmidt, 
2006); butter is however high in SFAs (Zock and Katan, 1997). However, it is worth mentioning 
that in the 1980s, the TFA content in Finnish margarines varied from 0 to 17% of the total FAs - 
soft margarines had more TFAs vs. hard margarines - (Hyvönen et al., 1993) and that the 
removal of TFA from margarines started in the mid-1990s (Valsta et al., 2010). Nowadays, 
according to the Finnish Food Safety Authority (Evira, http://www.evira.fi; Ritvanen et al., 
2012), spreads and shortenings have very tiny amounts of TFA (<2% of total FAs) in Finland.  
In the present doctoral thesis, frequent fish consumption (i.e. at least twice per week) tended 
to be related to better global cognition and semantic memory. No data was available to allow a 
more detailed analysis concerning the type of fish/seafood. Other studies about fish 
consumption and cognition (Table 4) have shown variable results ranging from no association 
to borderline/positive association; for the risk reduction of dementia/AD (Table 5) although fish 
consumption (≥1/week) has shown mostly positive results. It has been also postulated that the 
78 
 
 
benefits of seafood may depend on the type of seafood, since the quantities of EPA and DHA 
vary among species (i.e. more in dark-meat fish than in light-meat fish/shellfish) and within a 
species according to environmental variables (e.g. wild vs. farm-raised) (Kris-Etherton et al., 
2002). Modifications of the FAs as a consequence of various cooking methods have also been 
shown; different effects of cooking on FAs could be explained by the kind of analysed food 
(initial fat content) as well as the cooking oil selected (Candela et al., 1997; Candela et al., 1998). 
For instance, the amounts of DHA and EPA may decrease and the n-6/n-3 ratio may increase 
because of excessive heat during deep-fat frying with sunflower oil - a typical manufacturing 
process for light-meat fish. Further, environmental pollutants (e.g. methylmercury, 
polychlorinated biphenyls [PCBs], and dioxins) found in certain fish may diminish the health 
benefits of n-3 FAs, and thus consumers need to be aware of both the benefits and risks of fish 
consumption for their particular stage of life (e.g. certain limitations in children and 
pregnant/lactating women vs. middle-aged/older men and women) (Kris-Etherton et al., 2002).  
The neuropsychological benefit of n-3 FAs has been studied also in several RCTs, but based 
on the results, positive associations can be proposed only for the cognitively impaired within 
specific cognitive domains (e.g. immediate recall, attention and processing speed subdomains), 
but not in healthy or AD subjects (Mazereeuw et al., 2012; Dacks et al., 2013). Discrepancies 
between studies may possibly be due to methodological differences e.g. in dose, testing 
methods, baseline n-3 FA levels, and ApoE ε4 genotype (i.e. that cognitive protection is limited 
only to the ApoE ε4 non-carriers). It is also possible that in individuals with a high cognitive 
reserve, the cognitive benefit of n-3 FAs supplementation may not be detectable. Nonetheless, it 
seems that supplementation may be more effective when the disease is not yet advanced, even 
though further studies are still needed to be assured of these potentially responsive 
populations. 
6.1.2 Coffee, tea and dementia 
The present project showed that moderate coffee consumption at midlife was associated with a 
decreased risk of dementia and AD in late-life. These results are in agreement with several 
studies on the effects of coffee or caffeine on cognition or neuropathology (Table 7). No 
significant associations with cognitive decline/dementia/AD have been found in some studies 
(van Boxtel et al., 2003; Ritchie et al., 2007; Ng et al., 2008; Laitala et al., 2009; Gelber et al., 2011), 
which could be due to differences in the categorization of coffee consumption, cognition 
assessment methods, population differences, or short follow-up time.  
In the present doctoral thesis, coffee drinking was protective against dementia even after 
adjusting for hypercholesterolemia and hypertension. Cholesterol and BP may be influenced by 
coffee drinking, and they are also related to cognition. It has been previously shown that coffee 
drinking in Finland was associated with increased serum cholesterol levels (Tuomilehto et al., 
1987), in particular when boiled, non-filtered coffee was consumed (Aro et al., 1989). Since the 
1980s, the majority of Finns have switched from boiled coffee to filtered coffee. Unfiltered 
coffee, rich in cafestol and kahweol, increases cholesterol levels, but caffeine might have a 
positive effect on serum lipids (Du et al., 2005). In addition, the incidence of hypertension has 
been reported to be somewhat higher in coffee drinkers compared with non-drinkers (Hu et al., 
2007). Interestingly, coffee seems to reduce the risk of dementia/AD despite these potential 
negative effects. Given the large amount of coffee consumption globally, coffee drinking might 
have important implications for the prevention or delaying the onset of dementia/AD. 
However, there is currently no agreement concerning the recommended amount of coffee/day. 
No association was found between midlife tea drinking and the risk of dementia/AD, 
similarly to findings from previous studies (Table 7). This could be due to lower caffeine 
content of tea, or to the fact that additional coffee components other than caffeine confer the 
protective effect. Since tea consumption was not very common in the CAIDE population, the 
statistical power was also rather low. 
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6.1.3 Healthy diet and dementia 
The results from this project indicated that adherence to a healthy-diet (composite dietary 
pattern) already at midlife was associated with a decreased risk of dementia and AD later in 
life. Although a healthy-diet is an important determinant for the level of several risk factors for 
dementia, i.e. BP, cholesterol, DM, and obesity, the effects of the healthy-diet remained highly 
significant even after adjustments for several such factors. 
Similar protective effects have been reported in several studies between the MEDI and the 
risk of dementia (Table 8; Lourida et al., 2013), all-cause mortality (Knoops et al., 2004; Mitrou et 
al., 2007; Sjögren et al., 2010; Buckland et al., 2011; McNaughton et al., 2012; Zazpe et al., 2014), 
and cardio-/cerebrovascular outcomes i.e. CVD/CHD/MI/CBVD/stroke (Fung et al., 2009; 
Scarmeas et al., 2011; Agnoli et al., 2011; Gardener et al., 2011; Guallar-Castillón et al., 2012; 
Hoevenaar-Blom et al., 2012; Misirli et al., 2012; Estruch et al., 2013; Tognon et al., 2014). There 
are very few studies which have examined the link between the DASH-style diet and 
cognition/mortality/CHD/ stroke, but they also suggest that the effect is parallel to that found 
for MEDI (Fung et al., 2008; Smith et al., 2010; Chen et al., 2010; Agnoli et al., 2011; Levitan et al., 
2013). The CAIDE Healthy-Diet Index (HDI) extends these findings by including more 
comprehensive DPs than those captured by the MEDI index. The CAIDE HDI-approach gives 
very practical information on the foods included, making it simple for everyone to calculate 
their adherence to a healthy diet. In the calculation of the index, the median values were used as 
cutoffs, and general dietary recommendations were used to define what was healthy and what 
was unhealthy; total EI could not be calculated and included in the index since our dietary data 
was based mainly on intake frequency. It would have been interesting to investigate whether 
total EI or share of fats in the daily EI or other dietary components have any associations with 
dementia risk. 
6.1.4 Combined effects of diet and ApoE on dementia risk 
In this project, the associations between midlife dietary fat intake and subsequent dementia/AD 
development were influenced by ApoE genotype. The protective effects of moderate PUFAs 
and MUFAs intake and the detrimental effects of SFA intake were observed particularly among 
ApoE ε4 allele carriers. No significant interactions were observed between the ApoE ε4 allele 
and fat intake in relation to cognitive functioning in individuals without dementia. There were 
also no significant interactions between the ApoE ε4 allele with either coffee/tea consumption or 
the HDI in relation to dementia risk, most likely due to the limited statistical power. 
In the CAIDE population, the ApoE genotype has been shown to modify the associations 
between several hazardous lifestyle-related factors (i.e. physical inactivity, alcohol drinking, 
smoking as well as the previously mentioned low dietary PUFA and high SFA intakes) and 
dementia/AD risk (Kivipelto et al., 2008). In the ApoE ε4 allele carriers, the risk varied from a 3-
fold increase in smokers to a 7-fold increase in those with a higher SFA intake; clustering of 
these factors also strongly increased the risk of dementia/AD. Similar ApoE modification 
patterns have been reported also in other populations (Luchsinger et al., 2002; Podewills et al., 
2005; Huang et al., 2005; Barberger-Gateau et al., 2007; Barberger-Gateau et al., 2011). However, 
the effect of the ApoE ε4 allele on dementia is believed to attenuate with increasing age (Farrer 
et al., 1997), which may explain the negative findings from studies conducted on older cohorts. 
Taken together, genetically susceptible individuals may be more vulnerable to environmental 
factors, and may thus benefit more from dietary and other preventive interventions. This is 
especially important as the proportion of ApoE ε4 allele carriers is somewhat higher in the 
Northern European countries (Ehnholm et al., 1986; Lehtimäki et al., 1990; Gerdes et al., 1992; 
Corbo and Scacchi 1999; Schiele et al., 2000; Crean et al., 2011). However, further studies need to 
be conducted to investigate gene-environment interactions in more detail in different 
populations. 
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6.2 POSSIBLE MECHANISMS 
6.2.1 Dietary fats 
The mechanisms by which dietary fats may affect cognitive performance/dementia are 
unknown, but several hypothetical pathways have been proposed. The effects of dietary fats 
could be partly mediated through vascular mechanisms. A higher intake of SFAs has been related 
to an increased risk of cardio- and cerebrovascular conditions, whereas consumption of PUFAs 
confers protection (Baum et al., 2012; Chowdhury et al., 2012). For example, modest (i.e. 1-2 
servings/week) oily fish (e.g. salmon) rather than lean fish (e.g. cod) consumption has 
recognized advantages for cardiovascular health, notably in reducing the risk of CVD/CHD 
(Mozaffarian and Rimm, 2006; Raatz et al., 2013). Further, RCTs replacing dietary SFAs with 
MUFAs have revealed decreases in BP and improvements in the blood lipid profile, insulin 
sensitivity, and glycemic response in various populations (Gillingham et al., 2011), all of which 
are also highly relevant to the cognitive decline and dementia (Tolppanen et al., 2012). Vascular 
factors may be important mediators since they have been related to impaired cognitive function 
and increased risk of dementia also through structural brain changes such as white matter 
lesions (WMLs; also known as white matter hyperintensities or leukoaraiosis) (Breteler et al., 
1994; Debette and Markus, 2010; Schmidt et al., 2011), or brain volumes (Debette et al., 2011; 
Giorgio and De Stefano, 2013) – in AD, a symmetric or asymmetric reduction in the 
hippocampal volume, in the volume of the entorhinal cortex and in the other medial temporal 
structures has been noted repeatedly (Bozzali et al., 2008). The results of the present project 
remained significant even after adjustments for several cardiovascular risk factors and 
conditions. However, it is impossible to exclude the possibility that other vascular factors such 
as silent cerebral infarcts (Vermeer et al., 2003), ultrastructural capillary changes in the brain 
(Farkas and Luiten, 2001), or endothelial dysfunction (a typical feature of atherosclerosis) 
(Roberts et al., 2005) may be important mediators in determining these associations. 
In addition, also non-vascular-related mechanisms may partly explain the findings. Dietary 
fats have been related to AD neuropathology (amyloid plaques and NFTs as pathological 
hallmarks) (Nelson et al., 2009), and FAs may play important roles in the synthesis and fluidity 
of nerve cell membranes and in synaptic plasticity and neuronal regeneration (Crupi et al., 
2013). In animal studies, SFAs have reduced the levels of hippocampal brain-derived 
neurotrophic factor (BDNF) that are relevant for neuronal plasticity and the maintenance of 
cognitive functions (Molteni et al., 2002). Furthermore, a diet high in SFAs and cholesterol may 
induce or exacerbate the hippocampal accumulation of Aβ (Oksman et al., 2006; Takechi et al., 
2010). In contrast, n-3 FAs may be able to reduce the production and accumulation of Aβ 
protein, e.g. by suppressing signal transduction pathways induced by Aβ, increasing the 
production of neurotrophic factors (e.g. BDNF), improving synaptic membrane fluidity, and 
regulating glutamatergic synaptic transmission by activating microglial cells and astrocytes 
(Cole et al., 2009; Luchtman and Song, 2013; Denis et al., 2013). A medical nutrition product 
based on n-3 FAs has been claimed to improve memory performance, by supporting synaptic 
function in the mild stage of AD (Scheltens et al., 2010; Scheltens et al., 2012). Interestingly, the 
presence of ApoE ε4 allele has been shown to exacerbate all the disturbances that have been 
related to AD neuropathology, in contrast to the protection offered by the other ApoE isoforms 
(Cedazo-Mínguez, 2007; Altman and Rutledge, 2010). A recent RCT has also revealed that the 
lipidation states of apolipoproteins and Aβ peptides in the brain differ depending on the ApoE 
genotype and cognitive diagnosis (e.g. higher among ApoE ε4 allele carriers vs. non-carriers, or 
among persons with MCI vs. persons with normal cognition), and that these concentrations can 
be modulated by diet (e.g. a diet with high SFA and glycemic index increases these fractions) 
(Hanson et al., 2013). 
Another possibility is attributable to inflammatory mechanisms (Leonard, 2007; Krstic and 
Knuesel, 2013) that are thought to be involved in the pathogenesis of AD; unsaturated FAs may 
81 
 
 
confer protection through a variety of anti-inflammatory mechanisms. Some effects of 
unsaturated FAs on inflammation can be mediated by reducing the production of pro-
inflammatory cytokines (e.g. interleukin-1β [IL-1β], tumour necrosis factor [TNF-α], IL-6 via 
nuclear factor k B [NFkB] pathway) (James et al., 2000; Das, 2008), by affecting eicosanoid 
(including prostanoids [prostaglandins, thromboxanes, prostacyclins] and leucotrienes) and 
docosanoid production, through pathways involving COX and LOX enzymes (including 
resolvins and protectins) (Calder, 2011; Luchtman and Song, 2013), or by affecting expression of 
genes (e.g. ANAPC5) that might influence inflammatory processes (Vedin et al., 2012). 
Furthermore, disturbances in the structural integrity of the blood-brain barrier (BBB) might serve as a 
novel mechanism that may underlie the detrimental effects of a Western diet (high in SFA and 
cholesterol) consumption on cognitive function (Kanoski and Davidson, 2011). It has been 
postulated that in healthy humans and rodents with an intact BBB blood-borne Aβ is effectively 
blocked from access to the brain, whereas in BBB disruption entry of Aβ from blood to brain is 
facilitated and this could contribute to cognitive impairment. The effect of dietary fat intake on 
cognitive performance/dementia could also be mediated through oxidative stress (which is 
extensive in Aβ-abundant areas) (Markesbery, 1997; Butterfield et al., 2001; Zhang et al., 2005), 
caused by reduced intake of PUFAs, notably DHA (Jicha and Markesbery, 2010; Hashimoto and 
Hossain, 2011). Experimental and preliminary data from ongoing clinical trials have also 
indicated that DHA may be more neuroprotective when combined with the polyphenolic 
antioxidant, curcumin (Cole et al., 2010). Additionally, a diet high in fat/SFA may lead to 
cognitive impairment also through other effects for example on insulin 
resistance/hyperinsulinemia (Greenwood and Winocur, 2005; Bayer-Carter et al., 2011). Further, 
alterations in the body fat may disrupt the estrogen balance and this could cause cognitive 
changes (Gibbs and Gabor, 2003; Bagger et al., 2004; Cui et al., 2013). 
6.2.2 Coffee, tea and caffeine 
Several potential mechanisms may explain the observed positive coffee-dementia association. 
Coffee drinking has been associated with a decreased risk of type 2 DM (Tuomilehto et al., 2004; 
Jiang et al., 2014), possibly due to an increase in insulin sensitivity by magnesium that is 
abundant in coffee (de Valk, 1999). Type 2 DM is known to increase the dementia/AD risk 
(Mayeux and Stern, 2012). One pathway could be via insulin degrading enzyme (IDE), an 
enzyme that degrades both insulin and amyloid-β (Qiu and Folstein, 2006). The insulin 
resistance which occurs in type 2 DM results in decreased amyloid-β degradation (de la Monte, 
2009). 
Caffeine can also affect the brain through its action on adenosine receptors; the presence of 
A2A receptor is essential for Aβ toxicity. Caffeine is a nonselective A1 and A2a adenosine receptor 
antagonist, and this blockade may have the consequence of activating cholinergic neurons 
(Fredholm et al., 1999). It has been shown in mice that both caffeine and other adenosine A2a 
receptor antagonists can prevent amyloid-β induced cognitive deficits (Dall’Igna et al., 2007). 
Furthermore, chronic caffeine administration was shown to exert neuroprotective effects in 
experimental models of hypoxia and ischemia, these being also related to caffeine’s action as an 
adenosine receptor antagonist (de Mendonça et al., 2000). 
The effects of coffee may also be due to its antioxidant capacity (Svilaas et al., 2004). The most 
abundant polyphenol in coffee - CGA (the ester of caffeic acid with quinic acid) - is thought to 
be responsible for a major part of the antioxidants present in coffee. The phenolic acids present 
in coffee have been reported to be more bioavailable in humans, on a molar basis, than the 
catechins present in green tea (Renouf et al., 2010a). The bioavailability of polyphenols (CGA) 
may be impaired by simultaneous consumption of other dietary constituents, especially 
proteins (from milk) when consumed in higher amounts (Duarte and Farah, 2011); the lower 
amounts (10%) of milk added to coffee may not alter the overall bioavailability of coffee 
phenolic acids (Renouf et al., 2010b). The catechins from green/black tea are rapidly absorbed 
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and milk does not appear to impair the bioavailability of tea catechins (van het Hof et al., 1998; 
Kyle et al., 2007). 
6.2.3 Healthy dietary patterns 
A healthy DP can influence dementia risk by several possible mechanisms, i.e. by specific 
characteristics of individual nutrients and/or their combination. Oxidative stress can contribute 
to neuronal damage in AD (Schrag et al., 2013), and the reduced oxidative stress associated with 
a healthy diet could be protective (Steele et al., 2007). High homocysteine levels due to dietary 
folate deficiency can have direct neurotoxic effects in cell lines and animal models (Morris, 
2003). The combination of vitamins E and C (Sato et al., 1993) has been shown to promote 
neuronal survival in the rat brain. Furthermore, unsaturated fatty acids may influence the 
pathogenesis of AD e.g. by modulating the composition and fluidity of neuronal membranes, 
reducing Aβ accumulation and preventing neuro-inflammation (Das, 2008). 
The role of a healthy DP in dementia prevention could be related to vascular mechanisms. A 
MEDI/healthy diet has been associated with improvements in cardiovascular health and 
reduced risk factors, including hypertension, dyslipidemia, DM, and obesity (Franco et al., 2004; 
Sánchez-Taínta et al., 2008). In individuals at high cardiovascular risk, a MEDI supplemented 
with extra-virgin olive oil or nuts reduced the incidence of major cardiovascular events (Estruch 
et al., 2013). The potential benefits of fish consumption in reducing the risk of CBVD may be 
due to the wider array of nutrients found in fish (i.e. vitamins D and B complex, essential amino 
acids and trace elements [e.g. taurine, arginine, selenium, calcium, magnesium, potassium, 
iodine]) vs. n-3 FAs, the unique combination of the latter nutrients with n-3 FAs, better 
absorption of EPA and DHA from fish vs. fish oils, or the concomitant reduction of 
“detrimental” foods (e.g. red meat) (Chowdhury et al., 2012; Kiefte-de Jong et al., 2012). In 
addition, dietary habits are known to be related to other social and lifestyle factors (Ambrosini 
et al., 2009; Simsek et al., 2013), which may partly explain the association between diet and 
dementia. 
6.3 METHODOLOGICAL ASPECTS 
6.3.1 Study population and dietary assessment 
CAIDE is a well-characterized longitudinal study specifically designed to investigate risk 
factors for dementia and AD. It includes population-based random samples of individuals 
investigated on two different occasions (at baseline within two cardiovascular studies: North 
Karelia Project and the FINMONICA study) with high participation rates: 77-96 % at baseline 
(Vartiainen et al., 1994) and 72 % at the first re-examination. In summary, the prospective 
population-based study design and the relatively high participation rates increase the reliability 
of the findings. Other strengths of the CAIDE study include the long follow-up period (14 years 
in study IV, and 21 years in studies I-III), the collection of dietary information already at midlife 
with a well-validated FFQ, availability of numerous health and lifestyle covariates, and 
comprehensive evaluation and diagnostic protocol at each examination. 
However, limitations should also be considered. First, dietary information was collected only 
once, not with repeated diet assessments – a factor increases the random measurement error 
leading to a possible underestimation of associations. It is impossible to be sure that some subjects 
may have changed their dietary habits between the dietary assessment and the initial cognitive 
testing. Thus, a single dietary assessment may not precisely reflect subject’s long-term intake, 
which is more likely to influence disease risk. Further, limitations are also that the FFQ was 
relatively short, including only ~20 mostly qualitative or frequency-based questions, and thus 
there were no information available about total EI. Second, reporting dietary habits can be 
influenced by cognition, but no cognitive assessment was available at the midlife examination. 
The influence of reverse causality is possible even though improbable, since there was a 14-21 
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year lag between the FFQ and initial cognitive assessment, i.e. it seems unlikely that many 
individuals had a substantial cognitive impairment at study entry or that possible dietary 
changes could have been caused by underlying health conditions/cognitive changes. If one 
postulates that there were some individuals exhibiting the early stages of dementia already at 
the baseline examination, these would have been unlikely to survive and been able to 
participate in the follow-up examination. Third, the possible effect of selective survival must be 
kept also in mind when interpreting the findings, since there was no data about the baseline 
risk factors regarding those who had deceased after the initial assessments. At the general level, 
the results are applicable to persons that survive into old age. Fourth, in some of the sub-group 
analyses as well as in the analyses regarding tea consumption (study III) where a smaller 
number of participants were available, it is possible that there were some false negative results 
due to insufficient statistical power. Fifth, the possibility of a bias due to a residual confounding 
effect cannot be totally excluded, even though there was adjustment in all the analyses for 
several possible confounders including sociodemographic, life-style and health-related factors, 
and some of the analyses were carried out also separately in sub-groups. Unfortunately, there 
were factors about which no information was available, and some of the variables used may 
have been unable to capture all the dimensions of the phenomenon in question. Sixth, the 
generalizability of the findings needs to be tested further among different racial/ethnic minorities. 
6.3.2 Outcome assessment 
Cognitive functions were investigated in three phases (i.e. screening, clinical and differential 
diagnostic phase) during late-life examination in 1998. However, only those persons scoring ≤ 
24 in the MMSE in the screening phase underwent the diagnostic examinations. Almost 50% of 
the persons that had MMSE below the cut-off point in the screening phase were nevertheless 
cognitively normal in the clinical phase suggesting that the cut-off score used was sufficiently 
sensitive for detecting AD in this population. The use of a higher cut-off score would have 
resulted in inclusion of a very large proportion of the population in the clinical phase, as the 
median MMSE was 26. In other types of dementia, memory deficits are not part of the initial 
manifestation of the disease, and in these cases the use of MMSE may have caused 
underdiagnosis. However, nearly all of those with dementia in the clinical phase went through 
brain imaging in the differential diagnostic phase. Autopsy data were not available to confirm 
the clinical diagnosis, but a previous neuropathologic study conducted in our clinic in Kuopio 
has shown that the accurary of clinical diagnosis of AD is good (96% for probable AD and 86% 
for possible AD) (Kosunen et al., 1996). 
The diagnosis of MCI in the present study was based on clinical judgement: the persons did 
not fulfill the diagnosis criteria for dementia, but had some subjective and objective cognitive 
impairment. Some cases of MCI and mild dementia may have been lost due to the MMSE cut-
off point. The CAIDE study was essentially designed to detect dementia, and it is unclear how 
sensitive and specific the screening procedure was in identifying those persons with MCI. 
However, the prevalence of MCI resembled that found in another population-based study 
conducted in the same region with a population of corresponding age, suggesting that any 
detection bias was minimal (Hänninen et al., 2002). 
6.3.3 Non-participation 
Non-participation may have somewhat influenced our results, since no information was 
available for the non-participants in the baseline surveys with respect to life-style characteristics 
or cognitive status. Nonetheless, the non-participation rates at baseline were rather low, ranging 
from 7 % in the cohort examined in 1972 to 17 % in the cohort examined in 1987 (Vartiainen et 
al., 1994). The main reasons for the non-participation at baseline were: address information not 
up-to-date, temporarily away from home, or unable to participate; very few individuals actually 
refused to participate in the surveys (Puska et al., 1979). 
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However, non-participation bias could be addressed for the follow-up examination. It has 
been shown that individuals with cognitive impairment are less likely to participate in studies 
(Launer et al., 1994). The dementia diagnoses for the follow-up non-participants were identified 
from medical records of local hospitals and health care centres. As anticipated, a higher 
percentage of dementia cases was detected among the non-participants than among the 
participants in the present study. Since medical records tend to underestimate the prevalence of 
dementia, this may lead to an underestimation of the effects of various risk factors (including 
diet-related factors) on dementia (Solomon et al., 2013).  
The non-participants in the late-life survey were older and less educated and had poorer 
health status at midlife (i.e. higher SBP, DBP, total serum cholesterol level, and BMI) compared 
to participants. Further, the non-participants were more often smokers at midlife, had more 
often heart diseases (atrial fibrillation, heart failure, and CHD; at midlife 10.0% vs. 8.8%, and in 
late-life 29.2% vs. 22.8%) as well as more asthma and chronic obstructive pulmonary disease 
(COPD; at midlife 6.8% vs. 5.7%) than the participants (Rusanen, 2013). Additionally, the total 
fat intake and the consumption of SFAs and MUFAs were higher, whereas consumption of tea 
was lower in this group. Thus, if the non-participants were at an increased risk of dementia and 
AD, then the results would actually underestimate the true effects of diet (as well as smoking, 
heart and pulmonary diseases) on the risk of dementia and AD. In studies I, II and III, the 
results remained unchanged whether or not the non-participants were included, indicating that 
the main results are not due to selective participation. In addition, the non-participation most 
likely did not bias the results with respect to the associations between midlife HDI and 
dementia/AD, since the non-participants did not differ significantly from the participants in 
their midlife adherence to a healthy diet (study IV). 
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7 Summary and conclusions 
The present doctoral thesis investigated the role of various dietary factors at midlife on late-life 
cognitive functioning and development of dementia/AD in a Finnish population, taking into 
account a broad range of potential confounders and effect modifiers. The main conclusions of 
the project can be summarized as follows (table 18): 
 
 
Table 18. Summary and conclusions. 
 
Sub-study n Covariates (model 2) Outcome Conclusions 
Study I 1341 Age, sex, education, 
follow-up time, other 
subtypes of fats from 
milk products and 
spreads, ApoE ε4 
carrier status and 
midlife vascular 
factors (smoking, 
SBP, serum total 
cholesterol, BMI). 
MCI, cognitive 
performance 
 
SFA intake from milk products and spreads 
was associated with MCI and poorer 
performance in several cognitive domains. 
PUFA intake from milk products and spreads 
and fish intake were related to better 
performance in several cognitive domains.  
Higher PUFA-SFA ratio tended to be 
associated with better performance on 
psychomotor speed and executive functions. 
Study II 2000 Same as in Study I 
plus presence of late-
life diseases (MI, 
stroke, DM). 
Dementia/AD Moderate PUFA and MUFA intake from 
spreads was protective against dementia/AD 
compared with low intake.  
Moderate SFA intake from spreads increased 
dementia/AD risk compared with low intake. 
These effects were more pronounced among 
ApoE ε4 carriers. 
Study III 1409 Same as in Study I 
plus community of 
residence, and PA. 
Dementia/AD Moderate coffee consumption (3-5 cups/day) 
was protective against dementia/AD. 
Tea consumption was not related to 
dementia/AD. 
Study IV 525 Age, sex, education, 
follow-up time, 
community of 
residence, ApoE ε4 
carrier status and 
midlife SBP, serum 
total cholesterol, BMI, 
and late-life 
MI/stroke/DM. 
Dementia/AD Highest adherence to a healthy diet was 
associated with a decreased risk of 
dementia/AD. 
 
Abbreviations: AD = Alzheimer’s disease; BMI = body mass index; 
DM
 
=  diabetes  mellitus;  MCI = mild cognitive impairment; MI = myocardial infarction;
 MUFA = monounsaturated fatty acid; PA = physical activity; PUFA = polyunsaturated fatty
 acid; SBP = systolic  blood pressure;  SFA = saturated
 
fatty acid. 
 
 
ApoE = Apoliprotein E;
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8 Implications and future perspectives 
This doctoral thesis indicates that diet is important in the prevention of late-life cognitive 
impairment and dementia. Based on the present findings and on the available literature, 
recommendations for healthy DPs in dementia prevention include eating more vegetables and 
fruits, fish, choosing products with more unsaturated fats and less saturated fats (i.e. choosing 
vegetable oil or margarine instead of butter for cooking or baking; prefering low-fat dairy 
products; reducing consumption of sausage foods or other high-fat meat products), reducing 
salt and sugar consumption. People who drink coffee or alcohol should maintain moderate 
consumption levels; currently there is no evidence to support issuing recommendations to 
people to start drinking coffee or alcohol for the specific purpose of preventing cognitive 
impairment. Genetically susceptible individuals may be able to lower their dementia risk by 
modifying unhealthy dietary habits. The CAIDE HDI could be a useful tool in nutrition 
education and for helping individuals to monitor their own dietary habits. Continued follow-up 
of the CAIDE population in the future could provide more information about dietary factors 
and patterns in relation to cognition in older age groups (75+ years). 
Dietary habits in Finland have improved since the 1970s, but during recent years there has 
been a renewed increase in the consumption of saturated fats (especially in the form of butter 
and fatty dairy products), and this has been reflected in increasing blood cholesterol levels 
(Vartiainen et al, 2012). Carbohydrate consumption has decreased, but this decrease is due to 
reduced bread consumption (leading to reduced intake of fibers), not reduced sugar intake. The 
intake of salt is also increasing (Raulio et al, 2013). The consumption of unsaturated fats, fish, 
vegetables and fruits is now closer to the recommended levels, but there is still room for 
improvement. 
Media has an important role in the dissemination of nutritional information to the general 
population. During recent years a new ‘fat war’ has been being waged in Finland, with much 
focus on the supposedly detrimental effects of lipid-lowering medications and criticisms of the 
current recommendations on reducing saturated fat intake. The main diet type ‘promoted’ by 
some sectors of the media has been low-carbohydrate/high-fat. This may be one possible reason 
behind recent changes in dietary habits in the population (Raulio et al, 2013). 
The fact that many of the dietary factors associated with dementia are also related to 
cardiovascular and other chronic conditions and if one could include dementia-related diseases 
in nutrition education then this could help to increase motivation and adherence to healthy DPs 
in the general population. However, more detailed dietary information is needed before specific 
recommendations for dementia prevention can be formulated. The association of several factors 
(i.e. cholesterol, BP, BMI) with dementia seems to be age-dependent, and risk factor profiles are 
different in midlife vs. late-life (Kivipelto et al., 2006; Barnes et al., 2009). Similar differences 
regarding healthy DPs may exist between midlife and older ages, and DPs need to be studied in 
various age groups in relation to dementia risk. Since neuropathological changes can begin 
already decades before the first appearance of any clinical symptoms of dementia, it is essential 
to study long-term dietary habits in order to identify actual risk factors vs. markers of ongoing 
pathological processes and reverse causality. Many other details are still unclear, such as the 
role of various nutritional supplements in relation to diet in dementia prevention, the specific 
roles of different nutrients (i.e. types of unsaturated FAs, different vitamin forms), the levels of 
adequate intake for various nutrients at different ages and in different groups at risk of 
dementia. 
Recent studies have suggested that the incidence of dementia may be declining (Qiu et al., 
2013; Matthews et al., 2013). One possible explanation is the changes in cardiovascular risk 
factors since the 1960s-1970s, i.e. decreasing prevalence of hypertension, hyperlipidemia or 
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smoking. However, both overweight and DM are becoming more common among middle-aged 
and older populations (Vartiainen et al., 2010; Luchsinger, 2010; Finucane et al., 2011; Fielding et 
al., 2013). New epidemiological studies are needed to confirm the trend of declining dementia 
incidence, and also to investigate dietary and other factors in the future generations of older 
people, considering that conditions in the population can change significantly during long-term 
follow-up studies. 
Even small intervention effects on common risk factors for dementia can have an important 
impact at the population level. At the moment there is no curative treatment for AD; all of the 
available drug treatments are merely symptomatic. No new Alzheimer drugs have entered the 
market since 2002. Since there is now more focus on the pre-dementia stages of AD, prevention 
represents a relevant intervention goal, and effective preventive interventions are needed in 
earlier stages of the disease. According to the Evidence Report on “Preventing Alzheimer’s 
Disease and Cognitive Decline”, there is a need for trials that consider multiple components of 
the same general factor and multiple factors simultaneously (Williams et al., 2010). The studies 
should also take into account the intensity, duration, and timing of the exposure, as exposures 
may be more influential and interventions more effective during critical/sensitive time 
windows. Further, the results from experimental animal models may not always be able to be 
extrapolated to humans (Demetrius, 2006), because of the much more complex human vs. 
animal cognitive performance. Thus, additional evidence is needed to clarify the apparent 
discrepancies between human epidemiological evidence and experimental animal models. 
Since dementia/AD is a multifactorial condition with a long sub-clinical, prodromal period, 
and diet is only one piece of a more complex puzzle, prevention trials targeting several risk 
factors simultaneously with extended periods of time may be more likely to succeed. These 
kinds of multi-domain RCTs are already ongoing in collaboration between researchers across 
Europe: the European Dementia Prevention Initiative (EDPI, http://www.edpi.org; Richard et 
al., 2012; Dehnel, 2013); their results can provide crucial information for formulating effective 
dementia prevention strategies including nutritional and exercise advice, cognitive training, 
and intensive monitoring of vascular risk factors. The EDPI includes three RCTs already in 
progress - the FINGER trial from Finland (Kivipelto et al., 2013), the Prevention of Dementia by 
Intensive Vascular Care (preDIVA) from the Netherlands (Richard et al., 2009) and the 
Multidomain Alzheimer Prevention Trial (MAPT) from France (Carrié et al., 2012) as well as a 
fourth which is being devised in the Netherlands, Finland and France - the Healthy Aging 
Through Internet Counselling in the Elderly (HATICE) (http://www.hatice.eu/). 
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The Effects of Midlife Diet 
on Late-Life Cognition
An Epidemiological Approach
As more individuals survive into 
advanced age, prevention of cognitive 
impairment and dementia is of 
increasing public health importance. 
Identifying modifiable risk and 
protective factors for dementia/
Alzheimer’s Disease (AD) is 
essential for formulating effective 
prevention strategies. This thesis 
investigated the role of midlife 
diet - dietary fat intake, coffee/tea 
consumption and healthy diet - in 
the development of dementia/AD and 
cognitive impairment later in life in 
a population-based study with a long 
follow-up time of over two decades.
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